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Mutation in the APC gene is present in over 80% of sporadic human colorectal cancer
tumours, both benign and malignant. It is responsible, when inherited in the germ line,
for the mendelian dominant condition of familial adenomatous polyposis (FAP). Germ-
line mutation in nucleotide mismatch repair genes, in contrast, is responsible for the
familial disorder of hereditary, non-polyposis colorectal cancer, and functional
deficiency in this group of genes is clonally present in around 15% of sporadic tumour.
Although these two types of genetic deficiency are both associated with colorectal
cancer, their roles appear to be very different: whereas deficiency in Ape facilitates
development of adenomas with a low transition frequency to cancer, deficiency in
mismatch repair genes is associated with malignant tumours which evolve rapidly from
precursor benign lesions, or perhaps may arise de novo. APC is a multifunctional protein
whose known functions include interaction with microtubules and the signalling protein
(3-catenin, a component of the Wnt-dependent transcriptional activation pathway. Its
precise role in initiating adenoma formation is, however, not clear. Use of murine
models of human colorectal cancer will lead to a further understanding of how the APC,
mismatch repair and p53 genes interact with each other in the process of cancer
development. Furthermore, these models should elucidate the role played by (3-catenin, a
mediator of the Wnt pathway. (3-Catenin is known to be modulated by APC and
involved subsequently in the activation of downstream target genes. However, it is still
unclear how mutations affecting (3-catenin interact with mismatch repair gene mutations.
This thesis, therefore, seeks to examine the cell biology of the earliest manifestations of
neoplasia in mice congenitally deficient in Ape or mismatch repair (Msh2 function.
I have investigated the pattern of (3-catenin staining in a spectrum of apparently
normal epithelium from animals bearing mutations in Ape (the Min mouse), p53 and
Msh2 and compared this with patterns of Ape and E-cadherin protein
immunohistochemistry staining. In general, (3-catenin and E-cadherin expression was
found at the lateral intercellular membrane in all types of epithelium, whereas Ape
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staining was found in the cytoplasm of epithelial cells in each organ but also showed
strong positivity at the apical surface in intestinal epithelium. In animals bearing
heterozygous mutation of Ape, enhanced P-catenin expression was identified in
intestinal and pancreatic lesions in Ape Min+/~ and (Ape Mm+/~/p53 "/") mice and in a subset
of intestinal lesions in Msh2 mice.
This thesis characterised in detail the pattern of P-catenin expression in intestinal and
pancreatic lesions arising in mice singly or multiply mutant for Ape, p53 and Msh2.
These lesions were first graded on the basis of morphology. Overexpression of P-catenin
was found in the majority of early intestinal lesions arising on an Ape Min+/~ background.
In all categories of lesion studied mosaic patterns of P-catenin expression were observed
with the proportion of cells showing a decrease in staining intensity associated with
increasing lesion size. p53 status did not have any effects on these patterns. Mice mutant
for the mismatch repair gene, Msh2, also showed increased expression of P-catenin in
intestinal adenomas and microadenomas. However, in contrast with Ape M,n+/' mice, a
subset of these lesions retained apparently normal expression. P-Catenin upregulation
was also found in the pancreas in foci of histologically abnormal cells in Ape Min+/' and
(Ape Mm+/'/p53 ~A) mice. PCR analysis of microdissected materials confirmed that
P-catenin overexpression was consistently associated with loss of the remaining wild
type Ape allele. Subsequently analysis of these foci (see below) confirmed these cells to
be dysplastic, based on their aberrant nuclear volume. In the (Ape Ml"+/'/p53 _/") mice both
adenomas and adenocarcinomas of the pancreas arose and were characterised by an
increased staining intensity of P-catenin. Taken together, these findings demonstrated
that increased expression of P-catenin is an efficient marker of early neoplastic change
in both murine intestine and pancreas in Ape mutant mice. However, they also showed
that dysregulation of P-catenin is not an obligate step in the development of earliest
intestinal preneoplastic lesions: genetic events other than complete loss of Ape function
appear competent to initiate the transition from normal to neoplastic epithelium.
I have further analysed the nuclear volume of cells within lesions both in the intestine
and pancreas because an increase in nuclear size was noted in the first part of study. This
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was performed using both three-dimensional (3D) and two-dimensional (2D) imaging.
The nuclear volume analysis of intestinal lesions in all genotypes of mice showed only
small differences in nuclear volume in all types of lesions compared to wild type mice
and normal intestinal crypt nuclei (p<0.05). In contrast, there was a marked difference in
nuclear volume of cells within pancreatic lesions arising in each mutant background
when compared to wild type and adjacent normal pancreatic nuclei (p<0.05). The largest
increase in nuclear volume was associated with mice doubly mutant for Ape and p53
(Ape Mm+/~/p53 v~). These mice showed significant increases in nuclear volume in all
sizes of pancreatic lesions. The increase in nuclear volume observed in all genotypes
was most extreme in small lesions but the increase was less prominent in larger lesions
(p< 0.05), suggesting that lesions pass through a critical stage of instability during their
growth. The change in nuclear volume is extrapolated to reflect an increase in
chromosome ploidy, which is an early cellular event in carcinogenesis. In summary, an
increase in nuclear size is an early cellular phenomenon in carcinogenesis, which is
influenced by mutation of both Ape and p53 genes.
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This thesis provides a new view of the role in carcinogenesis of the oncosuppressor
protein Adenomatous Polyposis Coli (APC). The evidence for this view, unfolded in the
following chapters, is drawn from observations in mice bearing germ-line defects in Ape
and other genes, and studied by immunohistochemical, morphometric and molecular
pathological techniques. The underlying motive in these studies, however, is the
profound social and medical implications of disorders of APC in man, and in particular
their roles in the causation of colorectal cancer.
1.1. Human colorectal cancer
1.1.1. Incidence and Epidemiology
Adenocarcinoma of the colon and rectum is the second commonest malignant tumour
in males and the third commonest in females in the Western world. In Scotland, a
country of around 5 million inhabitants, there are 27,000 new cases every year (HMSO
1989) a situation that has remained unchanged for the past 2 decades. The overall
survival of affected patients has also remained unchanged, despite many high
technologies in diagnostic methods and in surgery, which is the mainstay of treatment.
In world wide, it has been estimates that there are at least half a million new cases every
year, but colorectal cancer is much rarer in the Southeast Asian countries which are
different in environmental factors associated with colorectal cancer risk. In the 1950's,
epidemiological studied of immigrants from Japan (at that time a low incidence area) to
Hawaii (a western community with dietary and social habits close to those of the United
States) showed the strong influence of environmental factors in the pathogenesis of this
disease. The incidence of colorectal cancer in the Southeast Asian communities has risen
steadily. Age-adjusted incidence, male and female ratio; in Japan is now 14.8:10.1 per
100,000; in Singaporean Chinese is 20.2:18.1 per 100,000; in Singaporean Malays is
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6.9:5.5 per 100,000; in Hong Kong Chinese is 21.7:16.7 per 100,000; figures close to
those of UK (17.1:14.6 per 100,000) and USA (32.1:22.6 per 100,000) (Parkin et al
1992). In Thailand, the incidence (5.5:3.7 per 100,000) is still much lower (Vatanasapt
et al 1993). Incidence in India is 3.2:2.6 (Parkin et al 1992). These data clearly
demonstrated the existence of environmental agents in the genesis of the disease, most
probably in the diet.
Adenomas are uncommon before the age of 30, but occur with increasing frequency
as progressively older. The average age at diagnosis is about 50 years. Adenomas are
more common in males in all regions of colon whereas adenomas in the right colon have
been noted to show more severe dysplasia in females (Morson et al 1990). Up to the age
of 55, cancer of the colon is more common in females and becomes slightly more
common in males after the age of 55. In high-risk areas the incidence of right-sided
colon cancer may be higher in females of all ages.
1.1.2. Natural history and histopathology
In the west, approximately 60% of primary colorectal cancers arise in the sigmoid
colon or rectum (Damjanov et al 1996). The transverse colon accounts for a further
25%. The ascending colon is a predilection site and it appears that the incidence of
cancer in the right colon is increasing. The tumours are most commonly moderately
differentiated adenocarcinomas, but a significant proportion usually situated in the
caecum or ascending colon, which are mucin secreting or poorly differentiated. Directly
metastasise to the local lymph nodes and by haematogenous routes to the liver
occasionally or other organs. At the time of diagnosis, approximately 15% of tumours in
patients are restricted to the mucosa, 35% have not completely penetrated the muscle
wall, 35% have affected lymph nodes identifiable after surgical removal and the
remainders more distant metastases (Morson et al 1990). Prognosis is dependent upon
the stage of the tumour at the time of detection. Very few patients with distant
metastases survive, indicating the generally ineffective character of chemotherapy and
radiation therapy. In contrast, survival of patients with intramucosal tumours is close to
100%, regardless of stage, this survival is around 30%, but shows no substantial further
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reduction after 5 years, which indicates that early, appropriate intervention can effect
cure.
There is substantial evidence that almost colorectal adenocarcinomas develop from
pre-existing premalignant lesions. The most clearly evidence of these is the adenoma,
but intraepithelial dysplasia has also been described, particularly in the relatively rare
subgroup of cancers arising in patients with ulcerative colitis. Adenomas are benign
tumours arising as local proliferations of intramucosal glands. Initially flat or berry-like,
they can compose of a stalk. Histologically, adenomas are classified as tubular,
tubulovillous and villous. In surgical material approximately 10% of adenomas are
villous, but in autopsy studies only 1% of adenomas are tubulovillous or villous
(Damjanov et al 1996). Adenomas may show mild or low-grade dysplasia. Adenomas
can gradually grow in size and change from a tubular to a villous structure. The cells
show severe or high-grade dysplasia followed by malignant change resulting in local
invasion with eventual metastasis to distant site.
The evidence that adenomas can develop to carcinomas, and that most carcinomas
arise in this way came initially from epidemiological and histological studies. In brief,
adenomas are six times as common in surgical specimens of colorectal cancer than in
length, age and sex matched colorectal specimens from patients without cancer;
adenomas occur at earlier age than carcinomas; adenomas are larger and more numerous
in high risk populations for colorectal cancer; a series of adenomas will show all grades
of dysplasia ranging from slightly different from normal through to carcinoma in sitir,
and removal of adenomas greatly reduces the incidence of cancer in the intestine.
Furthermore, histological analysis of adenoma sometimes shows small foci of
adenocarcinoma, while similar analysis of carcinomas shows foci of adenoma. Finally,
evidence from patients submitted to repeated sigmoidoscopy but without therapy, was
observed progression from adenoma to carcinoma. The most definitive evidence for this
progression, however, has come much more recently, though analysis of the molecular
genetic events that are associated with adenoma and carcinoma growth.
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1.1.3. Molecular genetics of human colorectal cancer
Following the discovery of oncogenes, human colorectal cancer was one of the first
human tumours have been analysed in detailed at the molecular level, and still remains
unclear. As adenomas enlarge, they accumulate clonal mutations in the Ki-ras oncogene,
notably when there is villous formation, a histopathological feature associated with risk
of progression to malignancy. Evidence of loss of heterozygosity at potential
oncosuppressor loci such as DCC in 18q, and of trisomy of specific chromosomes
(notably chromosome 7) also appears in the larger adenomas (Damjanov et al 1996).
Dissection of small foci of carcinoma arising inside adenomas shows that this transition
is often associated with severe disruption of genomic stability. Carcinomas tend to be
aneuploid in DNA content and have multiple sites of LOH. A high proportion shows








The majority of these observations were from separate analyses of benign and
malignant tumours, collected from large numbers of patients, some were collected by
microdissected complex tumours that contained both benign and malignant tumour.
There was remarkable confirmation of the evolution of carcinoma from adenoma,
associated with conservation in the carcinoma of the same mutation in Ki-ras as was










Outstanding among these changes in molecular genetic is mutation and loss of
heterogeneity of the oncosuppressor gene APC. This is observed in over 80% of all
colorectal tumours, benign or malignant, and with no difference in incidence with
tumour progression. The frequency with inactivation of APC function, although clonally
expanded defects in both alleles, itself suggests that APC deficiency is an essential early
step in the pathway leading through the genesis of adenomas to the development of
carcinoma. Definitive evidence both for the importance of APC deficiency in this
circumstance and the possibility that there may be more than one genetic pathway
leading to colorectal cancer comes from studies of human syndromes in which
susceptibility to colorectal tumours is inherited.
1.1.4. Inherited Colorectal Cancer susceptibility syndromes
1.1.4.1. Familial adenomatous polyposis (FAP)
Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited cancer-
predisposition syndrome that is usually linked to mutation of the adenomatous polyposis
coli gene (APC) that has been localised to 5q21. The disease is classically characterised
by the development, usually during the teenage years, of at least 100 adenomatous
polyps in the colorectum. Adenomatous polyps are neoplasms that range from small,
often pedunculated lesions to large neoplasms that are usually sessile. In FAP, the
adenomas develop shortly after puberty. By 17 years of age carcinomas may arise to the
larger lesions. By 25 years of age, over 80% of individuals have cancer. By 40, virtually
100% of individual have cancer unless a prior colectomy has been carried out. Males
and females are equally affected. All adenomatous lesions arose as the result of
epithelial proliferative dysplasia, which ranged from mild to severe as identified as
carcinoma in situ. Furthermore, there was strong evidence that almost of invasive
colorectal adenocarcinomas arose from adenomatous polyps. Patients with FAP may
develop gastric fundic gland polyposis (50% of cases), duodenal adenomas and gastric,
pancreatic, biliary or distal small intestinal neoplasms (Damjanov et al 1996). Numerous
extraintestinal lesions related with adenomatous polyposis. These include desmoid
tumours, exostoses of the long bones and endostoses (particularly of the mandible),
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which have been referred to as osteomas. Congenital hypertrophy of the retinal pigment
epithelium (CHRPE) characterised by a hyperpigmentation of the retina caused by
increased numbers of large pigment granules, central nervous system neoplasms, and
epidermoid cysts. The association of FAP, desmoids, and exostoses has been termed
Gardner's syndrome, whereas the combination of cerebral neoplasia and FAP is known
as Turcot's syndrome. These two syndromes have been linked to mutation of the APC
gene.
Familial adenomatous polyposis carries a very high risk of progression to colorectal
cancer. In the majority of patients with FAP, one germline allele of APC is mutated,
insertion or deletion resulting in a truncated and thus inactive APC product. A second
somatic event involving mutation or less frequently allele deletion of the remaining APC
allele within a somatic cell results in tumour formation. Somatic mutations of APC can
be detected in tumour DNA from more than two-thirds of sporadic colorectal neoplasms.
Therefore, in addition to a cause of a rare familial syndrome when inherited as a
germline mutation, the APC gene is an important target for mutation in the common
sporadic variety of colorectal cancer.
APC deficiency is associated with adenoma formation, and this is in complete
according to the information given earlier about its incidence in sporadic tumours.
However, there is another inherited colorectal cancer susceptibility syndrome, which has
important implications for our understanding of the genesis of human colorectal cancer
in general, and also for the experiments to be described in this thesis. This syndrome is
"
Hereditary Non-polyposis Colorectal Cancer, HNPCC ".
1.1.4.2. Hereditary Non-polyposis Colorectal Cancer (HNPCC)
Hereditary non-polyposis colon cancer (HNPCC) is a common autosomal
dominant syndrome characterised by early onset carcinomas of the colon as well as
cancers of the endometrium, stomach, upper urinary tract, small intestine and ovary
(Fynch et al 1991, 1993, Watson and Fynch 1993). Approximately 5% of cases of
colorectal cancer were attributed to two autosomal dominant inherited syndromes,
FAP and HNPCC. Most patients with HNPCC had germ-line mutations of one of the
mismatch repair genes (MMR) (Fiu et al 1996).
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The process of mismatch repair (MMR) was first proposed to explain the results of
experiments on genetic recombination and bacterial mutagenesis. In the subsequent
30 years, a considerable amount of information has accumulated on this process.
Mismatch repair has long been commonly accepted to play two major roles in the
cell: (1) the repair of errors made during DNA replication, or as the result of some
types of chemical damage to DNA and DNA precursors and (2) the processing of
recombination intermediates to yield new configurations of genetic markers. More
recent studies have suggested that mismatch repair also played additional roles: (1) in
the regulation of recombination events between different DNA sequences, which
could result in different types of genetic instability (Rayssiguier et al 1989); (2) in
some types of nucleotide excision repair responsible for repair of physical/chemical
damage to DNA and (3) as part of a cell cycle check point control system by
recognising certain types of DNA damage and triggering cell cycle arrest. Therefore,
the process of mismatch repair is responsible for the recognition and repair of base
pair mismatches and single strand insertion/deletion loops (IDLs) that arise in the
genome through a variety of mechanisms during DNA replication, recombination or
chemical modification.
DNA replication seems to be prone to a process known as slippage, where one
DNA strand can ride up over the other, in a manner reminiscent of a zip fastener that
becomes snagged because its links are not taken alternately from left and right which
results in replicative error of DNA. This slippage is more likely to happen in regions
of repetitive sequence and was thought to occur because DNA polymerases were less
able to process through these regions. In higher organisms, these repetitive sequences
are called microsatellites, they are often found in the protein encoding regions of
many eukaryotic genes. Repetition in a microsatellite was based on a single base
"poly A", two bases (CA)n or three or more bases. When there was alteration in
microsatellite size somatically in tumour cells compared with normal tissues it was
termed "replication error, RER" (Aaltonen et al 1993, Peltomaki et al 1993, Aaltonen
et al 1994). However, when multiple microsatellites were seen affected, this process
was termed microsatellite instability. The importance of microsatellite instability as a
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mechanism in human carcinogenesis first became apparent with the study of a rare
dominant cancer predisposition syndrome, hereditary non-polyposis colorectal cancer
(HNPCC). DNA mismatch repair (MMR) is the form of DNA repair responsible for
the correction of mismatched and/or unmatched bases, as reviewed by Jiricny (1998).
The discovery of microsatellite instability in tumours and cell lines derived from
HNPCC patients (Ionov et al 1993, Peltomaki et al 1993, Aaltonen et al 1993,
Thibodeau et al 1993) and the knowledge that MMR mutations destabilised simple
repeats in yeast (Strand et al 1993) suggested that mutations in human homologues of
MMR components was involved in human cancer. This notion was confirmed when a
human homologue of bacterial mutS and yeast MSH2 was cloned and found to be
mutated in some HNPCC families (Fishel et al 1993, Leach et al 1993). Mutations in
human MSH2 were detected in approximately 50% of HNPCC kindreds (Liu et al
1996). hMSH2 is a member of a family of proteins that are homologous to the
Escherichia coli MutS protein, which is responsible for the initial recognition of
mismatched nucleotides generated during DNA replication (Fishel et al 1993, Leach
et al 1993). It was known that mutations in hMSH2 were also responsible for the
Muir-Torre syndrome (Marra and Boland 1995), a variant of HNPCC characterised
by cutaneous tumour manifestations in addition to the tumour types characteristic of
the HNPCC syndrome.
Tumours arising in the patients with the hereditary non-polyposis colorectal
cancer syndromes (Lynch syndrome) may account for up to 13% of cancers of the
colon and rectum. Affected patients do not develop polyposis, but carry a high risk of
developing colorectal cancers as well as other neoplasms. A somatic mutation
inactivating the remaining normal allele occurs in tumour DNA, resulting in loss of
function of the gene and decreased surveillance and repair of DNA mismatches that
arise and are propagated upon cell division in a dividing cell. In the Lynch I
syndrome, patients develop colon cancer at an average age of 44 years predominantly
(70%) in the right colon. Patients with the Lynch II syndrome develop extracolonic
malignancies in addition. These include endometrial cancer, transitional carcinoma of
ureter and renal pelvis, and adenocarcinoma of stomach, small intestine, ovary,
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pancreas and biliary tract. For diagnosis, the Amsterdam criteria for assignment as an
HNPCC case: (1) there must be three affected relatives, one of whom is a first-degree
relative of the other two; (2) colorectal cancer must be present in at least two
generations; (3) one or more of the cancers must have developed before 50 years of
age (Damjanov et al 1996).
1.1.4.3. Implications of the cancer susceptibility syndromes for colorectal
carcinomas in general
The existence of these 2 inherited syndromes, with their very different clinical
presentations, posses important questions on the ongoing of colorectal tumours and their
progression to malignancy. Do the tumours that arise in HNPCC patients start as
adenomas? Why does the tumour syndrome in HNPCC involve adenomas in small
numbers only, but sometimes more than one carcinoma, whereas the FAP syndrome is
characterised by hundreds or thousands of adenomas before a single carcinoma develop?
Are these rapidly progressing and more slowly progressing adenomas? And do these
questions have relevance to the evolution of sporadic colorectal cancer also? As these
questions lie close to the central themes of this thesis, they are discussed further now.
(i) APC is mutated in HNPCC adenomas in man
In HNPCC cancers, somatic mutation or promoter methylation of the wild type
allele results in complete loss of mismatch repair function and consequently the
cancers, which develop are characterised by microsatellite instability. Loss of
mismatch repair results in an increase in the mutation rate and RER+ tumours.
Approximately 10-15% of sporadic colorectal cancers is found to be RER+.
Microsatellite instability is not seen in normal intestinal epithelium in the patients
with HNPCC and is present in only 50% of HNPCC associated adenomas as opposed
to over 90% of HNPCC colorectal cancers (Aaltonen et al 1993, 1994). Thus, loss of
mismatch repair function does not give a selective advantage in normal epithelium or
in early adenomas. This suggests that tumour initiation and early development
involve the usual steps of mutation in APC. This appears to be the case, since the
frequency of APC mutations appears to be similar in both sporadic and HNPCC
associated colorectal tumours (Aaltonen et al 1993). The pattern of mutation in APC
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may be different and one study has found significant higher frequencies of mutation
at short mononucleotide repeat sequences in the APC gene in HNPCC associated
cancers (Huang et al 1996). This suggests that, somatic mutation or loss or down
regulation by methylation of the wild type allele of the mismatch repair gene may
have occurred before APC mutation.
(ii) p53 is frequently involved in colorectal cancer
Mutations in p53 are also associated with the development of aneuploidy. Mutations
in p53 gene are found in colorectal and pulmonary carcinomas in patients with
Li-Fraumeni syndrome (Birch 1990). Aneuploidy does not alter gene function but only
change gene dosage. Many cellular functions can certainly be radically altered simply by
changes in gene dosage but dominant oncogenes and many tumour suppressor gene
effects depend on function changing mutations so that chromosomal imbalance itself
cannot be the primary mechanism of genetic change in tumour evolution.
(iii) These 2 pathways are represented in sporadic tumours; one with microsatellite
instability and mismatch repair gene deficiency; the other with chromosomal instability
and often p53 mutation.
Mutation of p53 gene has been shown to occur in the adenoma to carcinoma
sequence and most probably occur before metastasis. p53 mutations thus appear to mark
the transition from a benign adenoma to a malignant carcinoma and are found in up to
70% of sporadic colorectal cancers.
(iv) These 2 pathways, both involve APC mutations, but phenotype, location,
histology, and prognosis of patients are different.
One hypothesis to draw together these observations in man may be stated as follows:
• APC is gateway to adenomagenesis
• A higher than normal mutation rate is required for onwards progression to carcinoma
• In the presence of mismatch repair gene deficiency this is achieved through
nucleotide mutations, frameshift mutations as a germ line defect, progression to
carcinoma will rapidly follow onset of critical APC deficiency that permits adenoma.
• In contrast, other means of acquiring high mutation rate may require separate genetic
events. Loss of p53 function, for example, would be permissive for cell survival (and
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replication) following double strand breaks, and so increase the likelihood
translocation, deletions and amplifications.
This thesis directly addresses the sequence of the assumptions underlying this
hypothesis. It asks: (1) Does lose of APC itself alter the stability of the genome, or is
coincident p53 null or Msh2 null status obligatory? (2) Is there an alternative gateway to
adenoma formation that does not involve APC knockout?
These questions are to be addressed through use of murine models in which there are
germ line deficiency of Ape, p53 and Msh2 alone and in combination. Before discussing
these models, however, it is relevant to give more detail of the molecular actions of these
3 genes.
1.2. Molecular actions ofAPC, p53 and Msh2
1.2.1. APC gene
a) Structure
The APC gene was mapped to human chromosome 5q21 and mouse chromosome
18. APC is a large gene originally described as consisting of 16 exons, one noncoding
and 15 coding (Groden et al 1991), and is expressed in all tissues analysed. The APC
is a 310 kDa cytoplasmic protein (Smith et al 1993) expressed in epithelial cells in
the upper portions of the colonic crypts, suggesting that it functioned in the mature
colonocyte (Smith et al 1993). Structural analysis of the APC protein reveal it
consists of 2844 amino acids organised into several different domains associated with
different functions. Amino-terminal 171 amino acids function in oligomerisation, the
amino-terminal third of the APC protein contains a series of heptad repeats that are
characteristic of amino acid sequences predicted to form coiled-coil structures
mediating protein-protein interactions. These repeats have been shown to mediate the
oligomerisation of APC in vitro (Su et al 1993, Joslyn et al 1993). The central part of
the protein contains 42 amino acid motif that is repeated 13 times. These include
heptad repeats and Arm repeats, as well as sites for phosphorylation and for
complexing with P-catenin. The sequence of 15 amino acids, repeated three times
between APC amino acid 1020-1169, represented a unique motif for P-catenin
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binding. The sequence contains a series of 7 motifs of the 20 amino acids represents
P-catenin binding and down regulation. The C-terminal third of the APC protein
contains approximately 200 amino acids originally referred to as the basic domain. It
is the C-terminal region of APC that contained sites that able to bind the tubulin
cytoskeleton in epithelial cells (Munemitsu et al 1994). This region also contained
site for binding EB-1 protein at 284 residues of the C-terminus (Su et al 1995), the
human homologue of the Drosophila discs large tumour suppressor protein (DLG)
located at the extreme C-terminus, 72 amino acids, of the C-terminus and possibly
p34cdc2 (Matsumine et al 1996, Trzepacz et al 1997).
The spectrum of mutations that occur in FAP and sporadic colorectal cancer reveal
more biological information about tumour development. Although mutations of APC
probably occur along the whole length of the molecule, only those mutations that
were advantageous would be selected. Both germline and sporadic APC mutations
tend to occur in the 5' part of the gene and result in a truncated protein (Nakamura
1993). In sporadic tumours, over 60% of the mutations were found between codons
1286 and 1513 which accounted for less than 10% of the coding part of the gene and
is termed the mutation cluster region (MCR) (Nakamura 1993). The MCR is located
near the P-catenin binding sites, mutations which occur here resulted in truncated
proteins which may bind to, but which are unable to promote degradation of p-
catenin (Peifer 1996, Munemitsu et al 1995).
Structure ofAPC




Cell fractionation studies showed that the APC protein occurred in the
cytoplasmic, membrane/skeletal fraction and nuclear fraction (White 1997). By using
HT-29, a colorectal cell line contained no intact APC protein and widely used for
experimental studies (Morin et al 1996), demonstrated that both EB1 and (3-catenin
were simultaneously bound to full-length APC in vivo, strongly imply the functional
interaction between these genes. They also found that the expression of APC in
HT-29 cells inhibited cell growth through increased apoptosis and the apoptosis
observed is p53-independent (Morin et al 1996).
EB-1 is a 30 to 35 kDa protein. EB1 binds to the carboxyl terminal domain of an
APC tumour suppressor protein and has recently been shown to be a component of
the microtubule cytoskeleton in mammalian cells and to be associated with the
mitotic apparatus. These observations may provide a physiological connection
between Ape and cellular division (Berrueta et al 1998). EB1 has been shown to be
localised both to cytoplasmic microtubules in interphase cells and to the spindle
microtubules during mitosis (Berrueta et al 1998). Localisation of EB1 with the
centrosomes and attachment to microtubules was visualised during prophase and
prometaphase and association to cytoplasmic microtubules was observed in anaphase
and telophase (Berrueta et al 1998, Morrison et al 1998).
Rubinfeld et al (1996) showed that when (3-catenin is present in excess, APC was
phosphorylated by GSK3(3 which resulting in degradation of (3-catenin via ubiquitin-
proteasome pathway (see details in section 1.4.2).
DLG tumour suppressor protein was identified as the human homologue of the
Drosophila discs large tumour suppressor protein. DLG protein was localised to the
cell-cell contact in epithelial cells where its interaction with cytoskeletal protein. It
was demonstrated that both APC and hDLG were concentrated at sites of synaptic
density in rat hippocampal neurons and at sites of cell-cell contact in epithelial cells
(Matsumine et al 1996), which suggested that the APC-DLG complex may
participate in regulation of both cell cycle progression and neuronal function.
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c) Function
Although APC function remains unclear there is now evidence that the APC
protein participates in a number of cellular processes including cell cycle regulation,
apoptosis, cell adhesion, cell migration, microtubule assembly and cell fate
determination (Munemitsu et al 1996, Baeg et al 1995, Rubinfeld et al 1995, Morin
et al 1996, Nathke et al 1996). Expression of APC has been reported to inhibit the
proliferation of fibroblasts by blocking progression into S phase of the cell cycle
(Baeg et al 1995), and APC was found to regulate passage through the Gi phase in
human colon cancer cell lines (Heinen and Groden 1999). A role has also been
proposed for that APC protein function in regulation of intestinal crypt fission and
cell proliferation in both the normal intestine of human familial adenomatous
polyposis patients and mice mutant for Ape (Ape Mm) (Wasan et al 1998). The first
reports on the intracellular localisation of APC came from experiments using
transient overexpression in various cell lines. In these studies the ectopically
expressed wild type APC colocalised with the microtubule network, whereas a
truncated APC, representative of that expressed in colon cancer cells, did not (Smith
et al 1994, Munemitsu et al 1994). Subsequently, it was reported that wild type APC
is present in highly concentrated clusters localised to actively migrating regions of the
cell membranes, with microtubules extending into the clusters (Nathke et al 1996,
Neufeld and White 1997). Others reported the Ape protein to be highly expressed in
developing rodent brain and to function in regulating microtubule dynamics
(Morrison et al 1997). It was concluded that APC might contribute to the process of
epithelial cell migration.
APC has also been implicated in the Wnt signalling pathway, through
modification of the levels of P-catenin. APC protein forms complex with P-catenin
and subsequently is phosphorylated by GSK3P, which enhance the degradation of
P-catenin by ubiquitin proteasome pathway. This role of APC in the Wnt signalling is
discussed in much greater details in section 1.4.1.
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1.2.2. p53 gene
Roles for the p53 protein have been suggested in many and varied cellular
processes, including DNA repair, recombination, differentiation and senescence. A
large body of data suggested that p53 suppressed growth through two mechanisms,
cell cycle arrest and apoptosis. Loss of function of p53 gene is associated with many
inherited and sporadic forms of malignancy in man.
a) Structure
The p53 gene is located on human chromosome 17pl3 and encodes 53 kDa
nuclear phosphoprotein. The p53 protein can be divided into three regions:
a. The amino terminal which contains a large number of acidic residues, no basic
residues and a large number of amino acids (including many Pro-Pro pairs);
b. The carboxy terminal which is very hydrophilic and contains many charged
residues;
c. The central region of the protein which contains several very hydrophobic regions
and very few charged amino acids.
The amino terminal region contains 72 amino acids (Fields and Jang 1990,
Raycroft et al 1990), which is transcriptional activation domain. The carboxy
terminus is a basic region, which is important in facilitating tetramerization. The
tetramerization regions composed of two domains, one a a-helix whose hydrophobic
amino acids are directly involved in protein-protein interaction, and the other is a
basic region, which stabilises the tetramers (Sturzbecher et al 1992, Clore et al 1994).
The tetramerization region also contains one or more nuclear localisation signals,
which are important in directing the subcellular compartmentalisation of p53
(Shaulsky et al 1990a). Recently, evidence showed that the central region contained
the domain that bound to DNA and, more particularly, to the target DNA sequences
of p53. Thus the central region and carboxy terminal of p53 protein are important in




The p53 gene product is a multifunctional protein, which plays roles in
modulating gene transcription, recognising cell cycle checkpoints, activating
apoptosis, controlling DNA replication and repair, maintaining genomic stability and
responding to genetic insults (Elledge and Lee 1995).
Most evidence suggests that p53 functions as a transcription factor: p53 possesses
sequence-specific DNA-binding activity and can activate the transcription of genes
that carry a target element within their promoter (El-Diery et al 1992). p53 activates
the transcription of genes involved in the induction of both growth arrest and
apoptosis through transcriptional activation of MDM2, p21/WAF-l/CIP-l and bax,
(White 1996, Oliner et al 1992) and perhaps other genes as well. p53 induces the
transcription of its own negative regulator MDM-2, which then serves as a negative
feedback loop to turn off the activity of p53 (Momand et al 1992) by binding of
MDM2 to the p53 amino domain (Oliner et al 1993).
p53 has been shown to induce both growth arrest and apoptosis, although either
response has been shown to be influenced by the physiological circumstances or cell
type. Thus genotoxic insults such as chemotherapy and radiation are known to induce
cell death through p55-dependent pathways (Clarke et al 1993) but not all cell types
exhibit p53 dependent apoptosis following y-irradiation induced DNA damage
(Clarke et al 1994). In addition to the role of p53 in Gi growth arrest and apoptosis,
p53 also plays a role in the control both of the Gi and S checkpoints and the G2 and
M checkpoints of the cell cycle (Mercer et al 1990). The response of epithelial stem
cells of the small intestine suggested that p53 might play a role in the deletion of
damaged cells with carcinogenic potential, whereas this process was limited in the
colon (Merritt et al 1994).
At the protein level, the wild type p53 gene product does not accumulate in
amounts that could be detected by immunohistochemistry because of a short half-life
of 6-20 minutes. However, it can be stabilised by DNA damage, which extend half-
life to 6 hours (Leahy et al 1996). Mutant p53, which is functionally inactive and
stabilised, could be detected in the nucleus of the cell (Leahy et al 1996). It has been
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shown that expression of both mutant variants of the mouse p53 gene significantly
increased the cellular resistance of haematopoietic cell lineages to y-irradiation (Lee
and Bernstein 1993).
The cellular localisation of the p53 protein varies during the cell cycle in serum-
stimulated, non- transformed Balb/c 3T3 cells. The protein is found in the cytoplasm
during Gj, entering the nucleus during the Gj/S transition where it remains until the
end of the G2/M phase. After DNA synthesis, it is found again in the cytoplasm
(Shaulky et al 1990b). However, in transformed or tumour cells, the p53 protein is
predominantly seen localised to the nucleus. These observations suggest that the
progression of the cell cycle required p53 protein. Abnormalities in chromosome
segregation and mitotic delay following irradiation in p53 deficient mice was also
reported (Bouffler et al 1995), which suggested a G2/M checkpoint role for p53.
The p53 tumour suppressor gene is the most frequently mutated gene in human
tumours and reintroduction of p53 into transformed cells can induce either growth
arrest or apoptosis (White 1996). Thus, p53 aberrations can contribute not only to
tumorigenesis but also to resistance to radiation and chemotherapy. However, the
resistance to radiation and chemotherapy in rapidly dividing tumours is not solely
dependent upon the states of p53. For example, Bcl-2, which is known to be to
involve in cell survival as an anti-apoptotic signal is often highly expressed in
tumours which are resistant to chemotherapy, and has been shown to confer
resistance to cell death normally induced by a variety of chemotherapeutic agents
(cited by Hoffman and Liebermann 1994). In addition, Bcl-2 suppresses p53-
dependent as well as y>53-independent pathways (Wang et al 1993). Thus, a
pharmacological attack targeted to the checkpoint sites of cell death may be critical
for effective cancer therapy.
1.2.3. MSH2 gene
Mutation of the mismatch repair genes hMSH2 and hMLHl have been found in a
high proportion of individuals with hereditary nonpolyposis colon cancer (HNPCC).
The pairing of mismatched nucleotides occurs by polymerase misincorporation, by
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damage to nucleotide precursors, by damage to DNA and during genetic
recombination (Friedberg et al 1995). Mismatch repair differs from nucleotide and
base excision repair in that the components of the system recognises normal
nucleotides that are either mispaired or unpaired, rather than recognising abnormal
nucleotides (Fishel and Kolodner 1995). The most extensively characterised MMR
system was the DNA adenine methylase instructed MutHLS pathway in Escherichia
coli (Modrich 1991). In this pathway, mismatches and small insertion/deletion loops
(IDLs) were initially recognised and bound by the MutS protein. Mismatch-bound
MutS formed a complex with the MutL protein, which was required for the activation
of MutH, a latent endonuclease that generates a nick in the newly synthesised DNA
strand, from which the excision and repair of the lesion took place. MutL was
therefore believed to act as a molecular matchmaker in coupling mismatch
recognition by the MutS to MutH activation (Sancar and Hearst 1993). Mutations in
components of MMR led to an increase in the spontaneous mutation rate, giving rise
to a mutator phenotype. The MutHLS system of bacteria appears to have been
conserved throughout evolution (Fishel and Kolodner 1995).
Two lines of experimentation indicate that eukaryotes had a broad-spectrum
mismatch repair system related to the bacterial MutHLS system. A series of genetic
studies led to the identification of eukaryotic homologues of the bacterial mutL and
mutS gene products (Reenan and Kolodner 1992); and biochemical studies of
eukaryotic cells demonstrated in vitro nick-directed mismatch repair reactions had
mechanisms similar to those catalysed by the E. coli MutHLS system (Fang and
Modrich 1993). More recently, biochemical fractionation studies have led to the
purification of eukaryotic homologues of the bacterial MutL and MutS proteins
(Drummond et al 1995). In the yeast, MSH2 recognised mismatched nucleotides as a
heterodimer with G/T-binding protein (Drummond et al 1995) and MSH3 and MSE16
appeared to modify the specificity of this recognition. Furthermore, although they
demonstrated binding of MSH2 alone to DNA containing mismatched nucleotides or
lesions binding appeared to be an order of magnitude lower than where MSEL2 was
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complexed with either MSH3 or MSH6 (Alani et al 1995, Fishel et al 1994a, Fishel et
al 1994b).
In human cells, it is clear that the post-meiotic segregation phenotype was closely
linked with mismatch repair and thus implied an important role for this process in
meiotic recombination. The characterisation of the S. cerevisiae MutS and MutL
homologues (MSFI and MLH respectively) made possible the identification of human
MMR genes (Leach et al 1993, Fishel et al 1994a, 1994b, Nicolaides et al 1994,
Papadopoulos et al 1994, Kolodner et al 1995). To date, germ-line mutations in four
mismatch repair genes have been shown to be associated with HNPCC: hMLHl
(Bronner et al 1994), hPMSl and hPMS2 (Nicolaides et al 1994) and hMSH2 (Leach
et al 1993, Fishel et al 1993). It has been estimated that approximately 50% of the
HNPCC kindreds are associated with germ-line mutations in hMSH2 (Borresen et al
1995, Miyaki et al 1995, Froggatt et al 1995). Furthermore, it appears that the
majority of both HNPCC and sporadic tumours that displayed microsatellite
instability had mutations in either hMSH2 or hMLHl, whereas mutation in hPMSl,
hPMS2, hPMS3, and hPMS6 accounted for a small fraction. This leave 10-40% of
sporadic microsatellite unstable tumours still unaccounted for (Borresen et al 1995,
Liu et al 1995, Liu et al 1996). During the past three years, six components of the
human mismatch repair system have been cloned (Fishel et al 1993, Leach et al 1993,
Bronner et al 1994, Nicolaides et al 1994, Palombo et al 1995). These were hMSH2
(human mutS homologue 2), hMLHl (human mutL homologue 1), hPMSl and
hPMS2 (human homologues of mutL) and hMSH6 [a human mutS homologue,
originally named GTBP (G/T-binding protein/pl60)]. There is other human mutS
homologue, hMSH3 (dup-1), role in mismatch repair is so far unclear (Fujii and
Shimada 1989, Fishel and Kolodner 1995, Drummond et al 1997, Marra et al 1998).
All MutS homologues characterised to date are highly conserved at their C-terminal
regions, which contain the consensus ATP-binding site. Assuming that, following
binding at the mismatch site, hMutSa (heterodimers of hMsh2 and hMsh3) undergoes
an ATP-dependent conformational change and translocates along the double helix in
a manner similar to the MutS homodimer, thereby generating a looped structure, it
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would be predicted that ATPase-defective mutants would be MMR deficient
(Iaccarino et al 1998).
The recent discovery of MMR defects in hereditary cancer syndromes and in
sporadic tumours of various types has provided strong support for the role of
mutations in cancer development. Two lines of evidence suggested that hMSH2 was
one of the HNPCC genes. First, it mapped to the same chromosomal position as the
markers linked to the disease. Second, phenotypic instability, a characteristic of
mismatch repair defects, was found in tumours from these patients. Current data
suggested that hMSH2 was one of the major HNPCC genes, causing 30-40% of all
cases (Fishel et al 1993, Leach et al 1993, Liu et al 1996), but three other
components of the human mismatch repair have also been cloned and shown to be
mutated in the germline of HNPCC patients. The most important of these genes,
hMLHl, mapped to chromosome arm 3p and accounted for an additional 30% of the
germline mutations in HNPCC families (Bronner et al 1994, Papadopoulos et al
1994, Liu et al 1996, Tannergard et al 1996). The two hPMS genes, which mapped to
chromosome arms 2q (hPMSl) and 7p (hPMS2), have been found mutated in the
germline of a few HNPCC patients (Nicolaides et al 1994, Liu et al 1996).
The use of small animals as models for tumorigenesis in a controlled experimental
manner has been a mainstay of cancer research for long period of time. The mouse
model may offer the most profound lessons to understanding human cancer. It is now
well documented that different mouse strains exhibit markedly different propensities to
cancer, whether they are spontaneous or induced. Mouse genetics offer the opportunity
to identify the loci and genes responsible for altered penetrance or expressions of cancer
phenotypes. However, the development of molecular genetic techniques to identify
specific cancer associated gene lesions, combined with breakthroughs in the
manipulation of the germ line of mice, have greatly facilitated the generation of
powerful new models for understanding the mechanistic roles of specific genes in cancer
initiation and progression.
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1.3. Murine models of oncosuppressor gene deficiency
There are many strains of mouse developed as model for human colorectal cancer.
Much of the attention today in colorectal cancer susceptibility was focused on tumour
initiation events. The availability of reliable mouse models for initiation now allows the
researchers to focus on genes involved in progression of cancer.
1.3.1. Mouse model for Ape gene study: The Min mice
The Min (multiple intestinal neoplasia) mouse is an important mouse model of
human intestinal polyposis syndromes such as familial adenomatous polyposis (FAP)
and Gardner's syndrome (Shoemaker et al 1997, Moser et al 1990). The Min mouse
is heterozygous for a nonsense allele at codon 850 of Ape gene, the mouse
homologue of APC (Su et al 1992). The Min mutation was discovered by phenotypic
screening after random germ-line point mutagenesis with ethylnitrosourea (ENU),
which is point mutagen (Moser et al 1990). The allelic Ape loss in Mm-induced
adenomas involved somatic hemizygosity of chromosome 18 (Justice et al 1992,
Luongo et al 1993, Luongo et al 1994). Min mice displayed an anaemic phenotype,
which was traced to bleeding from multiple polyps in the intestine (Moser et al
1990). The phenotype of these mice differed from the human FAP phenotype in a few
aspects. In the Min mice, tumours occurred in the small intestine whereas in human
FAP patients, the majority of tumours developed in the large intestine (Bilger et al
1996). In addition, about 10% of female Min mice developed mammary tumours,
which has not been seen in human FAP patients (Moser et al 1993). The incidence of
polyps in Min mice varied greatly depending on the strain background and if polyps
were left untreated, they become invasive (Moser et al 1992). On a C57B1/6
background, Min mice developed approximately 30 tumours in their intestine,
whereas on a mixed AKR x C57B1/6 background, this number decreased to an
average of about six tumours and the mice lived longer. These results suggested that
AKR strain of mice carried genes that acted to reduce polyp formation in Ape Mm
mice. The neoplastic phenotype of Ape Mm heterozygotes was expressed in the
intestinal epithelium of sensitive animals with 100% penetrance. On resistant
34
backgrounds, longer-lived animals also developed other types of neoplastic lesions,
including mammary adenocarcinomas (Moser et al 1993). The penetrance of these
lesions was far less than 100% of Ape Mm animals. However, the penetrance could be
increased even on the short-lived sensitive genetic background by appropriately timed
somatic ethylnitrosourea (ENU) treatment (Moser et al 1993). A second class of
neoplastic lesion in non-endodermal tissue was the desmoid fibrosarcoma, found in
the peritoneal muscle wall. In the mouse, as in human a heterozygous defect in the
Ape or APC gene predisposed to a broad range of hyperplastic and neoplastic lesions
in an embryonically diverse range of tissues.
Adenomas in human FAP kindreds differ from those in the Mm mouse in two
respects:
1. The loss of function of the normal allele occurs by intragenic inactivating
mutations or interstitial deletions in human, but by loss of the entire chromosome
in the mouse: and
2. Loss has been detected in no more than 71% of tumours in the human, but in
100% in the mouse.
The overall conclusion from these studies was that adenoma formation in the Min
mouse required loss of normal Ape function. Because Ape loss correlated completely
with adenoma formation, this gene qualifies as a tumour suppressor gene controlling
at least tumour establishment. Accordingly, restoration of wild type activity should
prevent tumour formation.
By backcrossing Min mice from the AKR x C57B1/6 background to pure
C57B1/6 and using simple sequence length polymorphisms (SSLP), the Min
modifying locus was mapped to chromosome 4 and controlled about 50% of genetic
variation in tumour number in two intraspecific backcrosses (Dietrich et al 1993).
The locus was named Mom-1 for modifier of Min 1, it was found to lie in the region
of synteny conservation with human chromosome Ip36-p35, a region of frequent
somatic loss of heterozygosity in a variety of human tumours, including colon
tumours. When the AKR allele of Mom-1 was transferred onto the sensitive C57B1/6
background, the tumour incidence in Ape Min\ Mom-1AKR/Mom-l/11/6 was reduced
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two-fold. When both alleles of Mom-1 were derived from the AKR strain, the tumour
incidence was reduced four-fold (Shoemaker et al 1997). In the progeny of a cross-
involving Ape Mm and a targeted p53 mutant allele (Donehower et al 1992), the
multiplicity of adenomas in Ape in mice was independent of the p53 genotype (Dove
et al 1994). Defects in p53 caused aneuploidy in mouse embryo fibroblast cultures
(Carder et al 1993). Furthermore, as intestinal tumours progress in the human, p53 is
often mutated. The levels of p53 polypeptide were very low in the intestinal tract and
in adenomas (Purdie et al 1991), except after ionising radiation (Merritt et al 1994).
Other Ape mutant mice
Ape-deficient mice have been generated by gene targeting (Fodde et al 1994,
Oshima et al 1995). The targeting resulted in the truncation of the Ape gene product
at amino acid 716. The heterozygous mice developed multiple polyps throughout the
small intestine, which was similar to the phenotype seen in Min mice. Tumour
analysis indicated that the wild type Ape gene was lost during tumorigenesis (Oshima
et al 1995). The homozygous mice died in utero before day 8 of gestation, as has
been found in Min mice. Shibata et al (1997) used a conditional gene targeting
system, the Cre-loxP system, recombination mediated by the Cre recombinase deletes
a region of Ape encompassing exon 14 and induced a frameshift mutation at codon
580. LoxP sites were inserted in the introns 13 and 14 of the Ape gene by targeted
mutagenesis and mutant allele was introduced into the mouse germ line. Mice
homozygous for Apc-loxP insertion were normal. However, upon infection of the
colorectal region with an adenovirus encoding the Cre recombinase, which results in
excision of Ape specifically in Cre-loxP, the mice developed adenomas in the
colorectal region within 4 weeks. The adenomas showed deletion of Ape exon 14,
indicating that the loss of Ape function was caused by Cre-loxP-mediated
recombination (Shibata et al 1997).
Crossing between tumour suppressor gene knockout mice was also generated.
Mutation in Ape predisposed an individual to colonic adenomas, while p53 lack was
associated with the conversion from adenoma to adenocarcinoma. The ability of
mutations in both the Ape and p53 tumour suppressor genes to co-operate in the
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induction of induce intestinal tumour in the mouse was examined (Clarke et al 1995).
Mice heterozygous for Ape developed adenomas of both the small and large intestine
with a small percentage of cases progressed to adenocarcinomas. {Ape Mm/p53 y~)
mice have a shorter survival time because the high incidence of thymic lymphoma,
extra-thymic lymphoma, sarcoma and pancreatic abnormalities compared to
(.Apc+/+/p53 ~/_) and (Ape Mm/p53 v~) mice. Therefore, (Ape Mm/p53 mice have a
predisposition to pancreatic abnormalities, either preneoplastic foci/dysplasia or
pancreatic acinar cell adenocarcinoma. This is accompanied by loss of heterozygosity
(LOH) at the Ape locus, which supported a role for Ape in the genesis of extracolonic
cancers.
Furthermore, Reitmair et al (1996) analysed the phenotype of {Ape Mm/Msh2 v")
mice. They demonstrated that mice heterozygous for Ape and carrying a germline
defect in the Msh2 mismatch repair gene develop more and faster growing intestinal
tumours than mice carrying the Ape mutation alone. Additionally, whist adenomas
from the Ape Ml" mice all exhibit deletion of the wild type Ape allele while the
adenomas from {Ape Ml"/Msh2 v~) mice appeared to inactivate the wild type Ape allele
by somatic mutation. Taken together the above studies indicate that Ape is a target of
the RER phenotype in colon cancer.
1.3.2. Mouse model for mismatch repair gene, Msh2 deficiency: The Msh2 mice
In order to further characterise the function of Msh2 in a mammalian model
system, mice deficient for Msh2 have been generated using embryonic stem cell
technology (de Wind et al 1995, Reitmair et al 1995). Msh2 mice are susceptible to
lymphoid tumours at an early age (de Wind et al 1995, Reitmair et al 1995)
approximately 30% developed leukaemia/lymphomas between the ages of two to five
months and all succumbed to leukaemia/lymphoma within 12 months (Reitmair et al
1995). Cells isolated from the lymphoid tumours displayed microsatellite instability
as expected for MMR-deficient cells and extracts derived from Msh2 fibroblast
cells lacked mismatch binding activity and acquired microsatellite instability and
tolerance to methylating agents (de Wind et al 1995), which was present in wild-type
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and heterozygous cells. As expected, Msh2 deficiency resulted in mutator phenotype
as well as microsatellite instability in Msh2 cells and tissues. (The mutator
phenotype results from the mutator hypothesis of tumorigenesis which suggests that
loss of chromosomal stability or maintenance functions results in elevated mutation
rates, leading to the accumulation of the numerous required for multistep
carcinogenesis). In spite of the mismatch repair gene (MMR) defect, these mice are
known to be viable and fertile for at least three generations. This finding was
consistent with the discovery of HNPCC patients that appear to be deficient in MMR
throughout their somatic tissues (Parson et al 1995). This high incidence of early
onset lymphoma might simply reflect the exacerbation of a natural predisposition to
lymphoma in this particular inbred background (Teich et al 1984). Alternatively, it
has been proposed that the high incidence of lymphoma in Msh2 mice might be
partly due to increased translocations in lymphoid tissues due to higher
recombination rates between diverged retroviral sequences dispersed throughout the
mouse genome (Reitmair et al 1995).
Ape Ml" mice were crossed with Msh2 +/~ mice to generate offspring bearing defects
in Ape and Msh2 gene. Interestingly, approximately 70% of the (.Ape Mm/Msh2 v~)
mice that survived to six months began to develop gastrointestinal tumours and
approximately 7% of the (Ape Mm/Msh2 "/") mice developed keratoacanthoma, which
is one type of skin tumours, that were associated with the inactivation of the Ape gene
(Reitmair et al 1996). This mouse model can be used as a model system for HNPCC
if the leukaemia/lymphoma phenotype could be suppressed.
Biochemical analyses revealed that on the cellular level one mismatch repair gene
mutation (heterozygous condition), as opposed to homozygous inactivation, did not
severely affect mismatch repair (Parsons et al 1993) and animal studies have shown
that Msh2 v" mice led to predisposition for cancer (Reitmair et al 1995). In addition to
colorectal cancer, many families had an excess incidence of adenocarcinoma of the
endometrium. Cancer of the stomach, ovary, small intestine and pancreas, as well as
transitional cell carcinoma of the ureter and renal pelvis, were found less frequently
(Mecklin et al 1986, Lynch et al 1988, Vasen et al 1990, Lynch et al 1993, Watson
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and Lynch 1993, Lynch and Lynch 1994). Msh2 deficiency resulted in the
development of many colonic aberrant crypt foci, as well as reduced survival of the
mice, secondary to both a greater number and more rapidly developing adenomas. In
what was assumed to be a direct consequence of failure of this process, microsatellite
instability was increased in murine Msh2 cells. However, the consequences of
Msh2 deficiency were complex, with Msh2 cells also showing hyper-recombination
and increased survival after exposure to methylating agents in vitro (de Wind et al
1995). This property suggested that Msh2 status might affect the ability to undergo
apoptosis, with increased resistance to methylating agents arising from failure to
detect damage and hence initiated apoptosis. Results from several different tumour
cell lines deficient in mismatch repair were consistent with this hypothesis (Karran
and Bignami 1994). Toft et al (1999) characterised an in vivo Msh2-deficient
apoptotic response to methylating agents and raised the possibility that Msh2
deficiency might predispose to malignancy not only through failure to repair of
mismatch DNA lesions but also through the failure to engage apoptosis. The
mechanism of inactivation of the wild type Ape allele depended on Msh2 status
(Reitmair et al 1996). DNA mismatch repair was a post-replicative process that
corrected DNA polymerase insertion errors that have escaped proofreading. It was
known to operate in mammalian cells, although the detailed mechanism was best
understood in E. coli.
1.3.3. Mouse model for p53 deficiency: Thep53 knockout mouse
The p53 tumour suppressor gene is more frequently mutated in human cancer than
any other known gene. In some types of tumours such as colon carcinomas, p53 was
mutated in greater than 80% of cases (Baker et al 1990). Most p53 mutations
occurring in human tumours were point mutations mapping to the DNA binding
domain of the p53 protein (Hollstein et al 1991). Since the importance of the p53
gene in cell cycle control and cancer prevention, development of a mouse model was
an obvious priority. Three research groups generated p53 null mouse strains
independently by gene targeting techniques (Donehower et al 1992, Jacks et al 1994,
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Purdie et al 1994). The majority of p53 null mice developed normally. However, a
fraction of the female null embryos display defects in neural tube closure resulting in
an overgrowth of neural tissue in the region of the mid-brain, a condition known as
exencephaly (Armstrong et al 1995). The first reported p53 knockout mouse strain
was one in which parts of intron 4 and exon 5 of the p53 gene were replaced with a
neo cassette, such that p53 conserved region II and consequently the DNA-binding
domain was disrupted (Donehower et al 1992). Other groups created a mutation that
deleted the region between p53 exons 2 and 6, replacing it with a neo gene expression
cassette, equivalent to approximately 40% of the coding sequence (Clarke et al 1994,
Jacks et al 1994).
Analysis of all those three strains of p53 null mice gave rise to the same
conclusions (reviewed in Macleod and Jacks 1999):
(1) p53 was generally not required for normal embryonic development (Donehower
et al 1992, Jacks et al 1994, Purdie et al 1994);
(2) p53 null mice were predisposed to cancer, all three strains of p53 null mice
developed lymphomas predominantly and sarcomas to a lesser extent
(Donehower et al 1992, Jacks et al 1994, Purdie et al 1994). Donehower's mice
were analysed on 75% C57B1/6: 25% 129/SV genetic background. At 10 months
of age all mice had developed tumours or died with an average tumour latency of
4 to 5 months. More than 70% developed either thymic lymphoma or generalised
B cell lymphoma. The surviving mice were predominantly affected by sarcomas
of varying types such as osteosarcoma, haemangiosarcoma and undifferentiated
sarcoma. There were also rare cases of mammary gland carcinoma. Similar
results were observed by Jacks et al (1994) after deletion of exons 2 to 6 in mice
on the same genetic background: 75% C57B1/6: 25% 129/SV. Thymic lymphoma
was the predominant tumour type and various types of sarcoma were observed in
the remaining mice. However, carcinomas were not observed in these mice,
although several cases of teratoma were found. In the third study of p53 null
mice, Purdie et al (1994) analysing a similar p53 null mutant to Jacks et al (1994)
(deletion exons 2 to 6) in mice on a different genetic background, 129/Ola. Very
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similar results were observed despite the difference in genetic background, most
mice died from thymic lymphomas and a small number of mice died from
sarcomas. There was a slight decrease in tumour latency on the 129/Ola
background. However, Purdie et al observed pituitary adenocarcinomas in their
p53 null mice these were not seen by Donehower et al or Jacks et al,
(3) Other genetic events were probably involved in tumour development since the
average tumour latency was about 4 to 5 months;
(4) p53 heterozygotes developed a different spectrum of tumours to p53 null mice;
predominantly sarcomas of varying types and a small number of
adenocarcinomas. Lymphomas were observed at a much lower frequency in p53
heterozygotes than in p53 null mice (Purdie et al 1994).
(5) Reduction in p53 gene dosage might be enough to drive tumorigenesis in some
tissues; Donehower et al (1992) and Purdie et al (1994) observed that there was
only about 50% of tumours in the p53 heterozygous mice showed LOH at the p53
locus.
1.3.4. Multistep in carcinogenesis in mouse models
a) Apc,p53 and Ki-ras gene interaction
APC inactivation is an early event in the genesis of colorectal cancer followed by
activation of ras and loss of p53 and DCC or related genes. Mouse models have been
used to examine the cooperativity of both oncogenic ras and inactivation of p53 with
APC mutations in tumour formation. In one study the ectopic expression of
oncogenic Ki-ras plus inactivation of p53 resulted in proliferation of gut epithelium
but not promote the formation of adenomas (Kim et al 1993). When this was
superimposed on a mutant Ape background, the number of tumours was only
modestly increased above that observed with the mutant Ape mouse alone. It was
suggested that the failure of Ki-ras and p53 inactivation to promote tumorigenesis
was due to the continuous process of epithelial cell renewal that occurs in the
intestine and the failure of the transgenes to be expressed in the stem cells of
intestinal crypts. Initiation of tumours in the intestine of the Ape mutant mouse might
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occur in the crypt cells and co-operation between various gene defects might have to
occur or more specifically, in a stem cell in order to promote tumours,
b) Ape and Msh2 gene interaction
This exclusively of mutations in APC and mismatch repair genes led to the
proposal of independent pathways to tumour formation, one characterised by
microsatellite instability and another in which inactivation of APC was involved.
However, in a much more extensive sampling involving both cell lines and tumour
samples, Huang et al (1996) reported an equal propensity for APC mutations in cell
lines and tumours with or without microsatellite instability. Lengauer et al (1997)
demonstrated that colorectal tumours without microsatellites instability exhibit a
_2
striking effect in chromosome segregation, resulting in gains or loss in excess of 10
per chromosome per generation. This form of chromosomal instability reflected a
continuing cellular defect that persisted throughout the lifetime of the tumour cell and
was not related to chromosome number. Thus, persistent genetic instability might be
critical for the development of all colorectal cancers. Moreover, their data indicated
that the mismatch repair deficiency contributed to the activation of the APC gene.
This was evident from the significant excess of frameshift mutations in APC in the
RER background relative to the nonRER background. The frameshift mutations were
characteristic of those expected from the RER phenotype as 81% occurred in
microsatellite repeat sequence, while this was the case for only 37% of the APC
frameshift in the nonRER background. By using a mouse model, Reitmair et al
(1996) also concluded that defected in mismatch repair genes resulted in contributed
to mutations in Ape. Mice heterozygous for wild type Ape and carrying a germline
defect in the Msh2 mismatch repair gene developed more and faster growing
adenomas than mice carrying only the Ape mutation did as well as reduced survival
of the mice. Additionally, adenomas from the Ape Ml" mice all exhibited deletion of
the wild type Ape allele while the adenomas from (Ape Mm /Msh2 ) mice appeared to
inactivate the wild type Ape allele by somatic mutation. Taken together the above
studies indicated that Ape was a target of the RER phenotype in colon cancer.
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c) Ape and methylating agents
Although hypomethylation was originally proposed as a contributing factor in the
multistep progression of colorectal cancer (Fearon and Vogelstein 1990), more recent
evidence has demonstrated this to be a protective effect (Laird et al 1995). Ape Mm
mice there were also heterozygous for DNA methyltransferase, were treated with
DNA methyltransferase inhibitors and were found to be far less prone to the
development of adenomas than control Ape Mm mice (Laird et al 1995). It was
suggested that C to T transitions resulting from methylation of cytosine occurred at a
lower frequency in the methyltransferase compromised animals. However, the target
for the protective effect of methyltransferase inhibition was not likely to be the wild
type Ape allele as this was almost always inactivated through loss of the wild type
Ape allele in the tumours of Ape Mm mice and not through point mutation (Luongo et
al 1994, Oshima et al 1995, Levy et al 1994, Laird et al 1995). It was suggested that
p53 was a possible target since it commonly has C to T transitions but p53 mice
carrying a mutant Ape allele were not more prone to polyp formation than Ape Min
mice alone. Activation of APC gene expression by the DNA methylating agent —
N-methyl-N-nitro-N-nitroguanidine (MNNG) in HCT-116 colon cancer cell line
showed the increased nuclear transcription of the APC gene and correlated with a
concurrent increase in the p53 protein level (Narayan and Jaiswal 1997), which
suggested a role for p53 in a stress response pathway involving APC.
1.4 Wingless/Wnt signalling pathway
1.4.1. Wnt signalling
In Drosophila, the Wingless pathway mediates anteroposterior patterning within
each segment of the fly embryo (Wieschaus and Riggleman 1987). In vertebrates, the
Wnt pathway important in the induction of the dorsoventral and anteroposterior
embryonal axes. Since the initial identification of Wnt-1 as a proto-oncogene (Nusse
and Varmus 1992), Wnt-1 and Wnt-related genes have been shown to encode
secreted factors involved in cell growth, differentiation, organogenesis and
oncogenesis in both vertebrates and invertebrates (Nusse and Varmus 1992, Nusse
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1997). In response to a Wnt signal in vertebrates or to a wingless signal in
Drosophila, a receptor encoded by the frizzled gene family (Bhanot et al 1996, Yang-
Snyder et al 1996) is activated and transmitted the signal to cytoplasmic downstream
components. These components including dishevelled (dsh), zeste-white 3 kinase
(zw3) and armadillo (arm), which were homologous to the vertebrate proteins Dsh
(Siegfried et al 1992), GSK-3P (He et al 1995, Siegfried et al 1992) and P-catenin
(McCrea et al 1991), respectively. p-Catenin, the mammalian homologue of
Drosophila armadillo protein, was first identified as a cadherin-associated protein at
cell-cell junctions (McCrea et al 1991).
Binding of a Wnt molecule to a frizzled receptor activates Dishevelled, which
inhibits the activity of the APC-Axin-GSK-3P complex of proteins. Dishevelled
activation also lead to the activation of JNK kinases. Integrin-linked kinase (ILK)
promotes the stabilisation and nuclear import of P-catenin. Overexpression of ILK in
epithelial cell lines promotes the nuclear translocation of P-catenin (Novak et al
1998) stimulating the activity of a reporter gene with multimerised Lef-1 binding
sites. ILK overexpression also disrupts cell-cell adhesion and stimulates both
fibronectin matrix assembly and anchorage-independent growth (Wu et al 1998,
Radeva et al 1997). The mechanism by which ILK activation results in nuclear
accumulation of P-catenin could involve inactivation of GSK-3P. P-Catenin was also
shown to form a complex with processed presenilin proteins in the endoplasmic
reticulum, an interaction that resulted in stabilisation of P-catenin. In response to Wnt
signalling, P-catenin is translocated and accumulates in the nucleus, binding to —
Lef-l/Tcf proteins, interfering with Lef-l/Tcf acetylation, and perhaps displacing
Groucho corepressors. The association of Lef-l/Tcf with P-catenin results in
transcriptional activation. The P-catenin regulates gene expression by direct
interaction with transcription factors such as Lef-1, providing a molecular mechanism
for the transmission of signals from cell-adhesion component or Wnt protein to the
nucleus (Behrens et al 1996). Recently, c-myc oncogene has been identified as a
target gene in the Wnt signalling pathway (He et al 1998). Further, AP-1 has been —
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Figure 1.1 Diagram of Wnt signalling pathway and interaction of the
components in the pathway
(A) The interactions ofWnt components in the Wnt signalling pathway. At the top, p-catenin
binds to cadherins, mediating interactions with the actin cytoskeleton. In the cytoplasm p-
catenin interacts with Axin and APC. GSK-3P phosphorylates Axin, which subsequently
interacts with p-catenin and APC, leading to the phosphorylation and degradation of P-
catenin. Nuclear Lef-l/Tcf interacts with Groucho co-repressors, preventing transcription of
Wnt target genes. (B) Signalling events and interactions that stabilise P-catenin, leading to
the activation of Lef-l/Tcf-mediated transcription. Binding of a Wnt molecule to Frizzled
receptor activates Dishevelled (Dsh), which inhibits the activity of the APC-Axin-GSK-3p
complex of proteins. ILK can promote the stabilisation and nuclear import of P-catenin. The
mechanism by which ILK activation results in nuclear accumulation of p-catenin could
involve inactivation of GSK-3p. P-catenin has also been shown to complex with processed
presenilin proteins (PS) in the endoplasmic reticulum (ER), an interaction that results in
stabilisation of P-catenin accumulation in the nucleus and the binding of Lef-l/Tcf proteins,
which subsequently interfere with Lef-l/Tcf acetylation and perhaps displacing Groucho co-
repressors. The association of Lef-l/Tcf with P-catenin results in transcription activation.
Adapted from Eastman and Grosschedl 1999.
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demonstrated as a target gene of (3-catenin-Tcf/Lef signalling in human colorectal
carcinomas (Mann et al 1999). A model of the Wnt signalling pathway is summarised
in Figure 1.1.
1.4.2. P-Catenin
P-Catenin was first identified as one of a small group of proteins that
coimmunoprecipitate with the cell adhesion molecule E-cadherin. p-Catenin also plays
important roles in cell adhesion and cell signalling. The protein influences adhesion by
providing a functional bridge between cadherins and the actin cytoskeleton. P-Catenin
has been intensively studied because:
1. The interaction between P-catenin and cadherin adhesion molecules
2. P-Catenin was similar to the Armadillo protein of Drosophila which is an important
element in the Wnt/Wingless signalling pathway and
3. P-Catenin also complexes with the APC protein, the product of a tumour suppressor
gene that was mutated in colon cancer.
a) Structure
The P-catenin gene (CTNNB1) was mapped to human chromosome 3p21 and mouse
chromosome 9. The gene product was a 92 kDa protein, which appeared to be important
in the functional activities of both APC and E-cadherin. The CTNNB1 gene has 16 exons
and spans 23.2 kb (Nollet et al 1996). Alternative splicing within exon 16 produces a
splice variant that is 159 base pairs shorter in the 3-prime untranslated region. The
promoter region was shown to be GC-rich and to contain a TATA box (Nollet et al
1996). P-Catenin was found to be composed of an N-terminal head domain of about 130
amino acids. The N-terminus of P-catenin contains a consensus phosphorylation site for
glycogen synthase kinase 3P (GSK-3P) and point mutations that altered serine or
threonine residues within this sequence were sufficient to stabilise the protein (Yost et al
1996). The N-terminus is followed by 12 tandem imperfect sequence repeats, each of
about 42 amino acids, called armadillo or arm repeats which are also found in many
other cytoplasmic proteins. The crystal structure for the 12 arm repeats of P-catenin was
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solved recently (Huber et al 1997). Structural analysis has revealed that arm repeats
were a-helical and pack against one another to form an elongated superhelix of —
a-helices. The groove created by the twisted superhelical structure is highly charged and
proposed to be the interacting surface for 3-catenin targets. The C-terminal domain of --
3-catenin is composed of about 100 amino acids (McCrea et al 1991). The three regions
have distinctive charge distributions; the head and tail regions are acidic, whereas the







3-Catenin is a component of the Wnt/Wingless growth factor signalling pathway
(■wingless is the Drosophila homologue of Wnt) (Gumbiner 1995, Miller and Moon
1996). This pathway plays a key role in development (Willert and Nusse 1998). In
Drosophila, this pathway was shown to mediate anteroposterior patterning within each
segment of the fly embryo (Wieschaus and Riggleman 1987).
3-Catenin was found to be a membrane associated protein, which existed as
homodimers. 3-Catenin is either localised to the membrane or is found free in the
cytoplasm. Separate roles have been proposed for this localisation either in the
Wnt/Wingless pathway or through interaction with the cadherins. Normally, 3-catenin is
predominantly located in the cytoplasm as pools of free monomelic protein. The cellular
levels of the 3-catenin protein as well as subcellular localisation are normally very
tightly regulated. In the absence of a Wnt signal, GSK33 phosphorylates APC and —
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P-catenin (Miller and Moon 1996, Munemitsu et al 1996, Yost et al 1996, Aberle et al
1997, Behrens et al 1998, Cadigan and Nusse 1998, Hart et al 1998, Ikeda et al 1998).
Axin facilitates GSK3(3 phosphorylation of APC and (3-catenin in vitro. Phosphorylation
of (3-catenin leads to its ubiquitination and targeting to the proteasome, resulting in —
(3-catenin degradation (Aberle et al 1997, Salomon et al 1997).
In contrast, following stimulation of the Wnt pathway, GSK3(3 is inactivated and
leads to the accumulation of free intracellular (3-catenin. (3-Catenin binds to APC
through two motifs located in the central third of the APC proteins, which is either
absent or truncated in almost all tumour cells containing mutations in APC (Nakamura
1993, Polakis 1995, Kinzler and Vogelstein 1996). (3-Catenin also binds to the Lef/Tcf
transcription factor (Fagotto 1998). (3-Catenin binds to a region within the first 56 amino
acids of all known Lef/Tcf transcription factors (Behrens et al 1996, Huber et al 1996,
Molenaar et al 1996). Lef/Tcf transcription factors are sequence-specific DNA binding
proteins that function as context-dependent transcription factors, unable to work on their
own but requiring the cooperative effort of adjacent DNA binding transcription proteins
or non-DNA binding cofactors (Carlsson et al 1993, Giese and Grosschedl 1993). Tcf
proteins are 'architectural' transcription factors that activate transcription by inducing
binding of DNA; binding of (3-catenin to Lef-1 has been shown to substantially alter the
ability of this transcription factor to bend DNA (Behrens et al 1996). (3-Catenin
associates with several proteins, but the direct target of (3-catenin is thought to be Tcf-1
and Lef-1. Moreover, others have shown that (3-catenin contains importin-like sequence
that mediate nuclear localisation independently of Lef-l/Tcf proteins (Kussel and Frasch
1996). In the nucleus, the (3-catenin-transcription factor complex regulates transcription
of target genes including c-myc (Ben-Ze'ev and Geiger 1998, He et al 1998). Recently,
evidence has been produced showing that P-catenin is imported into the nucleus
independently of Lef/Tcf binding and also exported from nuclei (Prieve et al 1998).
c) The consequence of P-catenin mutation
Elevation of cytoplasmic P-catenin occurs following either activation of the Wnt
signalling pathway or inactivation of APC. It has recently been shown that mutations in
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P-catenin which delete the N-terminal region also stabilise the protein and result in
cytoplasmic accumulation of P-catenin in a manner that appeared to be independent of
regulation by Wnt or APC (Yost et al 1996, Munemitsu et al 1996, Rubinfeld et al 1997,
Barth et al 1997). Several reports have emphasised that the tumour suppressor
adenomatous polyposis coli (APC) function to affect intestinal tumorigenesis through its
regulation of P-catenin signalling. Additional evidence for the importance of P-catenin
signalling in tumorigenesis has come from the observation that some human colorectal
neoplasms with wild type APC genes have mutations in P-catenin (Ilyas et al 1997,
Morin et al 1997). Mutations in the N-terminal regulatory domain of P-catenin were
found in 48% of colorectal tumours lacking APC mutations and were associated with the
early adenomatous stage of colorectal cancer (Sparks et al 1998). P-Catenin mutations
were also observed more frequently in small colorectal adenomas than in larger
adenomas and invasive carcinomas (Samowitz et al 1999). Somatic mutations of the
catenin gene were found in approximately 50% of transgenic mouse lines of
hepatocellular carcinoma and 36% of human hepatocellular carcinomas (de la Coste et
al 1998). Increased expression of p-catenin was also identified as an early event in
colorectal carcinogenesis and was often associated with a subsequent inactivation of the
p53 tumour suppressor gene in human cell line (Damalas et al 1999).
p-Catenin immunoreactivity is normally detected exclusively in the cell membrane
and cytoplasm of morphologically normal intestinal epithelial cells with predominant
distribution in the differentiated non-proliferative cell population. In contrast, P-catenin
was seen to be localised predominantly in the nucleus of adenomas from Min/+ mice
and transgenic mice expressing a mutant truncated form of the APC gene (Sheng et al
1998). P-Catenin was expressed predominant at the cell membrane and cytoplasm of the
nontransformed rat intestinal epithelial (RIE-1) cells in culture, whereas predominantly
nuclear localisation of P-catenin was observed in the human colon cancer cell line
SW480. In azoxymethane (AOM) treated rats, overexpression and localisation of —
p-catenin was observed in all adenomas (Sheng et al 1998).
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P-Catenin also functions in cell-adhesion by linking cadherin to the actin
cytoskeleton (Aberle et al 1994), it binds directly to the cytoplasmic domain of cadherin
molecules, and simultaneously bind to the unrelated protein oc-catenin, which is in turn
linked to actin filaments. Catenin-mediated linkage to the cytoskeleton appears to be
crucial to the function of adherins junctions; cadherin is unable to mediate cell adhesion
in cells lacking either a- or P-catenin. Both catenins therefore regulate cadherin function
in adhesion and are key mediators between the cadherins, APC and the Wnt signal
transduction pathway. The evidence is summarised as follows:
1. P-Catenin is a target of tyrosine kinases and phosphatases that regulate cell adhesion.
2. P-Catenin is a major component of the Wnt/Wingless signal transduction pathway that
is important in cell-fate divisions and pattern formation during development.
3. P-Catenin mediated signals between cadherins and the Wnt/Wingless signalling
pathway.
4. Mutations in Ape protein and P-catenin resulted in constitutive activation of P-catenin
signalling and were correlated with cancer formation.
5. p-Catenin might regulate role ofApe protein in organising microtubules.
1.4.3. E-cadherin
Cell-cell adhesion plays an important role in tissue morphogenesis and
homeostasis (Gumbiner 1996, Huber et al 1996a), and is commonly mediated by the
cadherins, a family of calcium-dependent transmembrane adhesion receptors (Geiger
and Ayaton 1992, Kemler 1992, Takeichi 1991 and 1995).
a) Structure
The cadherin gene (HSECAD) is located on human chromosome 16q22.1 and
consists of 6 exons. It codes for a transmembrane protein with a molecular mass of
120 kDa, which exists as a homodimer (Nagar et al 1996, Shapiro et al 1995). The
extracellular N-terminal end contains five repeat domains which each contain a
histidine-arginine-valine (HAV) motif (Overduin et al 1995) and is essential for the
mature molecule to exert its role in cell-cell adhesion. The extracellular domain also
possesses a flexible hinge region. The cytoplasmic domain is a highly conserved
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region that is common to all members of the cadherin family. The two parts of the
molecule are connected by a single, 32 amino acid, hydrophobic, membrane spanning
domain,
b) Function
In epithelial cells, cell-cell adhesion is mediated primarily by epithelial (E)-
cadherin, a 120 kDa transmembrane glycoprotein, localised at the adherens junctions
(Takeichi 1991). The cadherins and catenin, however, are more than just intercellular
glue. (3-Catenin seems to participate in signal transduction pathways independently
from its role in cell-cell adhesion and thus linked the cell surface to downstream
cytoplasmic and nuclear events. E-cadherin is essential for the formation and
maintenance of epithelium. Cadherin-mediated adhesion is a highly dynamic process
that is regulated by several signal transduction pathways. Cadherin receptors exist as
dimers at the cell surface. The receptors interact with the same type of molecules in
neighbouring cells (homophilic binding). This interaction occurs in an antiparallel
fashion and results in the lateral clustering or zipping up of cadherin complexes at
sites of cell-cell contact. Functional adhesion requires calcium ions, to stabilise the
extracellular domain, and association of the receptors with actin cytoskeleton, which
is indirectly mediated by the actin binding protein a-catenin and a-actinin. The
cytoplasmic domain of E-cadherin binds to the catenins ((3-catenin and y-catenin).
(3-Catenin links E-cadherin to a-cadherin and the actin cytoskeleton and the linkage
to the actin cytoskeleton is essential for the adhesion function of cadherins at the
zonula adherens junction. Binding of the cadherin-catenin complex to transmembrane
tyrosine kinases and phosphatases juxtaposes adhesion and signalling complexes such
that cells can respond to extracellular signals with rapid and local changes in
adhesion. Activation of tyrosine kinases leads to tyrosine phosphorylation of catenins
and downregulation of cadherin-mediated adhesion, which result in the dissociation
of the cadherin-catenin complex from the actin cytoskeleton and a concomitant
decrease in intercellular adhesion.
The importance of E-cadherin in the control of cell motility has led to speculation
about its role as an 'invasion suppressor'. During tumorigenesis in epithelial cells,
51
E-cadherin adhesiveness is frequently reduced or abolished in a variety of different
ways. Transfection of invasive E-cadherin-negative cell lines with fully functional
E-cadherin expression vectors, resulted in loss of invasive features (Vleminckx et al
1991). Loss of E-cadherin mediated adhesion results in increased dedifferentiation of
tumour cells (transition from adenoma to carcinoma) (Perl et al 1998). Loss of
expression of E-cadherin is thought to occur late in carcinogenesis and although few
mutations of HSECAD have yet been described in colorectal cancer, mutations in
other cancers occur along the whole length of the HSECAD gene without an obvious
'hot spot'. However, loss of E-cadherin function can also occur in the absence of
HSECAD gene mutation. Mutation of other members of the E-cadherin-catenin-unit
(ECCU), such as a- and P-catenin, abolish E-cadherin-mediated adhesion (Oyama et
al 1994, Morton et al 1993). It has been shown that phosphorylation of p-catenin
renders it useless for ECCU (and thereby E-cadherin) function, the epidermal growth
factor receptor (Shiozaki et al 1995), c-erb-B-2 (Ochiai et al 1994), hepatocyte
growth factor receptor (Shibamoto et al 1994) c-met, and the oncoprotein ppbO v src
(Behrens et al 1993) are all able to phosphorylate P-catenin. Finally, and possibly
most importantly for tumour development, functional control was also dependent
partially on APC, since both E-cadherin and APC compete for P-catenin binding
(Hulsken et al 1994). E-cadherin has been postulated as a mediator of contact
inhibition in cells. Finally, when the actin filaments of the cytoskeleton polymerise,
they released DNAses and because of its association with the actin cytoskeleton, —
E-cadherin has been implicated in the control of apoptosis (Salomon and Diaz-Cano
1995). Recent evidence suggests that the E-cadherin gene is regulated by the
interplay between Myc and AP-2. AP-2 was the transcription factor that has been
shown to bind to the bHLHZip domain of c-myc (Batsche et al 1998)
1.4.4. Members of the Wnt signalling pathway
1.4.4.1. Frizzled
In Drosophila melanogaster, Frizzled encoded an integral membrane protein with
seven potential transmembrane domains. The homologues frizzled-1 and frizzled-2
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(fz-1, fz-2) have been cloned from rat and human, by Northern analysis revealed
expression in a wide variety of tissues including kidney, liver, heart, uterus and ovary
(Chan et al 1992, Zhao et al 1995). Six novel mammalian frizzled homologues have
been identified recently, each of them seemed to be expressed in a distinctive set of
tissues during development or postnatally (Wang et al 1996).
The frizzled proteins have been identified as receptors for the Wnt pathway. The
prototypic member of frizzled family, Frzb, was cloned and protein was purified from
bovine cartilage (Hoang et al 1996). Members of the Frzb family seem to be
surprisingly similar in their specificity for inhibiting Wnt signalling. Frzb-1,
originally discovered by primary protein sequencing of highly purified cartilage-
derived protein preparations, contains an N-terminal domain with 50% identity to the
cysteine-rich domain of Drosophila Frizzled (Hoang et al 1996). The open reading
frame revealed the presence of a signal peptide and a hydrophobic domain followed
by multiple potential serine/threonine phosphorylation sites and a serine-rich C-
terminus
Frzb-1 prevented Wnt-1 induced cytosolic accumulation of (3-catenin in human
embryonic kidney cells (Lin et al 1997). Moreover, they also studied structure and
function, which showed that complete removal of the frizzled domain of Frzb-1
abolished the Wnt-l/Frzb-1 protein interaction and the inhibition of Wnt-1 mediated
axis duplication in Xenopus embryos (Lin et al 1997). In contrast, removal of the C-
terminal portion of the molecule preserved both Frzb-Wnt binding and inhibitory
function of Wnt signalling (Lin et al 1997). Partial deletion of the Frzb-1 cysteine-
rich domain maintained Wnt-1 interaction, but inhibitory function was lost (Lin et al
1997). Thus, the frizzled domain was necessary and sufficient for both activities (Lin
et al 1997).
Frizzled (fze3) is a human homologue of Drosophila, fzd7, mapping to human
chromosome 2q33. Fze3 was specifically expressed in oesophageal carcinoma tissue
compared with the adjacent normal mucosa (Tanaka et al 1998). They found that fze3
protein contained an N-terminal signal sequence, 10 cysteine residues typical of the
cysteine-rich extracellular domain of Fz family members, 7 putative transmembrane
53
domains and an intracellular C-terminal domain. They suggested that fze3 gene
expression might downregulate APC function and enhanced (3-catenin-mediated
signals in poorly differentiated human oesophageal carcinomas.
1.4.4.2. Axin
The human Axin gene maps to chromosome 16pl3.3 and encodes a 900 amino
acid polypeptide with 87% identity to the mouse protein (Zeng et al 1997). The
sequence also contains a regulator of G protein signalling domain terminus of
Drosophila and vertebrate "dishevelled" proteins (Zeng et al 1997).
The amino-terminal domain of human Axin, which contains the regulator of G-
protein signalling (RGS) domain, binds directly to the APC tumour suppressor
protein at a site in the APC protein that is often deleted in neoplasia (Hart et al 1998).
Human Axin (hAxin) contains independent binding sites for APC, P-catenin and
GSK-3P and overexpression of hAxin strongly promotes the downregulation of wild
type P-catenin in colon cancer cells whereas mutant oncogenic P-catenin is
unaffected (Hart et al 1998). Moreover, the downregulation was increased by deletion
of the APC-binding domain from Axin, suggesting that APC might function to
depress Axin activity and hAxin dramatically facilitated the phosphorylation of APC
and P-catenin by GSK-3P in vitro (Hart et al 1998). Thus, Axin provided the missing
link for the connection of APC and GSK-3P.
Mutations in mouse Axin gene caused axis duplication in homozygous mouse
embryo. A recent study in Xenopus identified Axin as a new potential component of
the regulation of P-catenin signalling (Zeng et al 1997). It was shown that murine
Axin inhibited the dorsal axis formation in Xenopus that was normally observed on
expression ofWnt-1.
Rat Axin (rAxin) consists of 832 amino acids and possesses Regulators of G
protein Signalling (RGS) in its N-terminal and C-terminal regions which is
dishevelled (Dsh) mouse homologous domains (Ikeda et al 1998). rAxin and Axil
contained GSK-3p and P-catenin binding sites in the central region at amino acids
298-506. rAxin showed 94% identity with mouse Axin and interacted directly with
54
the armadillo repeats of P-catenin (Ikeda et al 1998). Axil was identified, which
showed 44% amino acids identity with Axin (Yamamoto et al 1998). rAxin and Axil
were directly phosphorylated by GSK-3P and formed complex with (3-catenin by
binding to the N-terminal of P-catenin (Ikeda et al 1998). The binding site of both
rAxin and Axil for GSK-3p was distinct from the P-catenin-binding site and they
both promoted GSK-3p-dependent phosphorylation of P-catenin (Ikeda et al 1998,
Yamamoto et al 1998). The regulators of G-protein signalling (RGS) domain of
rAxin was demonstrated to form a complex with full-length APC but not a truncated
APC in vitro (Kishida et al 1998). Moreover, they also demonstrated that the down
regulation activity of APC on P-catenin required the binding of rAxin (Ikeda et al
1998). Therefore, Axin, rAxin and Axil negatively regulated the Wnt signalling
pathway by directly interacting with GSK-3P and P-catenin and mediated the signal
from GSK-3P to phosphorylate P-catenin. These results indicated that Axin or rAxin
or Axil, APC, GSK-3p, and P-catenin formed a tetrameric complex which resulting
in the regulation of the stabilisation of P-catenin, subsequently, leading to negatively
regulation of the Wnt signalling pathway.
1.4.4.3. Glycogen synthase kinase 3P (GSK-3P)
Glycogen synthase kinase 3P (GSK-3p) is an isoform of GSK-3, and was
originally characterised as a serine/threonine kinase that phosphorylates and
inactivates glycogen synthase, and subsequently was demonstrated to be identical to
protein kinase FA that activates ATP-Mg-dependent type-1 protein phosphatase (Plyte
et al 1992). GSK-3P was implicated in the regulation of several physiological
responses in mammalian cells by virtue of its activity phosphorylating many
substrates including neuronal cell adhesion molecule, neurofilament, synapsin I, tau,
transcription factors and APC (Mandelkow et al 1992, Plyte et al 1992, Yang et al
1992, Rubinfeld et al 1996). The cDNAs of GSK-3P in mammals have been isolated
and they encoded the protein kinases with Mrs of 51 and 47 kDa, respectively
(Woodgett 1990).
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Both structure and function of mammalian GSK-3p were homologous to the
Drosophila zeste-white3/shaggy gene product (Ruel et al 1993). Furthermore, it has
been shown that GSK-3(3 phosphorylated APC and that the phosphorylation enhanced
the binding of APC to P-catenin (Rubinfeld et al 1996). The wild type GSK-3P
phosphorylates P-catenin at a conserved N-terminal site (Rubinfeld et al 1996). It was
well known that APC was required for the degradation of P-catenin, although the role
of APC was not well understood (Polakis 1997). It has been shown recently that the
ubiquitination-proteasome pathway was involved in the degradation of P-catenin and
that mutations in the GSK-3P consensus phosphorylation site of P-catenin prevented
ubiquitination (Aberle et al 1997). Thus, it appeared that GSK-3P phosphorylated —
P-catenin and that the phosphorylation of P-catenin was essential for its degradation.
1.4.4.4. Transcription factors: Tcf family
There are four known members of the transcription factors Tcf and Lef family in
mammals: the lymphoid-specific factors Tcf-1 and Lef-1 (van de Wetering et al 1991,
Travis et al 1991) and the less well characterised Tcf-3 and Tcf-4 (Castrop et al
1992). Tcf-1 and Lef-1 are the two members of a small subfamily of vertebrate high-
mobility-group (HMG) box transcription factor genes (van de Wetering et al 1991,
Waterman et al 1991, Travis et al 1991).
In mammalian cells, Lymphoid enhancer-binding factor {Lef-1) interacted with —
P-catenin and coexpressed Lef-1 and P-catenin formed complex that was localised to
the nucleus and was detected by immunoprecipitation (Behrens et al 1996). The N-
terminal domain of Lef-1 was necessary and sufficient for the interaction with —
P-catenin (Behrens et al 1996). Lef-1 was closely related to Tcf-1, which has a similar
expression pattern in the mouse (Oosterwegel et al 1993, van de Wetering 1991) and
to Tcf-3 and Tcf-4 (Korinek et al 1997, Molenaar et al 1996). Functional and
biochemical characterisation of Lef-1 has indicated that this protein has no
transcriptional activation potential by itself and was unable to stimulate transcription
from a synthetic enhancer containing multimerised Lef-1 binding sites (Travis et al
1991, Waterman et al 1991). Lef-1 stimulated the function of the T-cell receptor a
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(TCR a) enhancer in collaboration with other DNA-binding proteins (Travis et al
1991, Waterman et al 1991). Lef-1 acted as an architectural transcription factor that
introduced a sharp bend in the DNA (Giese et al 1992, Love et al 1995) and
contained a context-dependent activation domain, which functioned only in a specific
context of other transcription factors (Carlsson et al 1993, Giese and Grosschedl
1993). The amino-terminal 76 residues of Lef-1 could be associated directly with —
P-catenin (Behrens et al 1996, Huber et al 1996). A similar P-catenin interaction
domain has been identified in the Lef-l-related proteins Tcf-1, Tcf-3 and Tcf-4,
which in combination with overexpressed P-catenin stimulated transcription from
multimerised Lef/Tcf binding sites (Korinek et al 1997, Molenaar et al 1996). Other
reported that the association of P-catenin with Lef-1 in the nucleus suggested the
DNA-binding or regulatory properties of the transcription factor might be altered and
Lef-l-induced DNA bending could affect gene regulation (Giese et al 1995). The
architectural transcription factor Lef-1 was shown to be a strong candidate as a
downstream target of P-catenin, was given the observations that: Lef-1 bound directly
to p-catenin, P-catenin modulated the DNA-binding properties of Lef-1 and Lef-1,
like p-catenin and members of the Wnt pathway, induced axis duplication of Xenopus
embryo (Behrens et al 1996). Tcf/Lef transcriptional activation and upregulation of
cytosolic P-catenin in a mammalian system were induced by Wnt-1 (Young et al
1998).
In the absence of Wnt signalling, Lef-l/Tcf proteins suppressed transcription in
association with Groucho and the cyclic AMP response element binding protein
(Eastman and Grosschedl 1999). Recent work has established genetic and
biochemical interactions between Lef-l/Tcf proteins and Groucho, a transcriptional
corepressor that interacted with several DNA-binding proteins such as Hairy,
Engrailed and Dorsal (Cavallo et al 1998, Roose et al 1998, Fisher and Caudy 1998,
Levanon et al 1998). In addition, Lef-1 and Tcf-1 had different nuclear localisation
properties (Prieve et al 1998) and might differ in their binding of various Groucho
family members (Roose et al 1998, Levanon et al 1998).
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1.4.4.5. Groucho
Groucho (Gro) is a broadly expressed Drosophila corepressor involved in
segmentation, sex determination and neurogenesis (Hartley et al 1988, Paroush et al
1994, Parkhurst 1998, Fisher and Caudy 1998). Stifani et al (1992) described human
homologues of Drosophila groucho protein, which were designated as transducin-like
enhancer of split (TLE). In mammals, multiple homologues with a similar overall
domain structure have been identified. These were termed TLE1-4 in man (Stifani et
al 1992) and m.Grg-1, -3, -4 and -5 in mouse (Mallo et al 1993). Liu et al (1996)
demonstrated TLE1 and TLE2 genes map to 19p 13.3 by in situ hybridization.
Groucho expressed nuclear proteins that do not bind to DNA. Groucho acted as a
corepressor that mediates repression by a variety of specific DNA binding protein
(Parkhurst 1998). Groucho interacts with AML1 and AML2 (AML genes are
members of gene family of heterodimeric transcription factors) on T cell receptor
regulation and Wnt signalling (Levanon et al 1998). Corepressors are defined as
proteins that are required for the repressor activity of a specific transcription factor
but did not have the ability to bind DNA alone. TLE/Gro interacted with LEF-1, and
inhibited LEF-7 :p-catenin-dependent transcription (Levanon et al 1998). Groucho
binds a region of human Tcf-1 that is separated from the (3-catenin binding domain.
The mechanism by which Groucho represses transcription could involve recruitment
of repressive chromatin through interactions with histone H3 (Palaparti et al 1997).
1.4.4.6 Dishevellled
Dishevelled (Dsh) encodes a cytoplasmic protein (Dsh) with no known
biochemical function and little homology to other proteins (Klingensmith et al 1994).
In the mouse, three dsh genes (Dvl-1, Dvl-2 and Dvl-3) have been cloned by
homology (Sussman et al 1994).
Amino acid sequence comparison of all known dsh genes reveals regions of high
homology in the amino-terminus and in the central domain while the carboxy-
terminus is highly divergent (Klingensmith et al 1994). The N-terminal conserved
domain shares homology to Axin, which also plays an important role in Wnt
signalling (Zeng et al 1991, Ikeda et al 1998, Behrens et al 1998). This N-terminal
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domain is referred to as the DIX (Dishevelled and Axin) domain. The central region
of Dsh contains a domain referred to as discs-large homology region (Dhr) or PDZ
(Klingensmith et al 1994, Ponting 1995), which is found in several other proteins
such as PSD-95, ZO-1 and Discs-large (Ponting 1995). Structural analysis
demonstrated that a carboxy-terminal four-residue motif (X-Thr/Ser-X-Val) binds to
the PDZ domain of PSD-95 (Doyle et al 1996) and to the PDZ domain of the human
homologue of the Drosophila discs-large tumour suppressor gene product, DlgA
(Morais Cabral et al 1996). The carboxy-terminal is recently described domain
referred to as the DEP (Dsh/egl-10/Pleckstin) domain (Ponting 1996).
Dsh proteins are localised predominantly in the cytoplasm of the cells (Yanakawa
et al 1995). Studying in vitro showed a fraction of Dsh protein localised to the cell
membrane (Yanakawa et al 1995), which suggested that the membrane fraction of
protein is active in signalling. The molecular mechanism by which Dsh/Dvl is
involved in signal transduction of Wnt is largely unclear, especially in mammalian
system.
Siamois, is a Xenopus zygotic homeobox gene, was specifically activated by —
(3-catenin, which appeared to mediate the effects of the Wnt pathway on axis
formation (Carnac et al 1996, Fagotto et al 1997). Siamois was a mediator of the Wnt
signalling pathway and that the synergy between the Wnt and mesoderm induction
pathways occurred downstream of the early target genes of these two pathways
(Carnac et al 1996).
1.5. |3-Catenin downstream target genes
1.5.1. c-Myc
c-Myc was one of the first cellular oncogenes to be discovered (Bishop 1983), it
has been shown to play a role in growth control, differentiation and apoptosis and
abnormal expression has been associated with many naturally occurring neoplasms
(Askew et al 1991, Evan and Littlewood 1993, Evan et al 1992). Takahashi et al
(1991) refined the assignment of c-Myc to chromosome 8q24.12-q24.13. The gene
product encoded by the c-myc oncogene is a transcription factor. A molecular weight
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of 65,000, which is located predominantly in the nucleus and binds to DNA (Persson
and Leder 1984).
The carboxy terminus of c-myc is composed of 90 amino acids, contained three
structural domains that are homologous to domains found in other transcription
factors, including the leucine zipper, a helix-loop-helix motif (HLH) and an adjacent
domain rich in basic amino acids (Blackwell et al 1990, Murre et al 1989). There are
two nuclear localisation signals in the carboxy terminus (Henriksson and Luschher
1996). The transcription activation domain has been mapped to the amino terminus,
has short 'acidic' proline-rich and glutamine-rich clusters similar to those associated
with some transactivation domains (Kato et al 1990), which contained multiple
phosphorylation sites.
c-Myc is expressed in almost all proliferating normal cells where its expression
was strictly dependent on mitogenic stimuli. It is downregulated in many kinds of
cells when they are induced to terminally differentiate (Evan and Littlewood 1993).
The expression of the c-myc gene is closely correlated with growth and removal of
growth factors at any point in the cell cycle results in its immediate downregulation
(Dean et al 1986, Waters et al 1991). c-Myc expression is absent in quiescent cells
(Waters et al 1991). Overexpression of c-myc in growing cells led to reduce growth
factor requirements and a shortened Gi phase (Karn et al 1989) while reduced
expression caused lengthening of the cell cycle (Shichiri et al 1993). It has been
reported that c-myc was able to increase the expression levels of cyclins E and A and
suppressed the expression of cyclin D1 (Hanson et al 1994, Perez-Roger et al 1997,
Philipp et al 1994, Solomon et al 1995). Recently, it has been reported that c-myc
affected the cell cycle at multiple independent points (Mateyak et al 1999). c-Myc
mediated apoptosis was dependent on p53 in some cell types (Hermeking and Eick
1994, Hsu et al 1995). Deregulated myc expression resulted in more tumorigenesis
when expressed in mice with a p53 null background (Evan and Littlewood 1998,
McCormack et al 1998). A molecular framework was provided by He et al (1998) for
understanding of the overexpression of c-myc in colorectal cancers. They showed that
expression of c-myc was suppressed by wild type APC and activated by (3-catenin and
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that effects were mediated through Tcf-4 binding sites in the c-myc promoter (He et
al 1998). In colorectal cancers with APC mutations or activating (3-catenin mutations,
increased (3-catenin/Tcf-4 activity led to overexpression of c-myc, which then
promoted neoplastic growth (He et al 1998). Thus c-myc was a target gene in the Wnt
signalling pathway.
1.5.2. Cyclin D1
CCND1 gene map to chromosome Ilql2-ql3 (Hinds et al 1994). Cyclin D1 gene
encodes a regulatory subunit of a multiprotein cyclin D1-dependent kinase
holoenzyme complex, which phosphorylates and inactivates the tumour suppressor
protein pRB (retinoblastoma protein) (Goodrich et al 1991, Weinberg 1995). N-
terminal contains the sequence Leu-X-Cys-X-Glu, which is shared by DNA viral
oncoproteins (SV40 T antigen, adenovirus E1A, and human papillomavirus E7).
Cyclin D1 is degraded by the ubiquitin pathway and its degradation is enhanced
by phosphorylation on threonine 286 by glycogen synthase kinase 3(3 (Diehl et al
1998). Cyclin D1 is one of the key regulators of Cdk4 and Cdk6 and is thought to
have an important role in Gi progression (Resnitzky et al 1994, Resnitzky and Reed
1995). Cyclin D1 was amplified and overexpressed in a number of breast and prostate
tumours, pancreatic cancer, colon adenocarcinomas and squamous cell carcinomas of
the head and neck (Lammie and Peters 1991, Buckley et al 1993, Tarn et al 1994,
Gausauge et al 1997, Han et al 1998, Maeda et al 1998). This circumstantial evidence
for the involvement of cyclin D1 in oncogenesis was substantiated when it was
shown that cyclin D1 cooperated with Myc family members in the induction of
tumours in transgenic mice (Bodrug et al 1994, Lovec et al 1994, Wang et al 1994).
It has been reported that cyclin D1 is a target gene for repression by c-myc (Philipp et
al 1994). Moreover, they also reported that the repression occurred at the level of




API was mapped to human chromosome Ip32-p31 (Hattori et al 1988), and to
mouse chromosome 4 (Bahary et al 1991). AP-1 is one of the genes affected by —
P-catenin overexpression (Mann et al 1999). The direct interaction of the (3-catenin-
Tcf/Lef complex with the promoter regions of both components of the AP-1 complex
was also reported (Mann et al 1999). AP-1 has been shown to increase the expression
of urokinase-type plasminogen activator receptor (uPAR) in the colorectal cancer cell
line RKO (Lengyel 1996).
1.5.4. Integrin-linked kinase (ILK)
The integrin-linked kinase (ILK) was identified from a yeast two-hybrid genetic
screen by using as bait the cytoplasmic domain of the Pi integrin subunit (Hannigan
et al 1996). ILK can interact with pi and P3 integrins. The kinase activity of ILK was
modulated by interaction of cells with components of the extracellular matrix
(Hannigan et al 1996) or by integrin clustering. Overexpression of ILK in epithelial
cells resulted in the stimulation of anchorage-independent cell growth (Hannigan et al
1996) and cell cycle progression (Radeva et al 1997). In the cell cycle progression
was caused by the constitutive upregulation of expression of cyclin D1 and cyclin A,
resulting in the hyperphosphorylation of the retinoblastoma protein (Radeva et al
1997). Overexpression of ILK in epithelial cells also resulted in the induction of
tumorigenicity in nude mice (Wu et al 1998), indicating that ILK was a
protooncogene. Overexpression of ILK in intestinal epithelial cells as well as in
mammary epithelial cells resulted in an invasive phenotype concomitant with a
down-regulation of E-cadherin expression, translocation of P-catenin to the nucleus,
formation of a complex between P-catenin and the high mobility group transcription
factor, LEF-1, and transcriptional activation by this LEF-l/P-catenin complex (Novak
et al 1998). They demonstrated that the oncogenic properties of ILK involve
activation of the LEF-l/P-catenin signalling pathway (Novak et al 1998).
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Chapter 2
Comprehensive study of Ape, P-catenin and
E-cadherin expression in mutant mice
The previous chapter introduced APC as a multifunctional protein with major but
tissue-specific oncosuppressor activity. While one of its roles is to bind and facilitate
the destructive proteolysis of the signalling molecule P-catenin, other roles include
regulation of microtubule dynamics in cell movement and cytokinesis and perhaps
the organisation of receptor arrays at cell-to-cell junctions. It is far from obvious why
these different functions should be associated with a single protein, why this protein
should be critical for prevention of carcinogenesis in certain epithelia, or why
deficiency of its function should be an early rather than later manifestation of the
carcinogenesis process. This thesis presents data that relate to these questions. In this
chapter the distribution of Ape is studied in a variety of normal murine tissues, with
special reference to epithelia. By immunohistochemistry, the localisation of Ape is
compared with that of other molecules concerned with Wnt signalling (P-catenin and
E-cadherin which is an integral membrane protein binding to P-catenin). The data
show patterns of distribution, particularly prominent within the hierarchy of cells in
complex epithelial tissues such as the intestinal tract, that indicate that the association
of Ape and P-catenin is a dynamic one. While in some cells, E-cadherin, Ape and —
P-catenin appear in a similar, membrane related position, in others they are clearly
demonstrated colocalisation. In particular, in animals genetically modified to have
deficient Ape expression, the quantity and location of intracellular P-catenin in
certain cells of some tissues is modified dramatically. These cells may be the
founders of neoplastic clones and their detailed study is the subject of the next
chapter.
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From the above, it is clear that Ape, P-catenin, and E-cadherin are involved with
each other both in normal circumstances and in carcinogenesis. The Ape protein is an
important protein in regulation of P-catenin levels in the Wnt signalling pathway.
Here, I decided to focus on the pattern of Ape expression in epithelial cells from each
organ in Ape Min, (Ape Mm/p53 v~) and (Ape Mm/Msh2 "A) mice. In addition, P-catenin
and E-cadherin expression was also investigated in the same specimens in Ape Mm,
{Ape Mm/p53 -/") and (Ape Mm/Msh2 ~A) mice, so that the relationship between Ape and
either P-catenin or E-cadherin protein could be demonstrated.
64
2.1 Materials and Methods
2.1.1. Mice
Mice mutant for Msh2 (de Wind et al 1995), p53 (Clarke et al 1993) and Ape Mm
(Moser et al 1992) were maintained as out-bred colonies segregating for Ola/129, Balb
C, SWR and C57B1/6 genomes. Mice were monitored on a daily basis for signs of ill
health and were killed when they showed overt signs of neoplastic disease.
2.1.2. Tissue processing
Each organ was removed from mice immediately after killing by cervical dislocation.
Intestinal contents were cleaned out by gently flushing with phosphate buffered saline.
The whole piece of intestine was placed on Whatman filter paper number 1. The intestine
was opened longitudinally along the anti-mesenteric surface from one end to the other,
spread out flat and fixed in methacarn (see appendix B) at room temperature overnight.
Other organs were cut longitudinally into 0.5 mm thick slices so that the fixative could
penetrate through the specimen and fixed in 10% buffered formalin overnight at room
temperature. "Swiss roll" preparation of the intestine was made by holding one end of a
piece of intestine with tissue forceps and rolling to the other end. The rolls of intestine
were fixed in position with disposable needles 25 gauge. All the specimens were
dehydrated through graded ethanol solutions (70%, 85%, and 90%, two changes every 20
minutes and absolute ethanol for 40 minutes, 3 times). The specimens were cleared in
xylene (every 40 minutes, 3 times) and blocked in paraffin wax at 60 °C. The specimens
were in paraffin wax for 40 minutes, 3 changes of paraffin wax.
2.1.3. Optimisation of the immunohistochemistry technique
The core method was immunohistochemistry with monoclonal or polyclonal
antibodies, detection by a commercial avidin-biotin immunoperoxidase complex method,
after application of an appropriate secondary antibody.
2.1.3.1. Primary antibodies
All primary antibodies in this study were optimised to find the correct working
concentration, using 3 to 4 serial dilutions as follows:
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Rabbit polyclonal APC, 3161 (Midgley et al 1997, purified rabbit antiserum to human
APC C-terminal peptide, corresponding to codons 2813-2827; contained protein 0.116
pg/pl) 0.0232, 0.00232 and 0.000232 pg/pl;
Mouse monoclonal Ki67 (Novocastra, UK, 100 pg/ml) 0.05, 0.1, 0.2 and 0.3 fig/pl;
Rabbit polyclonal p53 (CM5, Novocastra, UK, 100 pg/ml) 0.001, 0.002, 0.003 and 0.004
pg/pl;
Mouse monoclonal (3-catenin (IgGi, clone 14, Transduction Laboratory, UK, 250 pg/ml)
0.0025, 0.005, 0.0075 and 0.10 (ig/fil;
Mouse monoclonal E-cadherin (Transduction Laboratory, UK, 250 pg/ml) 0.00125,
0.0025 and 0.050 fig/pl;
Rat monoclonal BrdU (Harlan SeraLab, UK, 500 pg/ml) 0.0025, 0.005, 0.0075 and
0.01 |ig/pl
Primary antibody was diluted in 20% normal serum in Tris buffered saline and
0.1%Tween 20 (see appendix B). The normal serum was from the species corresponding
to the secondary antibody used in the staining. Activity of the diluted primary antibody
was first confirmed on frozen tissue sections from tissues with known expression since
frozen tissue sections do not require any antigen retrieval technique. Incubation was for
either an hour at room temperature or overnight at 4 °C. Optimisation on paraffin
embedded tissues was then performed for both incubation times and with the same
concentration of primary antibodies used in frozen sections. The optimum working
condition for each primary antibody obtained from the optimisation reactions was as
follows:
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Primary antibody Working concentration
(pg/ml)
Incubation time Temperature
APC 0.00232 Overnight 4 UC
Ki67 0.1 1 hour Room temperature
(3-catenin 0.005 1 hour Room temperature
E-cadherin 0.0025 Overnight 4 °C
BrdU 0.005 1 hour Room temperature
p53 0.002 Overnight 4 UC
2.1.3.2. Secondary antibodies
Secondary antibodies used in this study were swine anti-rabbit biotin-conjugated
secondary antibody (SAR) (Dako, Denmark), rabbit anti-mouse biotin-conjugated
secondary antibody (RAM) (Dako, Denmark) and rabbit anti-rat biotin-conjugated
secondary antibody (RAR) (Pierce, USA). Secondary antibody was diluted in to 2 to 3
dilutions in 20% normal serum in Tris buffered saline and 0.1% Tween 20 (see appendix
B) and incubated as follows;
Swine anti-rabbit biotin-conjugated secondary antibody (SAR) (Dako, Denmark, 1.07g/l)
0.05, 0.027 and 0.014 pg/pl
Rabbit anti-mouse biotin-conjugated secondary antibody (RAM) (Dako, Denmark, 0.85
g/1) 0.04, 0.021 and 0.015 pg/pl
Rabbit anti-rat biotin-conjugated secondary antibody (RAR) (Pierce, USA, 0.5 mg/ml)
0.05, 0.01 and 0.002 p.g/|J,l
The optimum concentration of secondary antibodies for this immunohistochemistry
staining was shown in the table below
Secondary antibody Working concentration
(pg/pl)
Primary antibody
Swine anti-rabbit/Biotin 0.027 APC and p53
Rabbit anti-mouse/Biotin 0.021 Ki67, (3-catenin and E-cadherin
Rabbit anti-rat/Biotin 0.01 BrdU
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2.1.3.3. Antigen retrieval technique
Each primary antibody required different techniques of antigen retrieval in formalin-
fixed paraffin-embedded tissue sections to reveal antigenic sites altered or obscured by
fixation. To define the optimum conditions, paraffin tissue sections were subjected to
following conditions:
(a) No pretreatment;
(b) Pretreatment by trypsin digestion: after sections were dewaxed and rehydrated,
incubation in 0.1% trypsin solution (see appendix B) for 30 minutes at 37 °C;
(c) High temperature pretreatment: dewaxed and rehydrated sections were immersed in
either 0.05 M citrate buffer (see appendix B) or 0.1 M EDTA buffer (see appendix
B), followed by microwaving at 700 watts for 5 minutes, 3 times;
(d) DNA denaturation: dewaxed and rehydrated sections were exposed to 1 N HC1 at
60 °C for 10 minutes or 2 N HC1 at 27 °C for 25 minutes (this method was used
exclusively for BrdU antibody staining)
From the above conditions we found that the optimum condition for each primary
antibody was as follows:
Primary antibody Pretreatment condition
APC None
Ki67 High temperature, in citrate buffer
p53 High temperature, in citrate buffer
(3-catenin High temperature, in citrate buffer
E-cadherin High temperature, in citrate buffer
BrdU 2 N HC1 at 27 UC, 25 minutes
2.1.3.4. Blocking endogenous peroxidase activity
Because horseradish peroxidase was used as the detection system in these reactions, it
was necessary to block endogenous non-specific peroxidase in the tissues by
pretreatment with hydrogen peroxide. In a series of optimising trials, the conditions









Ki67 1.5% in distilled water 15 Room temperature
p-catenin 1.5% in distilled water 15 Room temperature
BrdU 1.5% in distilled water 15 Room temperature
APC 3.0% in distilled water 20 Room temperature
p53 0.5 % in methanol 15 Room temperature
E-cadherin 0.5 % in methanol 15 Room temperature
2.1.3.5. Permeabilisation of the sections
In some conditions, permeabilisation prior to antibody exposure was found to
improve the ultimate antigen visualisation. Saponin and TritonX-100 methods were
tested and the final conditions used were; permeated the sections with 0.1% saponin
(saponin 10 mg dissolved in 100 ml of distilled water) for 30 minutes.
2.1.3.6. Double labelling immunohistochemistry of P-catenin and BrdU
Additional optimisation was required for double immunostaining of P-catenin and
BrdU. The final conditions were high temperature pretreatment, followed by immersion
in 2 N HC1 at 27 °C for 25 minutes, and finally blocking of endogenous peroxidase in
1.5% hydrogen peroxide for 15 minutes. BrdU staining was visualised with horseradish
peroxidase and P-catenin staining was visualised with alkaline phosphatase. Alkaline
phosphatase is an intestinal isoenzyme. Endogenous alkaline phosphatase can be
inhibited by the addition of levamisole to the Tris buffer pH 8.2 prior to the preparation
of the working solution. After optimisation of each step of the immunohistochemistry
technique in this study I outline the protocol for the techniques used in this study in the
following table 2.1.
69























































































































2.1.4. Purification of rabbit polyclonal APC antibody
Protein A Sepharose beads (Pharmacia, Sweden) 0.5 g were swelled by suspension in
2.0 ml of distilled water for 3 hours, centrifuged at 13,000 rpm, for 20 seconds, and
washed by multiple resuspensions and centrifugation in distilled water. The washed
beads were loaded into a 1 cm diameter column equilibrated in 20 mM sodium
phosphate buffer pH 7.0 (see appendix B). Five hundred microliters of crude APC
antiserum was applied to the protein A column followed by 3 column volume of 20 mM
sodium phosphate buffer. For elution of the immunoglobulin bound to the Sepharose,
1.5 ml of 0.1 M. glycine buffer pH 3.0 (see appendix B) was applied and 3 drops of each
fraction was collected into 2 drops of 0.5 M. Tris/HCl pFl 9.0 (see appendix B) to give
20 fractions in total. 1 pi of each fraction was spotted onto nitrocellulose membrane and
allowed to air dry for 1 minute. The nitrocellulose membrane was stained in 0.25%
Coomassie brilliant blue, in 10% methanol and 7% acetic acid (see appendix B) for 30
seconds, washed in 10% methanol and 7% acetic acid for 5 minutes and air-dried at
room temperature. Positivity staining (immunoglobulin enriched) fractions were
aliquoted, 0.02% sodium azide (see appendix B) added to each aliquot, and stored at
-20°C. The protein A column was stored in 20% ethanol in 0.1 M sodium phosphate
buffer pH 7.0 (see appendix B), at 4 °C, and could be re-used (for further purifications of
the same antiserum).
2.1.5. Immunohistochemistry
Immunohistochemistry was performed on 3 micron paraffin sections, mounted on
poly-l-lysine coated, cleaned glass slides. Following antigen retrieval (as required) and
hydrogen peroxide treatment, the sections were exposed sequentially to 20% normal
serum in 0.1%Tween 20/TBS (see appendix B) to block non-specific antibody-binding
sites, to primary antibody in the same buffer, 3 buffer washes, secondary antibody and
ABComplex/HRP detection system, all in 0.1%Tween 20/TBS buffer. The complex was
developed with diaminobenzidine 0.5 mg/ml (DAB, see appendix B) for 5-8 minutes at
room temperature, lightly counterstained with Harris haematoxylin (see appendix B) 20
to 25 seconds. Details of the protocol are in the appendix A.
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2.2. Results
2.2.1. Immunohistochemistry pattern of APC antibody staining
The expression pattern of Ape was studied in the epithelial cells of normal mice and
animals bearing germline alterations in the Ape, Msh2 and p53 genes by antibody
staining. In normal animals Ape protein staining was found positive in cytoplasm in
columnar epithelium in the intestine whereas in the lower third of the crypts was almost
always negative. In addition, the intestinal columnar epithelium of the luminal surface
showed strong staining along their apical surfaces, this apical polarity pattern continued
up to the villi, where the cells also showed accentuation of staining on their lateral
margins. Diffuse cytoplasmic positive Ape staining was found in columnar epithelial
lining in bronchiole of the lung. Similarity diffuse cytoplasmic Ape expression was
found in hepatocytes, in cuboidal epithelium of the fallopian tube, uterine gland,
proximal and distal renal tubules, epididymis, mammary gland and salivary gland. This
pattern of Ape staining also found in the endothelial lining cells in lymphatic vessels in
the spleen, lymph node and uterine body. The stratified squamous epithelium in
epidermis showed cytoplasmic staining of Ape protein. Muscle and brain tissue showed
diffuse cytoplasmic staining whereas neurons and pancreatic acinar cells showed
negative staining, although pancreatic ductal epithelium showed cytoplasmic positive
staining. The Ape positivity also was observed in the podocyte in renal glomerulus,
chondrocyte, and inner nuclear layer of retina and in nucleus of Sertoli cell in the testes.
The cardiac muscle showed negative Ape staining.
The staining intensity of Ape was weak or absent in intestinal lesions arising in
Ape Min+/\ (Ape Min+/Vp53 "7") and (Ape Min+/7Msh2 "A) mice.
2.2.2. Immunohistochemistry pattern of E-cadherin staining
The pattern of E-cadherin expression was investigated in the epithelial cells of
various tissues in Ape Min+/\ (Ape Mm+/7p53 ~/~) and Msh2 _/~ mice as above. The pattern of
E-cadherin expression within morphologically normal epithelium: columnar, cuboid,
endothelial lining and stratified squamous epithelium was at the lateral cell membrane in
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all types of epithelium with the exception of the proximal renal tubule which showed
strong E-cadherin staining at the basement membrane and diffuse staining in cytoplasm.
E-cadherin staining was also noted in non-epithelium cells such as pancreatic acinar
cells and in the zona pellucida. No E-cadherin expression was seen in brain, retina,
cardiac and skeletal muscle. Thus, although Ape and E-cadherin was found to be
colocalised in intestinal epithelial, there are many circumstances in which this
expression differed substantially. In particular in endothelial lining cells, stratified
squamous epithelium, muscle, brain, retina and in zona pellucida.
E-cadherin expression was found to be positive by immunostaining in large
adenomas but reduced or absent in small lesions. This pattern of E-cadherin staining in
the lesions was true for all genotype combination.
2.2.3. Immunohistochemistry pattern of P-catenin staining
The expression pattern of P-catenin in the epithelial cells of various organs in
Ape Mm+/'t (Ape Mm+/7p53 "/") and Msh2 mice was investigated. In normal animals,
P-catenin immunopositivity was found at the lateral cell membrane of normal epithelial
cells. p-Catenin expression was also observed in the nucleus of the Paneth cell. P~
Catenin expression was observed at the lateral cell membrane of the columnar
epithelium in the intestine, with immunoreactivity of epithelial cells increased gradually
from the bases of the crypts to the luminal surfaces. A similar pattern of P-catenin
expression was found at the lateral cell membrane of bronchiolar epithelium in the lung,
including endothelial lining cells in the alveoli, uterine body, choroid plexus in the brain,
ventricle in the brain, lymphatic vessel in the spleen and the lymph node. P-Catenin
positivity was found at the lateral cell membrane of pancreatic acinar cells, hepatic bile
duct, Graaffian follicle, fallopian tube, uterine gland and epididymis. Whereas diffuse
cytoplasmic including basolateral positive staining of P-catenin was observed in the
cuboidal epithelium in renal tubule of the renal cortex, mammary gland and salivary
gland.
P-Catenin stained strongly in the cytoplasm of the stratified squamous epithelium of
the epidermis. In non-epithelial cells such as chondrocytes, P-catenin showed positive
73
staining at the cell membrane of chondrocytes. In the cardiac muscle P-catenin
expression was found strongly expressed at the intercalated disc. There was P-catenin
expression observed at the cell membrane of Sertoli cell in the testes, and in the
cytoplasm of granulosa lutian cell. P-Catenin staining was found to be diffusely positive
in outer and inner plexiform layers of retina, hippocampus, cytoplasmic of granular layer
and pyramidal layer of the cerebrum including molecular layer and granular layer of the
cerebellum. (3-Catenin showed negative staining in muscle and Purkinje cell in the brain.
Thus, although P-catenin and E-cadherin frequently co-localised in epithelial cell
type, there are some circumstances in which their expression differs. In particular, in
cardiac muscle, chondrocytes and neurons.
Overexpression of P-catenin was found in dysplastic and neoplastic cells in the
intestine and pancreas in Ape Mm+/~ and (Ape Min+/7p53 mice, in comparison with
adjacent morphologically normal cells. They showed both nuclear and cytoplasmic
staining of P-catenin, which will be studied in detail in the next chapter.
Example of tissues stained with Ape, P-catenin and E-cadherin are shown in the
figure 2.1 to 2.5. Summaries of the patterns of immunohistochemistry staining are
presented in the following tables:
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Table 2.3. Immunohistochemistry staining pattern in (Ape Ml"+/'/p53 ~A) mice
Organs P-catenin Ape E-cadherin
Intestine, normal (+) at lateral cell
membrane of
epithelium
(+) in cytoplasm and
apical surface of
epithelium
(+) at lateral cell
membrane of
epithelium
Intestinal adenoma (++++) in nuclei and
cytoplasm
(+) range from weak to
unstained
Negative/positive
Pancreas (+) at lateral cell
membrane of
pancreatic acinar cell
(+) in cytoplasm of
ductal epithelium
(+) at lateral cell
membrane of
pancreatic acinar cell
Pancreatic lesion (++++) in nuclei and
cytoplasm of lesions
(+) in cytoplasm of
ductal epithelium
(+) at periphery of
pancreatic tumour cells
Uterus (+) in uterine
epithelium
(+) in cytoplasm of
epithelium
(+) at border of
epithelium





(+) in corpus luteum
and epithelium of
Fallopian tube
Testes (+) at membrane of
Sertoli cell
(+) in nucleus of Sertoli
cell
Negative
Epididymis (+) at lateral cell
membrane of
epithelium
(+) in cytoplasm of
epithelium
Negative






Kidney (+) in cytoplasm of
renal cortex tubules,
granular pattern
(+) in cytoplasm and
nuclei of proximal and
distal tubules, podocyte
(+) in cytoplasm of
proximal and distal
renal tubules










Table 2.3. Immunohistochemistry staining pattern in (Ape Ml"+l/p53 ) mice (cont.)
Organs P-catenin Ape E-cadherin
Lung (+) at lateral cell
membrane of
bronchiolar epithelium
(+) in cytoplasm of
bronchiolar and
alveolar epithelium
(+) at lateral cell
membrane of
bronchiolar epithelium
Heart (+) at intercalated disc
of cardiac muscle
(+) in cytoplasm of
cardiac muscle
Negative
Brain Positive Positive Negative
Retina (+) in outer and inner
plexiform layers
(+) in inner nuclear
layers
Negative






Mammary gland (+) at base of
epithelium
(+) in cytoplasm of
alveolar epithelium
(+) at lateral of
epithelium
Salivary gland (+) at lateral cell
membrane of glandular
and ductal epithelium
(+) in cytoplasm of
glandular epithelium
(+) at lateral cell
membrane of glandular
and ductal epithelium
Muscle Negative (+) in cytoplasm of
muscle fibre
Negative
Bone (+) in chondrocyte (+) in chondrocytes Negative
Skin (+) at lateral cell
membrane of
epithelium
(+) in cytoplasm of
epithelium




Table 2.4. Immunohistochemistry staining in (Ape Mm+,'/Msh2 "") mice
Organs P-catenin Ape E-cadherin
Intestine, normal (+) at lateral border of
epithelium
(+) in cytoplasm and
apical surface of
epithelium
(+) at lateral surface
of epithelium
Intestinal adenoma (++++) in cytoplasm
and nuclei
Weak staining (+) in small lesions
but negative in large
lesions
Pancreas (+) at lateral cell
membrane of
pancreatic acinar cell
(+) in ductal epithelium (+) at lateral cell
membrane of
pancreatic acinar cell
Pancreatic lesion (++++) in nuclei and
cytoplasm of lesions
(+) in ductal epithelium Negative
Uterus (+) at lateral cell
membrane of
endothelium
(+) in cytoplasm of
endothelium
(+) at lateral cell
membrane of
endothelium





(+) in corpus luteum
and epithelium of
Fallopian tube
Testes (+) at membrane of
Sertoli cell
(+) in nucleus of Sertoli
cell
Negative
Epididymis (+) at lateral cell
membrane of
epithelium
(+) in cytoplasm of
epithelium
Negative







Kidney (+) in cytoplasm of
renal cortex tubules
(+) in cytoplasm of
proximal and distal renal
tubules, podocyte
(+) in cytoplasm of
proximal renal
tubules
Liver (+) in cytoplasm of
hepatocytes (granular
pattern), epithelium of
(+) in cytoplasm of
hepatocytes




Table 2.4. Immunohistochemistry staining in (Ape tn+/Msh2~") mice (cont.)
Organs P-catenin Ape E-cadherin
Lung (+) at lateral cell
membrane of
bronchiolar epithelium
(+) in cytoplasm and
apical surface of
bronchiolar epithelium




Heart (+) at intercalated disc (+) in cytoplasm of heart
muscle
Negative
Brain Positive Positive Negative
Retina (+) in outer and inner
plexiform layers
(+) in inner nuclear
layers
Negative










Mammary gland (+) at the base of
epithelium
(+) in cytoplasm of
alveolar epithelium
(+) at periphery of
alveolar epithelium
Salivary gland (+) at lateral border of
glandular and ductal
epithelium




Muscle Negative (+) in cytoplasm of
muscle fibre
Negative
Bone (+) in chondrocyte (+) in chondrocytes Negative




(+) in cytoplasm and
nuclei of epithelium





Table 2.5. Immunohistochemistry staining in Ape Mm+/~ mice
Organs P-catenin Ape E-cadherin
Intestine, normal (+) at lateral border of
epithelium
(+) in cytoplasm and
apical surface of
epithelium




(++++) in cytoplasm and
nuclei
(+) range from weak to
unstained
Negative/positive
Pancreas (+) at lateral cell membrane
of pancreatic acinar cell
(+) in cytoplasm of
ductal epithelium
(+) at lateral cell
membrane of
pancreatic cell
Pancreatic lesion (++++) in cytoplasm and
nuclei of pancreatic lesions




Uterus (+) at lateral cell membrane
of endothelium
(+) in cytoplasm of
endothelium
(+) at lateral cell
membrane of
endothelium
Ovary (+) in corpus luteum and
epithelium of Fallopian tube
Epithelium of
Fallopian tube
(+) in corpus luteum
and epithelium of
Fallopian tube
Testes (+) at membrane of Sertoli
cell
(+) in nucleus of Sertoli
cell
Negative
Epididymis (+) at lateral cell membrane
of epithelium
(+) in cytoplasm and
nuclei of epithelium
(+) at periphery of
epithelium






Kidney (+) in cytoplasm of renal
cortex tubules
(+) in cytoplasm of
proximal and distal
renal tubules, podocyte
(+) in cytoplasm of
proximal renal tubules
Liver (+) in cytoplasm of
hepatocytes (granular
pattern), epithelium of bile
duct
Negative (+) endothelial lining
Lung (+) at lateral border of (+) in cytoplasm of (+) at lateral border of
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bronchiolar epithelium bronchiolar epithelium bronchiolar epithelium
Table 2.5. Immunohistochemistry staining in Ape Ml"+/~ mice (continued)
Organs P-catenin Ape E-cadherin
Heart (+) at intercalated disc of
cardiac muscle
Negative Negative
Brain Positive Positive Negative
Retina (+) in outer and inner
plexiform layers
(+) in inner nuclear
layers
Negative






Mammary gland (+) at base of glandular
epithelium
(+) in cytoplasm of
epithelium
(+) at lateral cell
membrane of
epithelium
Salivary gland (+) at lateral, base of
epithelium and in cytoplasm
(granular pattern)
(+) in cytoplasm of
epithelium
(+) at periphery of
epithelium
Muscle Negative (+) in cytoplasm of
muscle fibre
Negative
Bone chondrocyte chondrocyte Negative
Skin (+) at lateral cell membrane
of stratified epithelium of
epidermis
(+) in cytoplasm of
epithelium




Table 2.6. Immunohistochemistry staining in Msh2 mice
Organs P-catenin Ape E-cadherin
Intestine, normal (+) at lateral cell
membrane of epithelium
(+) in cytoplasm and
apical surface of
epithelium




Negative in small lesions
but (+++) in large lesions
Weak Negative
Pancreas (+) at lateral cell
membrane of pancreatic
acinar cell
(+) in cytoplasm of
ductal epithelium
(+) at lateral cell
membrane of pancreatic
cell
Pancreas lesion No lesion No lesion No lesion
Uterus (+) at lateral cell
membrane of epithelium
(+) in cytoplasm of
epithelium
(+) at lateral cell
membrane of epithelium




Testes (+) at membrane of
Sertoli cell
(+) in nucleus of Sertoli
cell
Negative
Epididymis (+) at lateral cell
membrane of epithelium
(+) in cytoplasm and
nuclei of epithelium
(+) at periphery of
epithelium






Kidney (+) in cytoplasm of renal
cortex tubules
(+) in cytoplasm of
proximal and distal
renal tubules, podocyte
(+) in cytoplasm of
proximal renal tubules




Negative (+) endothelial lining
Lung (+) at lateral border of
bronchiolar epithelium
(+) in cytoplasm of
bronchiolar epithelium
(+) at lateral border of
bronchiolar epithelium
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Table 2.6. Immunohistochemistry staining in Msh2 '' mice (continued)
Organs P-catenin Ape E-cadherin
Heart (+) at intercalated disc (+) in cytoplasm of
muscle fibre
Negative
Brain Positive Positive Negative
Retina (+) in outer and inner
plexiform layers
(+) in inner nuclear
layers
Negative






Mammary gland (+) at base of glandular
epithelium
(+) in cytoplasm of
epithelium
(+) at lateral cell
membrane of epithelium




(+) in cytoplasm of
epithelium
(+) at periphery of
epithelium
Muscle Negative (+) in cytoplasm of
muscle fibre
Negative
Bone chondrocyte chondrocyte Negative
Skin (+) at lateral cell
membrane of stratified
epithelium of epidermis
(+) in cytoplasm of
stratified epithelium of
epidermis
(+) in cytoplasm at




Figure 2.1 The pattern of P-catenin, Ape and E-cadherin staining in the normal intestine
and kidney in Apcm", p53 and MshZA mice
A-C Photographs demonstrating the staining in normal intestine: (A) Photograph showing
normal pattern of P-catenin in intestinal epithelium (magnification x400? inset xlOOO), (B)
Photograph showing normal pattern of Ape staining (magnification x400, inset xlOOO) and (C)
Photograph showing normal pattern of E-cadherin staining (magnification x400, inset xlOOO).
D-F Photographs demonstrating the staining in the kidney: (D) and (F) Photographs showing
normal pattern of P-catenin and E-cadherin staining in proximal renal tubules (arrows)
(magnification x400)? (E) Photograph showing pattern ofApe staining in podocytes (xlOOO).
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Figure 2.2 The pattern of P-catenin, Ape and E-cadherin staining in the ovary and testes in
ApcMl", p53 and MshTA mice
A-C Photographs demonstrating the staining in ovary: (A) Photograph showing P-catenin
expression in Graaffian follicle (inset mag. xlOOO), (B) Photograph showing Ape negativity in
ovarian follicle (inset mag. xlOOO), and (C) Photograph showing E-cadherin positive staining in
zona pellucida (inset xlOOO). D-F Photographs demonstrating the staining in the testes: (D)
Photograph showing P-catenin positive staining at cellular membrane of Sertoli cells (arrows,
mag. xlOOO), (E) Photograph showing Ape positivity in the nuclei of Sertoli cells (arrows, mag.
xlOOO) and (F) Photograph showing E-cadherin negative staining.
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Figure 2.3 Photographs showing the pattern of immunohistochemistry of P-catenin,
Ape and E-cadherin in retina and skin
A-C Photographs showing pattern of staining in retina: (A) p-catenin positive staining in
plexiform layers (arrows, mag. x400), (B) Ape positive staining in outer nuclear layer
(arrows, mag. x 1000) and (C) E-cadherin failed to show positivity in the retina. D-F
Photographs showing positive staining of P-catenin (D), Ape (E) and E-cadherin (F) in
the epidermis (arrows, mag. x400).
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Figure 2.4 The pattern of (3-catenin, Ape and E-cadherin staining in the heart and
lung in ApcMm,p53 and Msh2'A mice
A-C Photographs demonstrating the staining in the heart: (A) Photograph showing (3-
catenin expression at intercalated disc in cardiac muscle (arrows, mag. x400). (B) and
(C) Photographs showing negative staining of Ape and E-cadherin (mag. x400). D-F
Photographs demonstrating the staining in the lung: (D) and (F) Photographs showing (3-
catenin and E-cadherin positivity at lateral cell membrane of columnar epithelium(mag.




Figure 2.5 The pattern of p-catenin, Ape and E-cadherin immunohistochemical staining in intestinal
and pancreatic lesions arising in Apc+/~ and Apc+/Vp53~A mice
Photographs A-C showing intestinal lesions, photographs D-F showing pancreatic lesions at magnification
x400. (A) Photograph showing overexpression of P-catenin in intestinal lesion (arrow head) normal
pattern in epithelium covering lesion (arrow) (B) Photograph showing Ape negative staining in intestinal
lesions (arrow head) and normal pattern of staining in the epithelium (arrow) (C) Photograph showing
normal E-cadherin staining in epithelial (arrow) and no staining in the intestinal lesions (arrow head). Both
B and C showed some area of positive staining of Ape and E-cadherin respectively. (D) Photograph
showing P-catenin overexpression in pancreatic lesion (arrow head) compared with normal pancreatic
acinar cells (arrow) (E) Photograph showing absence of Ape staining in pancreatic lesion (arrow head)
compared with normal pancreatic acinar cells (arrow) (E) Photograph showing normal E-cadherin staining
at pancreatic cell membrane in normal (arrow) and pancreatic lesion (arrow head).
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2.3. Discussion
The data showed that the distribution of Ape is widespread, including epithelial,
mesenchymal and central nervous system tissues. It shows cytoplasmic, membrane-
related and nuclear patterns, which is similar to the pattern of staining in normal human
tissues (Midgley et al 1997). Of interest, strong positive Ape nuclear staining was noted
in the inner nuclear layer of retina and Sertoli cell, which are present in the seminiferous
tubules and functions in releasing an androgen-binding protein. These results were
supported by Neufeld and White (1997) who demonstrated nuclear localisation of Ape
in non-migrating cells whereas cytoplasmic localisation of Ape was found in migrating
cells (Neufeld and White 1997). In Ape Min+/~ mice, mutation of a wild type Ape allele to
produce the Min allele does not affect the expression pattern of Ape protein.
The pattern of P-catenin and E-cadherin expression in normal tissues in Ape Mm+/\
(Ape Mm+/~ /p53 ~A) and (Ape Mm+/~ /Msh2 v~) mice showed frequent co-localisation in
epithelial cells at the zonula adherens junction. E-cadherin staining was found positive in
epithelial cell types except in the epididymis. In non-epithelial cell types including
cardiac muscle, skeletal muscle, chondrocyte, neuron and inner nuclear layer of the
retina E-cadherin staining was negative. This is due to in the neuron, chondrocyte,
skeletal muscle and cardiac muscle consisting of N-cadherin (Takeichi 1987), OB-
cadherin (Okazaki et al 1994), M-cadherin (Donalies et al 1991) and H-cadherin (Lee
1996). These family members do not cross react with the antibody against E-cadherin
used in this study.
P-Catenin expression was found positive in all epithelial cell types and in non-
epithelial cell type including nervous tissue, cardiac muscle, connective tissue such as
chondrocyte whereas P-catenin was negative in skeletal muscle. Intense staining of —
P-catenin was observed at the intercalated disc in the cardiac muscle in which —
E-cadherin was found negative. The intercalated disc represents the boundaries between
individual cardiac muscle cells. It covers the ends of adjacent contiguous cardiac muscle
cells at the level of the Z line. This specialised attachment is called a fascia adherens,
which is similar to the zonula adherens of an epithelial cell (Kessel 1998). In the fascia
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adherens of cardiac muscle cells a different member of the cadherin family is present
other than E-cadherin as mentioned above. There is no fascia adherens in the structure of
the smooth and skeletal muscle cells. In the kidney, p-catenin expression was
demonstrated in cytoplasm and at basolateral cell membrane in renal tubule, in particular
in proximal and distal renal tubule, which showed colocalisation with E-cadherin.
Normally, E-cadherin expression is restricted to the distal renal tubule and collecting
duct in human (Vestweber et al 1985). There is evidence of the expression of —
cadherin-6, which is a fetal kidney cadherin, expressed in 32 primary renal cell cancer
and in the proximal renal tubule epithelium in human normal kidney (Paul et al 1997).
In addition, they also found cadherin-6 coprecipitated with P-catenin antibody in
primary renal cell cancer, which indicated the tendency of these types of renal tubules to
give rise to the majority of neoplasm of this organ. In my study E-cadherin was found
colocalised with P-catenin in proximal and distal tubules in mouse which is due to
species difference as previously observed (Piepenhagen and Nelson 1995). Nuclear
positive of P-catenin was found occasionally in renal proximal tubule could be the
resulting of proliferation in these epithelial cells.
In the normal mouse intestinal epithelium, Ape protein expression at the apical
surface of epithelium does not colocalise with P-catenin or E-cadherin but they show
colocalisation at the lateral cellular membrane of epithelial cell type. Miyashiro et al
(1995) reported the pattern of APC and a-catenin (a member of catenin family)
immunostaining in human osteosarcoma cell line using both microscopic and electron
microscopic studies. In this study they showed colocalisation of APC and a-catenin at
the lateral cell membrane. These studies support the concept that APC or Ape function
in regulation of cell adhesion with catenins and cadherins in the epithelium whereas the
APC or Ape in the microvilli in the apical surface has other functions independent of
catenins or cadherins.
The pattern of Ape, p-catenin and E-cadherin protein staining in normal tissues in
different genotype background of animal was not different, at least at the level of
immunohistochemistry. Interestingly, the expression of Ape and E-cadherin in the
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intestinal and pancreatic lesions showed absence of positivity to weak staining whereas
P-catenin was found very intense in the lesions arising in mutant animals. This
observation suggests a relationship between Ape, E-cadherin and P-catenin in the Wnt
signalling pathway in carcinogenesis which needs to be further investigated in detail.
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Chapter 3
P-Catenin dysregulation in murine intestinal
and pancreatic lesions
In the previous chapter, the expression of Ape and related molecules was described in
the normal tissues of wild type mice and genetic variants with germline deficiency of
Ape, p53 and Msh2. These mice are susceptible to neoplasia in various organs, however,
the opportunity to analyse and to examine the expression of these molecules and —
(3-catenin in particular, in such neoplasms, from their earliest origin through to more
advanced lesions. Ape Ml"+/' mice develop large and small intestinal adenomas, a small
proportion of which become malignant (Moser et al 1992, 1993). p53 deficient mice
develop predominantly lymphomas and sarcomas (Clarke et al 1993). In —
(Ape Mm+/Vp53 ~A) mice, cooperativity between these mutations has been demonstrated,
dysplasia and preneoplastic foci were seen in 61% of these animals and pancreatic acinar
cell adenocarcinoma in 22% and also were characterised by sarcoma and lymphoma,
both thymic and extra-thymic. (Ape Mm+/VMsh2 ~/~) mice are characterised by accelerated
intestinal tumorigenesis as well as reduced survival of the mice (Reitmair et al 1996). It
is of interest to focus on P-catenin expression in particular because of its functional
relationship to Ape. Therefore, I decided to focus on intestinal epithelial cells and
pancreatic acinar cells, which show dysregulation of P-catenin.
In light of the known development of intestinal adenomas in animals mutant for
Msh2 but wild type Ape, and the dependence of pancreatic adenoma predisposition in
p53 null on Ape Min background, it was of particular interest to study early events in
tumour development in the intestine and pancreas in these animals.
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3.1. Materials and Methods
3.1.1. Mice
Mice mutant for Msh2 (de Wind et al 1998), p53 (Clarke et al 1993) and Ape Mm
(Moser et al 1992) were maintained as out-bred colonies segregating for Ola/129, Balb
C, SWR and C57B1/6 genomes. Mice were monitored on a daily basis for signs of ill
health and were killed when they clearly showed signs of neoplastic disease.
3.1.2. Immunohistochemistry
Swiss rolls of the intestines were made as previously described (see 2.1.2). All tissues
were processed and paraffin-embedded (see 2.1.2). Three-micron sections were
subjected to high temperature antigen retrieval as required for (3-catenin
immunostaining, followed by blocking in 1.5% H2O2 solution and non-specific binding
by incubation in 20% normal rabbit serum. Sections were then incubated with a 1:50
dilution of mouse monoclonal antibody raised against (3-catenin (IgGi, clone 14,
Transduction Laboratories, UK) and subsequently with 1:400 dilution of rabbit anti-
mouse biotinylated secondary antibody (Dako, Denmark). The ABComplex/HRP (Dako,
Denmark) was used as the detection system and the labelled complex was developed
with diaminobenzidine 0.5 mg/ml (see appendix B). Details of the
immunohistochemistry protocol are in appendix A.
3.1.3. Histological Microdissection
This was performed as previously described (Going and Lamb 1996). Paraffin-
embedded tissues were cut at 7 microns, collected on clean plain glass slides and dried
in a 37 °C oven, overnight. They were subsequently dewaxed in xylene for 10 minutes
and re-hydrated in graded alcohol and distilled water. The sections were then stained in
0.05% aqueous toluidine blue (see appendix B) for 20 seconds, washed and stored in
distilled water until dissection. Excess water was blotted from the slide, which was then
placed on the stage of a stereo microscope. Proteinase K buffer solution (see appendix
B) was dropped onto the section. Dissection was performed with an electrolytically
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sharpened 25 mm length tungsten wire needle using a Leica mechanical
micromanipulator. Detail of the protocol for microdissection is in appendix A.
3.1.4. PCR analysis of Ape locus
Samples from the microdissection were digested overnight in buffer containing
proteinase K lmg/ml and 1% Tween 20 (see appendix B). The proteinase K was
subsequently heat-inactivated at 95 °C, for 10 minutes in a PCR thermal cycler. PCR
amplification of Ape (Min PCR) was then performed as previously described (Luongo et
al 1994) using the primers
5' TCTCGTTCTGAGAAAGACAGAAGCT 3' and
5' TGATACTTCTTCCAAAGCTTTGGCTAT 3'
Each 50 pi reaction contained; 0.05 pM of Ape PCR primers (Oswel, UK), 0.2 mM of
each dNTP, 5% DMSO, 10 mM Tris/HCl, 25 mM KC1, 50 mM MgCb, 2.5 units Taq
DNA Polymerase (PCR reagents were supplied by GIBCO/BRL), and 2 pi of DNA
template. Samples were amplified under the following conditions: 1 cycle at 94 °C for 2
minutes followed by 30 cycles at 94 °C for 1 minute, 60 °C for 1 minute, and 72 °C for 1
minute followed by 1 cycle at 72 °C for 10 minutes. One microliter of each PCR reaction
was then subjected to a second round of amplification using the nested primers
5' AGTAAGCAGAGACACAAGCA 3' and
5' CGGTGGTAGAAGCAGAACTT 3'
Each 50 pi reaction used 0.05 pM of nested primers, 65 mM MgCU and the same
concentration of other PCR reagents and subjected under the same parameters as in Min
PCR. Sixteen microlitres of each final PCR product was cleaved with the HindUl
restriction enzyme (GIBCO/BRL); pucl9 was included as a cleavage control. The PCR
products were analysed on 4% agarose gel stained with ethidium bromide 10 mg/ml (see
appendix B) viewed under UV light and photographed.
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3.2. Results
3.2.1. Expression of P-catenin in intestinal lesions
(A) Ape M"' and p53/Ape Ml" mutants
The pattern of P-catenin staining in intestinal lesions developing within Ape
heterozygotes was investigated. To control for staining variability between sections,
changes in the intensity of expression were always scored relative to normal epithelium
within the same section. The lesions were subclassified as: (I) single dysplastic crypts,
showing nuclear pleomorphism and stratification; (II) complex lesions, comprising
several architecturally distorted crypts in the lamina propia with virtually normal
overlying surface epithelium; (III) small adenomas, identified by the overall disturbance
of architecture including the surface and distinguished from the previous category on the
basis of increased size and surface involvement; and (IV) large adenomas (Figure 3.1).
There was a striking difference in (3-catenin staining intensity and distribution in
dysplastic crypts and small adenomas as compared with morphologically normal
epithelium. Whereas membrane staining was observed in the lower crypt epithelium of
normal mucosa, and nuclear staining was almost completely restricted to cells at the
crypt base, the dysplastic crypts, complex lesions and small adenomas showed intense
staining. This staining extended throughout the cytosol and included the nucleus in a
high proportion of cells. In some cells strong nuclear staining without concomitant
cytoplasmic staining was observed. These patterns of P-catenin staining in the dysplastic
crypts and small adenomas of both Ape Mm and (Ape Ml"/p53 ''') mice were more intense.
The pattern of P-catenin staining is summarised in Table 3.1 and Figure 3.3, it was
essentially identical in Ape Mm and (Ape Ml"/p53 mice, with all features described
below noted in both groups.
A substantial proportion of all lesion types showed heterogeneous staining of —
P-catenin even where only single crypts were involved (type I lesions, Figure 3.2B,
3.2E, Figure 3.3). The term 'heterogeneous or mosaic' was used to describe lesions in
which only a proportion of cells was characterised by increased intensity of P-catenin
staining. Thus, although the predominant pattern was as described, some cells retained
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the membrane restricted pattern characterised of normal cells. However, no lesions were
observed in which the cytosol and nuclear pattern were absent from all the cells. The
proportion of cells overexpressing (3-catenin was highest in type I, II and type III lesions.
Mosaic type IV lesions showed the lowest proportion of cells staining positive for —
(3-catenin (Figure 3.2F). Large areas of weak staining were observed in some late stage
lesions, including those categorised both as type IV (large adenomas) lesions (Figure
3.2G). Lesions in Ape Ml" and {Ape Mm/p53 ~/") mice are identical as described in table 3.1.
In all categories of lesion, the predominant pattern of increased (3-catenin staining
was within the nucleus and in cytoplasm. Any specific increase in the localisation of
(3-catenin to the cell membrane was not observed. However a pattern of strong nuclear
localisation without concomitant cytoplasmic staining was also observed within some
lesions. This pattern of staining was observed following fixation by both methacarn and
neutral buffered formalin.
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Figure 3.1 Photographs showing classification of the intestinal lesions
The intestinal lesions are classified as (A) a single dysplastic crypt (mag. X400), (B) a
complex lesion (mag. X400), (C) a small adenoma (mag. X200) and (D) a large adenoma
(mag. X200) as described in the text.
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Figure 3.2 The pattern of P-catenin staining in the intestine of ApcM,n+/" and
ApCM,n +/~/p53~/~ animals
(A-G) Photographs demonstrating the various features observed in animals with these
genotypes. All the features illustrated here were observed irrespective ofp53 status. All
scale bars represent 10 uM A) P-catenin staining in morphologically normal crypts of
the small intestine. P-catenin was detected throughout the cytoplasm of epithelial cells
but was strongly localised to the lateral borders. Strong nuclear localisation was
observed in cells at the crypt base (arrows) B) Heterogeneous expression in a type I
lesion. The majority of cells show the normal pattern of staining, with localisation to the
lateral borders. A subset of cells show increased cytoplasmic and nuclear staining. C)
Uniformly increased P-catenin staining within a type 1 lesion. D) Increased P-catenin
staining in a type II lesion. E) Heterogeneous expression in a type II lesion. Cells
showing increased P-catenin showed cytoplasmic localised and in some instances
nuclear localisation. F) Heterogeneous expression of P-catenin within a type III lesion.
G) Reduced expression within a type IV lesion. Where expression of P-catenin was
retained this was often localised to the nucleus.
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I II III IV I II III IV I II III IV I II III IV
B
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type of lesion
Figure 3.3 P-catenin expression patterns within each class of intestinal lesion.
A) Percentage of each lesion type showing either upregulation of P-catenin in all cells
(blue bars); a mosaic or heterogeneous pattern of upregulation as defined in the text (red
bars); or no upregulation (green bars). B) Histogram showing the percentage of cells
expressing high levels of p-catenin within lesions characterised by mosaic expression of
P-Catenin. Blue bars, ApcMm+/";Red bars, Apc7p5 Green bars, ApcMin+/~/Msh2~1'.
Mean values are given for each lesion category, as defined in the text. Error bars
represent SEM. Insufficient numbers of mosaic lesions were identified in Msh2 mice
to permit analysis.
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The same spectrum of morphological changes, from type I to type IV was observed in
Msh2 and (Ape Mm+/'/Msh2 animals, although fewer of type IV lesions were found
in the mice with Msh2 background. However, the pattern of P-catenin staining in
lesions differed from those in animals, which were Ape Min or (Ape M,n+/'lp53 ~") mice.
Significantly in Msh2 animals, type I, II and III lesions were identified which showed
normal P-catenin staining in all the cells (Figure 3.4B), a pattern which was never
observed in Ape Min or (Ape Mm+/'lp53 v") mice (Figure 3.4A). All type IV adenomas
however were characterised by increased intensity of P-catenin staining.
In (Ape Mm+/~IMsh2 ) mice, the majority of these lesions stained strongly for —
p-catenin (Figure 3.4C) but again a small number of type I and II lesions (5%) with the
normal pattern of P-catenin expression were identified (Figure 3.4D). All type IV lesions
arising in either Msh2 or (Ape Mm+/'/Msh2 mice analysed showed increased
intensity of P-catenin staining with an almost identical pattern to that observed in —
Ape M,n+/~ mice.
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Figure 3.4 The pattern of (3-catenin expression in the intestine of mice
(A-B) and ( Msh2~A,ApcMin+/) mice (C-D)
(A) Increased P-catenin staining in a type I lesion. (B) Normal pattern of P-catenin
expression in a type II lesion, with P-catenin strongly localised to the lateral borders. (C)
Increased P-catenin expression in a type II lesion. (D) Normal p-catenin expression in a
type II lesion, with retained localisation to the lateral borders. A type I lesion showing P-
catenin dysregulation is indicated for comparison (arrow). All scale bars represent
10pm.
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3.2.2. Expression pattern of P-catenin within the pancreas
(A) Ape Mi"+A and (Ape Ml"+/7p53 ~A) mice
Eighty three percent of mice mutant for both p53 and Ape developed pancreatic
tumours in this series. The tumours were adenomas or adenocarcinomas, predominantly
of acinar cell type, although foci of ductal differentiation were also observed. The
pattern of P-catenin staining was abnormal both within these lesions and also in areas
that appeared more normal morphologically. Within morphologically normal pancreatic
cells, P-catenin was usually observed at the cell membrane, without obvious nuclear
localisation. In (Ape Mm+/7p53 mice, all foci showing histological abnormality, both
adenoma and adenocarcinoma were characterised by high intensity of P-catenin staining
(Figure 3.5). In formalin fixed tissues (Figure 3.5C), the P-catenin distribution in these
lesions was membrane-associated, cytosolic and nuclear, as in the intestinal tumours of
these animals. However, following methacarn fixation, nuclear staining remained
prominent in the adenomas and adenocarcinomas, cytosolic staining was often absent. In
general, methacarn-fixed material showed less intense p-catenin staining at the cell
membrane of morphologically normal cells, making the contrast with the p-catenin
overexpression cells of the lesions more easily appreciated. The cell type observed in
these lesions was predominantly acinar, although some foci showed ductal
differentiation (Figure 3.5F, 3.5H).
The most remarkable feature in the pancreas of the Ape Mm+/~ animals, however, was
the presence of intense P-catenin staining in cell clusters that did not show the
morphological features of adenoma or carcinoma. The size of these clusters varied from
single cells (Figure 3.5A), through small aggregates of 2-10 cells (Figure 3.5B), to large
foci (Figure 3.5E). The presence of these p-catenin overexpression cell clusters gave the
pancreas a vivid patchwork appearance that had not been evident from inspection of the
haematoxylin and eosin stained sections. On closer examination and careful comparison
of adjacent sections stained by haematoxylin and eosin, and P-catenin
immunohistochemistry, it became clear that many of the clusters contained dysplastic
cells with enlarged, irregular nuclei. Such cells were never seen outside of P-catenin
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staining regions. It was also true, however, that a high proportion of P-catenin staining
cells in these preneoplastic foci showed no morphologically detectable change.
In view of these changes in preneoplastic foci in (Ape Min+/'/p53 mice, the pancreas
of Ape Mm+/~ mice with wild type p53 was studied with particular interest. Unlike the
{Ape Min+/'/p53 mice, these animals do not develop pancreatic neoplasia (Clarke et al
1995). (3-Catenin dysregulated foci were also seen in the pancreas of these mice, in
approximately the same numbers as in the mice with abnormal p53, although it was
technically difficult to develop this observation into a more quantitative score. The
dysregulated cells showed the same nuclear localisation of p-catenin as described above.
While many had apparently normal morphology, others showed dysplastic features.
In contrast, p-catenin dysregulated cells were never observed in normal animals (wild
type for Ape) or in p53 null mice on a wild type Ape background.
(B) Msh2 and {Ape Min+/7Msh2 A) mice
The pancreatic tissue derived from Msh2 mice and {Ape Mm+/'/Msh2 ") mice were
analysed. No abnormal expression of P-catenin or histological atypia was observed in
Msh2 "A mice. However, in {Ape Min+/'/Msh2 ~/~) mice again are identified foci of —
P-catenin dysregulation, these did not differ in morphological appearance from those
seen in Ape Mm+/~ animals. {Ape Mm+/'/Msh2 mice developed spontaneous pancreatic
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Figure 3.5 The pattern of P-catenin staining in the pancreas of Ap(^,m+/~ and ApcMm +/Vp53'A
mice
(A-E) are representative of the patterns of P-catenin staining and histological atypia observed in
the pancreas of both ApcMm+/~miceand ApcMm' /p53~A mice. (F-H) are representative of these
patterns in pancreatic adenomas and adenocarcinomas arising in mice. All scale
bars represent lOuM A) A single pancreatic acinar cell characterised by increased nuclear and
cytoplasmic expression. The surrounding acinar cells are representative of the normal pattern of
P-catenin staining, with localisation to the cell borders. B) Small focus of acinar cells with
increased expression. These foci were often composed of cells with increased nuclear size,
prominent examples of which are indicated by arrows. This focus also contains a cell (arrow
head) with no increase in nuclear expression of P-catenin. C) This picture demonstrates the
pattern of staining observed in formalin fixed tissues. Cells (arrowed or restricted to the upper
right hand portion of this photograph) showing increased nuclear and cytoplasmic staining of p-
catenin. D) A dysplastic adenoma showing increased p-catenin expression, but with no apparent
nuclear localisation. E) Increased P-catenin staining in a pancreatic focus, showing strong
nuclear localisation. Again, these foci were often composed of cells with increased nuclear size.
F) Heterogeneous P-catenin expression in an adenoma containing areas of acinar-ductal
transdifferentiation (arrow head). No p-catenin staining was detectable in normal ducts (arrow).
G) Weak staining of P-catenin within an acinar adenocarcinoma. H) Areas of ductal
differentiation within an acinar adenocarcinoma which retained high intensity of P-catenin
expression.
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3.2.3. Loss ofApe within intestinal and pancreatic lesions
To characterise the status of the remaining Ape allele in intestinal and the pancreatic
lesions arising in Ape Mi"+/~mice, PCR analysis on microdissected foci (Figure 3.6A and
3.6B) was performed. Lesions of various sizes were microdissected as described (see
appendix A) using serial sections were identified areas of increased (3-catenin staining as
a guide for microdissection. In this way it proved possible to analyse the status of the
Ape alleles in lesions as small as 50 cells. All lesions showing P-catenin dysregulation,
including the smallest were analysed by this method. Loss of the remaining wild type
Ape allele in both the intestinal and pancreatic lesions was found in Ape Min+/~ and
(Ape M"'+/~/p53 v~) mice whereas in (Ape Min+/'/Msh2 "/") mice the wild type Ape allele was
still intact (Figure 3.7).
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Figure 3.6 Photographs showing histopathological microdissected lesions
Photographs showing pale areas of intestinal lesion (A) and pancreatic lesion (B) stained
with toluidine blue, before microdissection. All photographs obtained at x400 of
magnification.
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Figure 3.7 PCR analysis ofApe alleles from microdissected tissues from ApcM,n and
Msh2~' mice
Photographs representative results from PCR analysis of microdissected lesions. WT,
the amplification products from the wild type Ape allele (111 bp). ApcMm', the
amplification product from the mutant allele (123 bp). (A) Samples were all derived
from lesions arising within ApcMm mutant mice and were as follow: lanel and 2,
pancreatic foci showing (3-catenin dysregulation; lane 3, normal pancreas; lane 4 and 5,
small intestinal lesions; lane 6 and 7, normal intestinal epithelium. (B) Samples were all
derived from lesions arising within ApcM'n and Msh2 mutant mice and were as follows:
lane 1 is negative control, lane 2 is HindiII restriction enzyme control, lane 3, 4 and lane
5 are intestinal lesions, lane 6 is normal intestinal tissue from ApcMm mice. Lane7 and
lane 8 are pancreatic lesions, lane 9 is normal pancreatic tissue from Msh2~/~ mice. All
results were obtained using microdissected areas containing approximately 50 cells.
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3.3. Discussion
This chapter shows that P-catenin dysregulation is a feature of early neoplasia in both
intestine and pancreatic epithelium of Ape Mm+/~ mice. It appears in the earliest single
crypt lesions in the intestine and also in lesions that are as small as single cells, which is
frequently seen as small cell clusters in the exocrine pancreas. In both sites, P-catenin is
distributed with a striking nuclear localisation, as well as being generally
overexpression. The significance of the cytosolic localisation is less certain, as this was
often absent from methacarn-fixed tissues. It was prominent, however after formalin
fixation, and may reflect the true distribution of P-catenin in the cytosol, but in a form
soluble by the glacial acetic acid/methanol/chloroform in methacarn.
The data also show that, as these abnormal foci progress to morphologically
identifiable adenomas and carcinomas, they also tend to lose the earlier overexpression
of P-catenin. Similar observations of the loss of P-catenin expression in late lesions have
been made from azoxymethane treated rat to induce intestinal adenomas (Sheng et al
1998).
Three additional findings are particularly significant in the interpretation of these
observations. First, even in the smallest P-catenin dysregulation lesions in Ape Mm+/~
mice, the normal Ape allele is lost. By microdissection, I analysed P-catenin
overexpression lesions of approximately 50 cells in size, which is equivalent to about 4-
5 cell divisions. The clarity of these results make it clear that these early lesions are
clonal derivatives of founder cells that have lost Ape, since a mixture of even a small
proportion of cells with a retained normal allele would have produced an obviously
different ratio of normal to mutant alleles from the pattern consistently observed.
Second, P-catenin dysregulation was never seen in the pancreas of animals with a wild
type Ape background. Third, in animals with wild type Ape but Msh2 null germline, P-
catenin dysregulation was observed in most intestinal adenomas but was absent from
some of the earliest lesions.
Inactivation of the remaining allele of the murine Ape was demonstrated in 100% of
tumour arising in Min mice (Levy et al 1994). Moreover, they observed inactivation in
108
the earliest recognisable phase of tumours, including some lesions containing as few as
two dysplastic crypts. The conclusion from my study is that P-catenin dysregulation
occurs as a direct consequence of loss of Ape-dependent proteolysis. In lesions within
both tissue types, P-catenin was predominantly localised to the nucleus, in agreement
with the report by Sheng et al (1998) that P-catenin was localised predominantly in the
nucleus of adenomas from Min/+ mice and transgenic mice expressing a mutant
truncated form of the APC gene. P-Catenin interaction with the transcription factor Lef-1
is known to activate transcription of the downstream target gene such as c-myc and —
AP-1, in the nucleus (He et al 1998, Mann et al 1999). The pattern of dysregulation was
not consistent in all the categories of lesions analysed. Thus, high intensity of P-catenin
staining were most consistently observed in early (type I and type II) lesions. Lower
degree of p-catenin staining was seen in larger lesions with only focal areas of weak
staining within some larger adenomas and adenocarcinomas. These findings suggested
that the genetic changes, which led to elevated P-catenin, were most relevant to the very
early stages of neoplasia. This concept was supported by observation of localised areas
of reduced or absent P-catenin staining within some adenomas and by studies of human
tumorigenesis in which down-regulation of both P-catenin and E-cadherin has been
reported in a range of carcinomas (Takayama et al 1996). In human colon cancer, about
48% of mutations in the NH2-terminal regulatory domain of CTNNB1 gene were found
in the early adenomatous stage of colorectal neoplasia (Sparks et al 1998). This study
was supported by the study of Samowitz et al (1999) whom demonstrated that the
percentage of p-catenin mutations in small adenomas (12.5%) was significantly greater
than that in large adenomas (2.4%) and invasive cancers (1.4%). Furthermore, mutations
of the P-catenin gene were also found in tumours derived from other organs both in
human and animals (de la Coste et al 1998). They found 26% of human hepatocellular
carcinoma had P-catenin mutations, and P-catenin mutations were found in 50% of
hepatic tumours in transgenic mice (de la Coste et al 1998).
Loss of P-catenin overexpression in late lesions is not absolute. In those lesions,
which no longer overexpressed P-catenin, further maintenance of the neoplastic state
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may be sustained by mutations in other genes. p-Catenin itself may be subject to
inactivation, or be down regulated by other signals emanating from altered gene
expression.
The absence of P-catenin overexpression in some intestinal type II lesions from
{Ape m+/'/Msh2 ~A) mice suggests that upregulation of P-catenin is not obligatory at this
stage. However, as the large lesions uniformly do overexpress P-catenin, it is clear that
inactivation of Ape is still selected for during adenoma growth. P-Catenin dysregulation
was shown as a common event observed in early lesions except in both Msh2 and
{Ape Min+/VMsh2 ~A) mice, which show the normal pattern of staining and distribution of
P-catenin in the lesions identified as type II. Thus, P-catenin overexpression was not
absolutely associated with early neoplastic change. These findings show that
dysregulated P-catenin is not an obligate event in early lesion formation. Furthermore, it
suggests Msh2 deficiency predisposes to such apparent p-catenin-independent events,
possibly through mutations in other components of the Wnt signalling pathway which do
not affect P-catenin levels or through mutations in other pathways. This data suggests
there are at least two pathways that permit the development of very small lesions. These
pathways appeared to converge as the proportion of lesions showing normal p-catenin
staining decreased with lesion size. The simplest interpretation of these results was that
the Msh2 background revealed the existence of a pathway to early lesion formation,
but further development of adenomas was still dependent on total loss of Ape function.
The data suggest there is an alternative genetic route to adenoma formation, independent
of Ape knockout, but ineffective in generating further progressive lesions. It could be of
significance in understanding the earliest stages of adenoma formation. The genetic
instability associated with Msh2 null status alone could not make the larger lesions thus
it is dependent on Ape knockout.
P-Catenin dysregulation was observed in clones within the pancreas of Min animals,
but these only progressed in the absence of wild type p53. This shows that functional
p53 stops preventing the development of neoplasia in this tissue, either by stopping cell
growth or initiating cell death.
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Nuclear size variation within even very small pancreatic lesions was noted, which
raising the possibility that loss of Ape function may promote genetic instability. Similar
nuclear abnormalities were identified in intestinal lesions. The roles played by both
tissue specificity and p53 in determining nuclear atypia were characterised in greater




Studies in this chapter pursued the initial observation of nuclear polymorphism in
pancreatic lesions. Nuclear size is determined by the relative quantities of DNA, histone,
acidic proteins, RNA and enzymes present within the nucleus. Genetic instability is
often reflected by changes in the nuclear volume. However, nuclear volume also
changes through the cell cycle in normal euploid cells as a consequence of the normal
replicative cycle. This chapter is focused upon changes in the nuclear volume in the
intestinal and pancreatic lesions arising in mice bearing defects in p53, Ape and the
mismatch repair gene, Msh2.
Mitotic nondisjunction can be a phenomenon of malignant cells, resulting in
chromosomal abnormalities. The term polyploidy is used to describe the situation where
more than two multiples of the haploid chromosome set are found. The naming of
polyploids is based on the number of sets of chromosomes found: a triploid has 3n
chromosomes; a tetraploid has 4n; a pentaploid has 5n and so forth. This condition is
relatively infrequent in most animal species although well known in lizards and
amphibians but much more common in plant species. In man, polyploidy is seen in both
the liver and in the pancreas. Odd numbers of chromosome sets are not usually
maintained reliably from generation to generation because a polyploid organism with an
odd number of homologues usually does not produce genetically balanced gametes.
Polyploidisation can originate in two ways: (1) the addition of one or more extra sets of
chromosomes which is identical to the normal haploid chromosome of the same species,
termed autopolyploidy; and (2) the combination of chromosome sets from different
species which may occur as a consequence of interspecific matings, termed
allopolyploidy.
Cell division involves both nuclear (mitosis) and cytoplasmic (cytokinesis) phases
giving rise to two new cells. The period between two mitotic divisions is defined as the
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somatic cell cycle and usually requires between 2-4 days. The time from the end of one
interval to the beginning of the next is called interphase. Interphase is divided into Gi, S
and G2 periods. The period of actual division, corresponding to the somatic mitosis, is
called M phase. Gi phase is the gap between mitosis and the onset of DNA replication.
During Gi phase RNAs and proteins are synthesised, but there is no DNA replication.
The initiation of DNA replication marks the transition from Gi phase to the period of S
phase. S phase is defined as a duration in which all DNA has been replicated and the
total DNA content increases from the diploid value of 2n to the fully replicated value of
4n. The period from the end of S phase until mitosis is called the G2 phase. During this
period, the cell has two complete diploid sets of chromosomes. Observations made in the
study of yeast fission showed that as cells grow during G2 phase, mRNA and protein
increase until mitosis is triggered, after which there is a sharp drop in both mRNA and
protein (reviewed in Lew and Kornbluth 1996). In labile cell such as haematopoietic
cells, cells undergo division without any stimuli. In permanent cell types such as neurons
and muscle cells, mature cells are considered to be withdrawn from the cell cycle into
another state that is called Go. In Go, they are unable to proceed into S phase. In stable
cell types such as the hepatocyte, fully differentiated cells can be stimulated to leave Go
and re-enter the cell cycle.
Circuits that respond to features such as completion of replication or cell mass are
called checkpoints. Genetic studies have identified many of the components of
checkpoints in the yeasts Saccharomyces cerevisiae (Murray 1995) and
Schizosaccharomyces pombe (D'Urso and Nurse 1995). The checkpoints play a role in
preventing the cycle from proceeding until a particular condition has been satisfied.
There are at least two points in the cycle at which a decision is taken on whether to
proceed; first is the commitment to chromosome replication, which occurs in Gi. Second
is the commitment to mitotic division, which occurs at the end of G2 phase. This
provides an opportunity for the cells to check that nuclear mass has increased to a level
adequate for division. In addition, there are systems to ensure that the fidelity of
replication is maintained, these are DNA damage checkpoints. The DNA damage
checkpoints act at three stages in the cell cycle, one at the Gi/S transition, one that
113
monitors progression through S and one at the G2/M boundary (Iatropoulos and Willium
1996). Arrest in Gi prevents copying of damaged bases, which would fix mutations in
the genome. Arrest in G2 allows DNA double-strand breaks to be repaired before
mitosis. Blocking cells with double-stranded DNA breaks from entering mitosis prevents
segregation of broken chromosomes, which would cause missegregation of genes distal
to the break. The other checkpoint prevents entry into S phase until DNA damage is
repaired this prevents the replication of DNA from damaged templates, which would
lead to DNA rearrangements.
Regulation of cell division is critical for the normal development of multicellular
organisms. The molecular processes, which regulate chromosome replication and cell
division, are fundamentally similar in all eukaryotic cells.
The cell cycle can be viewed as a kinase cycle with down-stream events such as
DNA replication occurring as a function of the activity of a particular cyclin-dependent
kinase (Cdk). The discovery that degradation of mitotic cyclins is necessary for cells to
exit mitosis showed that the proteolytic process is critical in the control of Cdk activity
and in driving the progression of the cell through the cell cycle. The ubiquitination
pathway has been found to trigger anaphase independently of Cdk activity, which
indicates that proteolysis directly controls a step in the chromosome cycle and is not
only used to drive the cell cycle.
The three cellular components involved in nuclear division are the DNA, the spindle
and the spindle pole or centrosome. Any defects that happen to any of these components
will result in genetic instability, which is characteristic of precancerous and cancerous
cells. Defects in the DNA could be responsible for chromosomal rearrangements such as
deletions, amplifications and translocations. Defects in the spindle could lead to mitotic
nondisjunction, producing loss or gain of whole chromosomes. Defects in the
centrosome could lead to changes in the ploidy of the genome. These three categories of
genomic change, chromosomal rearrangements, aneuploidy and polyploidy are all
common during cancer cell development.
The protein encoded by the p53 tumour suppressor gene, functions in the checkpoint
control that arrests cells with damaged DNA in Gi. Cells with functional p53 arrest in Gi
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when exposed to y-irradiation whereas cells lacking functional p53 do not. Although p53
protein normally has an extremely short half-life, DNA damage leads to the stabilisation
of p53, which then stimulates transcription of a number of genes including ATM (Ataxia
Telangiectasia Mutated) and p21. The ATM gene has been implicated in regulation of
p53. p21 (Dulic et al 1994, El-Deiry et al 1994), is a protein that binds to and inactivates
the cyclin-dependent kinases (Cdk) necessary for initiating DNA synthesis. As a result
cells are arrested in Gi until DNA damage is repaired. One report has even suggested
that p21 induction caused irreversible cell cycle arrest in both Gi and G2/M (Fang et al
1999).
p53 has also been implicated in the G2/M arrest and resulting in delayed DNA
replication. p53 regulates a mitotic spindle checkpoint that prevents DNA synthesis
before chromosomal segregation, which is a control of a G2/M checkpoint (Cross et al
1995, Guillouf et al 1995). Furthermore, p53 appears to be an integral part of the process
that regulates the number of centrosomes in a cell (Fukasawa et al 1996). These
functions of p53 in controlling the G2/M checkpoint may account for the phenotype of
genomic instability that is commonly associated with p53 mutation.
It has been reported that the APC protein inhibits cell cycle transition from the Gi to
S phase and that overexpression of the Cdk-cyclin proteins abrogate the cell cycle
blocking activity of APC (Baeg et al 1995, Heinen and Groden 1999). Recently, EB1,
which is a component of the microtubule cytoskeleton in mammalian cells, was
demonstrated to be colocalised both to cytoplasmic microtubules in interphase cells and
to spindle microtubules during mitosis in vitro (Berrueta et al 1998, Morrison et al
1998). Taken together with a study by Neufeld and White (1997) which showed nuclear
and cytoplasmic localisation of APC in human tumour cell lines, these findings are
consistent with a role for APC in both Gj and mitotic checkpoint control.
The mismatch repair system has been found to interact with the G2 checkpoint (Hawn
et al 1995) in response to methylating agent induced DNA damage. High levels of
hMSH2 protein were detected in the crypts of Lieberkuhn (Wilson et al 1995, Leach et
al 1996) which undergo rapid proliferation and are involved in the continuous
production of differentiated cells. The mismatch repair machinery has also been
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associated with apoptosis, which probably reflects the consequences of a mismatch
repair protein dependent checkpoint. Overexpression of hMSH2 and hMLHl has been
shown to lead to apoptosis in cells exposed to methylating agent (Zhang et al 1999),
although the mechanism by which hMSH2 and hMLHl may control apoptosis is still
unclear. Recently, a Msh2-dependent apoptotic response (mediated through a p53-
dependent pathway) was demonstrated in the mouse small intestine (Toft et al 1999).
Those previous studies suggested that mismatch repair gene is critical in the surveillance
of cells with damaged DNA.
In summary, there is a significant body of work implicating p53, Ape and the
mismatch repair proteins in control of cell cycle checkpoints in the cell cycle and
deficiency in these genes is associated with genetic instability.
DNA-aneuploidy and genetic instability is a feature of tumorigenesis which can be
scored by DNA ploidy analysis using image cytometry either by a two dimensional or a
three dimensional method. Image cytometry (ICM) is widely used to measure DNA
ploidy and has a number of advantages and limitations. ICM requires small numbers of
nuclei, 250 or more, and is usually applied to the disaggregated cells of solid tumours.
DNA content measured by image cytometry (ICM-DNA) has been used successfully to
identify aneuploid DNA content in a variety of malignancies and has enabled correlation
of ploidy with prognosis (Forsslund and Zetterberg 1990, Lukes et al 1994, Mir et al
1992). However, it should always be remembered that the DNA ploidy measured by
cytometry is only an estimate of the genetic material and can not reflect single events in
the genome nor the functional state of a tumour cell.
Earlier studies of DNA ploidy measurement in histological sections used a two-
dimensional (2D) approach (Moberger et al 1984, Greene et al 1991). However the
information obtained by 2D analysis was often subject to inaccuracy (Uyterlinde et al
1989, Mairinger et al 1994, Sperb et al 1993, Sapi et al 1993). The principal reason for
this was that in conventional 4 p. thick histologic sections, incomplete nuclear segments
occur as parts are cut off from nuclei with a diameter exceeding the section thickness.
This phenomenon is called capping (Bins and Takens 1985, Haroske et al 1984). In
thicker sections (8-10 p), capping is reduced but overlapping nuclei are still a major
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problem. Moreover, measurement of non-overlapping nuclei can be very time-
consuming and not always accurately reproducible. These problems can be overcome by
means of three-dimensional (3D) imaging, using a confocal laser scanning microscope
(CLSM) and thick histological sections. The basic principle of any scanning microscope
is that the sample is scanned with a probe that illuminates discrete points in the sample.
The signal from the interaction of the radiation probe with the sample is collected and
used to reconstruct an image. Both the lateral (x, y) and depth (z) resolution of a CLSM
is better than that of conventional microscopes, giving higher resolution images. With
CLSM, it is possible to optically section a thick histological section, without interference
from out-of-focus signals. Moreover, small samples can provide an adequate number of
nuclei for this method (Lajoie et al 1993). One problem with this technology is that the
stain used can affect the accuracy of the 3D measurement. The nuclear fluorescent stain
for routine two-dimensional and 3D CLSM morphometric and cytometric assessments
should have the following properties: (a) high specificity, proportionality, and sensitivity
for DNA; (b) stability (no or little bleaching); (c) simplicity of the staining procedure;
and (d) is inexpensive. Recently, two new cyanine fluorochromes, TOTO-1 iodide and
YOYO-1 iodide with DNA and RNA specificity have become commercially available
(Molecular Probes Inc., Eugene, OR). TOTO-1 iodide and YOYO-1 iodide bind to DNA
by intercalation. The relative fluorescence intensities of these dyes when bound to the
DNA bands obtained by gel electrophoresis indicate that dye-binding depends on DNA
content rather than base composition (Glazer et al 1990, Rye et al 1992). Moreover,
integrated TOTO-1 iodide and YOYO-1 iodide fluorescence showed good linearity with
the DNA content of diploid, tetraploid and octaploid liver nuclei (Tekola et al 1994).
Conventional two-dimensional studies of DNA ploidy can be performed using the
Highly Optimised Microscope Environment (HOME) which provides a simple facility
combining a microscope, electronic display and stage to enable location and relocation
of individual cells in pathological specimens. The system permits a variety of
morphological measurements to be taken on typical histological specimens.
From the observations made in the previous chapter it was noted that nuclear
pleomorphism was apparent in the pancreatic lesions arising in the mice mutant in Ape
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and p53. Two hypotheses for these observations were proposed; (a) that nuclear change
is an early event in the pancreatic lesions but not in the intestinal lesions; (b) that the
genotypes of the mutant mice were influencing the genetic instability in the lesions. To
test these hypotheses, a study was designed (a) to study nuclear change in small
populations of preneoplastic cells in mutant mice; (b) to determine the influence of a
range of genotypes of mice on the nuclear content seen in preneoplastic and neoplastic
lesions in the pancreas and in the intestine; and (c) to evaluate two dimensional analysis
using the HOME in comparison with three dimensional analysis performed using the
confocal laser scanning microscope.
The cell turnover rate was also measured by BrdU to clarify if any differences
observed in nuclear volume were related to cell turnover or if the change in the nuclear
volume could be directly attributed to genetic instability.
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4.1 Materials and Methods
4.1.1 Mice
Mice mutant for Ape Mm (Moser et al 1992) and Msh2 (de Wind et al 1998) were
maintained as out-bred colonies. Mice were monitored on a daily basis for signs of ill
health and prior to killing were injected intraperitoneally with BrdU (Boehringer
Mannheim, Germany) 250 mg per kg of body weight to permit cell turnover to be scored
in histological sections. Mice were killed by cervical dislocation 2 hours after BrdU
injection. The intestine and pancreas were removed immediately and immersed in
methacarn solution (see appendix B), left overnight at room temperature and processed
and embedded as previously described (see section 2.1.2)
4.1.2. Double labelling of P-catenin and BrdU
Immunohistochemical staining of P-catenin and BrdU was optimised as previously
described in session 2.1.3.
Three micron thick paraffin embedded sections were exposed to high temperature
antigen retrieval followed by incubation in 2.0 N HC1 at 27 °C for 25 minutes to
denature the DNA. Sections were permeabilised in 0.1% Saponin/TBS, subsequently
blocked in 1.5% hydrogen peroxide solution and incubated with 20% normal rabbit
serum in 0.1% Saponin/TBS (see appendix B) to block non-specific binding. Sections
were incubated with primary antibodies; mouse monoclonal anti-p-catenin
(Transduction Laboratories, UK) and rat monoclonal anti-BrdU (Harlan Sera lab, UK)
overnight at 4 °C, followed by incubation with secondary antibody rabbit anti-
rat/biotinylated (Immunopure, Pierce, USA) for 30 minutes at room temperature
followed by incubation in ABComplex/HRP for 30 minutes. The staining was visualised
with diaminobenzidine 0.5 mg/ml (see appendix B). The sections were next incubated
with secondary antibody rabbit anti-mouse/biotinylated (Dako, Germany), here
ABComplex/AP was used as a detection system. The labelled complex was visualised
with Vector Red (Vector Laboratory, UK). Details of the protocol are in appendix A.
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4.1.3. Triple labelling of immunofluorescence on 15 micron thick paraffin sections
Immunofluorescent triple labelling was initially optimised on three micron thick
sections. After dewaxing and rehydrating the sections, YOYO-1 iodide (Molecular
Probes, The Netherlands) was diluted in Tris/HCl, pH 7.6 in serial concentrations of;
0.1, 0.05, 0.025 pmol/(il to optimise the staining. The sections were dewaxed,
rehydrated, pretreatment in high temperature condition and HC1 as previously described
in section 4.1.2. Subsequently, section were permeabilised in 0.1% Saponin/TBS for 15
minutes on the shaking plate, followed by incubating with serial concentration of
YOYO-1 diluted in 20% normal goat serum, 0.025, 0.05, 0.075 and 0.01 pmol/pl,
overnight, in the dark at 4 °C and finally, washed well in 0.01% Saponin/TBS for 60
minutes at room temperature on the shaking plate. The optimum concentration of
YOYO-1 was 0.05 pmol/pl.
However, non-specific cytoplasmic fluorescence was observed in the stained
sections, which was thought to reflect RNA staining. The sections were incubated with
RNAse at a concentration of 7 pg/ml at 37 °C for 15, 30 and 45 minutes. Using this
approach, specific DNA staining in the nuclei was obtained after treatment with RNAse
at 37 °C for 45 minutes.
The next step was to optimise the use of the secondary antibodies for indirect
immunofluorescence. They were goat anti-mouse conjugated to rhodamine (Chemicon-
International, Inc.) and goat anti-rat Cy5 conjugate (Chemicon-International, Inc.).
These two secondary antibodies were diluted in serial concentrations of 0.5, 0.25, 0.125,
0.005, 0.0025 and 0.00125 pg/pl. The optimum concentration for goat anti-mouse
rhodamine was 0.25 pg/pl and goat anti-rat Cy5 was 0.0025 pg/pl.
Triple labelling immunofluorescence was first tried on three micron thick sections.
The sections underwent antigen retrieval in citrate buffer pH 6.0 and microwaved at 700
watts for 5 minutes, 3 times. After the sections were cool, they were immersed in 2 N
HC1 and incubated at 27 °C for 25 minutes. The sections were then washed well in water
and permeabilised with 0.1% saponin in TBS for 30 minutes at room temperature, on a
shaking platform. Then, sections were treated with RNAse 7 p.g/ml at 37 °C for 45
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minutes, followed by incubation with 20% normal goat serum for 30 minutes. The
sections were incubated with primary antibodies: (3-catenin and BrdU, diluted in 20%
normal goat serum overnight at 4 °C. Next day, the sections were washed with 0.1%
saponin in TBS for 15 minutes, 3 times. Secondary antibodies and YOYO-1 were
diluted and added to the sections and incubated in the dark, overnight at 4 °C. On the
third day, the sections were washed 3 times with 0.1% saponin in TBS in the dark, for
15 minutes, and observed under a fluorescence microscope. This protocol was also used
for triple labelling immunofluorescence on fifteen micron thick sections although the
protocol had to be modified for the thick sections.
Fifteen micron thick paraffin embedded sections were cut and mounted on poly-L-
lysine coated slides (see 2.1.5). Sections were dewaxed and rehydrated in graded
alcohols (see 2.1.5). High temperature antigen retrieval was performed as previously
described (see 2.1.5). Sections were then incubated at 27 °C for 25 minutes in 2.0 N HC1
to denature the DNA, followed by a rinse in running tap water. Sections were placed in a
slide rack and immersed in 0.1% Saponin/TBS (see appendix B) to permeabilise the cell
membrane for 2 hours. The sections were then placed in a moist chamber and covered
with 20% normal goat serum in 0.1% Saponin/TBS to block non-specific binding and
left overnight at 4 °C. Then, sections were incubated with primary antibodies: 1:50
mouse monoclonal anti-|3-catenin (Transduction Laboratories, UK) and 1:100 rat
monoclonal anti-BrdU (Harlan Sera Lab, UK) in 20% normal goat serum for 24 hours
at 4 °C. The sections were washed with 0.1% saponin/TBS for 8 periods of 15 minutes
on a shaking platform. Then the sections were incubated with secondary antibodies:
1:200 (0.25 p,g/p,l) goat anti-mouse/Rhodamine (Chemicon-International, Inc., UK),
1:800 (0.0025 (tg/p.1) goat anti-rat/Cy5 (Chemicon-International, Inc., UK) and 0.05%
(0.05 pM/pl) YOYO-1 (Molecular Probes, The Netherlands) for 24 hours in the dark at
4 °C. The sections were washed with 0.1% Saponin/TBS for 2 hours in the dark on a
shaking platform. The stained sections were immersed in PBS and examined under
CLSM.
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4.1.4. Method for nuclear volume analysis (2D)
Sections were double labelled with [3-catenin and BrdU and examined using the
Highly Optimised Microscope Environment (HOME). Lesions were identified on the
basis of altered (3-catenin staining in both the pancreas and the intestine. BrdU positive
and BrdU negative nuclei in the lesions were randomly chosen and assessed for nuclear
volume analysis (see appendix A).
4.1.5. Method of nuclear content analysis (3D)
Triple labelled sections were examined under a confocal laser scanning microscope
(CLSM). Individual sections were placed in a petri dish and immersed in phosphate
buffered saline. The lesions were identified as areas of high intensity of P-catenin
staining. Each lesion was scanned with wavelengths of 488 nm, 514 nm and 647 nm to
avoid cross talk between channels. Each section was scanned at lmicron steps. Images
were analysed with Imaris software and VoxelShopPro.
A subregion of the area of interest was selected and the complete nuclei of BrdU
positive and BrdU negative nuclei were randomly chosen. The nuclear mass and nuclear
volume was analysed. The threshold level of threshold segmentation had to be
determined, it was set at 40% of the maximum threshold. This threshold value was
obtained from a calibration test using Fluorescent latex microspheres (Polyscience Inc.,
excitation 488 nm) that were 10.16 pm in diameter. The fluorescent latex microspheres
were immersed in PBS identical to that used for the histological section and scanned
with CLSM, magnification of 630 immersion-objective lens. These microspheres
autofluorescence so that they can be examined under CLSM without any staining. The
images of the microspheres were transferred to Imaris software and VoxelShopPro. It
was then necessary to calibrate the programme by defining what level of fluorescence
represent a true image. This was performed using "threshold segmentation". The
threshold was initially set to the maximum value and subsequently reduced by 5% until
the images of the microspheres were cleared from the background. The threshold value
was found to be at 40% of the maximum. After threshold segmentation had been
performed, the objects were extracted and figures for nuclear mass and volume obtained.
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The optimisation of the latex bead volume was performed by Dr. Peter G. Bush and the
expected volume (n r3) of latex bead is 558 pm3.
VoxelShopPro volume determination of latex beads (10.16 pan diameter) using different
threshold values
Threshold 25% 30% 35% 40% 45% 50% 55%
Volume 781 692 623 569 528 485 442
758 668 609 552 507 456 363
756 674 608 554 514 468 422
761 675 602 553 511 468 446
764 682 613 557 514 468 412
755 658 606 554 502 452 422
742 655 621 566 521 473 423
744 731 616 561 516 472 380
740 670 601 547 502 462 424
825 688 593 541 499 457 379
663 592 539 498 464 401









Mean 762 678 612 558 514 466 412
N 10 12 12 12 12 14 20
SEM 7.95 5.87 5.26 4.79 4.32 3.24 5.30
NB. N = number of samples
SEM = standard error of the mean
123
4.2. Results
4.2.1. Three dimensional analysis of nuclear volume
The intestinal tumour lesions were classified as in section 3.2.1: (I) single dysplastic
crypts, showing nuclear pleomorphism and stratification; (II) complex lesions,
comprising several architecturally distorted crypts in the lamina propia with virtually
normal overlying surface epithelium; (III) small adenoma, identified by the overall
disturbance of architecture including the surface and distinguished from the previous
category on the basis of increased size and surface involvement; and (IV) large
adenomas. The pancreatic lesions were classified according to the area of the lesion:
type I is less than 1 mm2; type II is 1-25 mm2; type III is 25-50 mm2; type IV is 50-100
mm2; type V is 100-400 mm2 and type VI is 400-1600 mm2.
Triple labelling was performed on 15 micron thick sections from (Ape Min+/'/Msh2 ~/_)
mice to analyse the nuclear content in lesions from both in the intestine and pancreas.
The lesions were identified by their high intensity of P-catenin staining, labelled with
rhodamine (Figure 4.1C, top right), DNA in all nuclei was labelled by YOYO-1 (Figure
4.1C, top left), and those cells in S-phase were demonstrated by BrdU incorporation,
(Cy5 labelled, Figure 4.1C, lower left). For comparison an intestinal crypt from a wild
type mouse is shown in Figure 4.1 A. Overlaid pictures of the three immunofluorescence
label are shown in Figures 4.IB and 4.ID. The images were analysed using the Imaris
software program for DNA content. With the Imaris software program, the S phase
nuclei in the tumour lesions were identified by the blue channel (Cy5 staining) and the
nuclear mass was obtained with threshold segmentation in the green channel that
showed the DNA content by YOYO-1 (Figure 4.2). The results obtained show that in
wild type cells and type I and II intestinal lesions, the nuclear mass obtained from S
phase nuclei was no different from that obtained from BrdU negative nuclei in the same
specimen (Figure 4.3A). Whereas in type III and IV lesions the nuclear mass obtained
from S phase nuclei was larger than that obtained from BrdU negative cells. Similarly
data obtained for nuclear volume from the same nuclei showed an increase in the nuclear
volume of S phase cells only in type III and type IV intestinal lesions (Figure 4.3B).
However, the number of cell scored in this study was only 50 nuclei in total, which
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limited the power of this analysis. The crypt nuclei in both the lesion and in normal crypt
were packed together very densely making it very difficult to isolate individual nuclei
and measure the nuclear content (compared Figure 4.1 and 4.4). One advantage of this
approach is that the nuclear content value obtained should reflect the absolute nuclear
content of the three dimensional structure and so should be more accurate than the data
obtained from a two- dimensional study (HOME) which is a relative value.
In the pancreas, only a few S phase nuclei were observed in lesions, on average
0.05% of cells showed BrdU positivity, and no S phase nuclei were observed in the
normal pancreas (Figure 4.5). In pancreatic sections individual nuclei could be clearly
isolated so that the nuclear content analysis using pancreas was more accurate than in
the intestine (Figure 4.6). The result showed the pancreatic nuclear volume obtained
3 3from wild type animals is in the range of 50-250 jam and its mode is at 100 jam .
Whereas the nuclear mass of pancreatic acinar cells obtained from wild type mice varied
in range from 150,000 to 650,000 and its mode is at 150,000-250,000. However, this
approach was again hindered by the presence of overlapping cells and the presence of
some bi-nucleated cells. The most serious drawback was simply the time required to
analyse each nucleus. I spent 3 months analysing a total of 50 nuclei obtained from the
three- dimensional study, which is very time-consuming. I therefore decided to halt the
three-dimensional analysis of the nuclear content of the intestinal and pancreatic lesions.
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Figure 4.1 Triple labelling fluorescence of P-catenin, BrdU and DNA in the small
intestine in wild type mouse (A-B) and in the intestinal tumour lesion in ApcMm+/~,
Ap^/pSy- mice (C-D)
Photographs showing triple labelling immunofluorescence in mouse intestine: DNA
staining with YOYO-1 is shown in green (top left in A and C), P-catenin staining is
shown in red (top right in A and C), BrdU staining is shown in blue (lower left in A and
C) and an overlay of all three stainings is shown in lower right in A and C. A and B
photographs showing triple labelling immunofluorescence of wild type intestine. C and
D photographs showing the intestinal lesion type I. All the figures were obtained at
magnification x630.
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Figure 4.2 Photographs showing three dimensional structure of a single pancreatic
acinar nuclei within histological normal cell in a wild type animal
Photograph A and B are of a single pancreatic acinar nuclei in a wild type animal
obtained using the confocal laser scanning microscope. Photograph (A) shows a series of
images of DNA content following staining with YOYO-1 in a single pancreatic acinar
nuclei obtained using threshold segmentation. Photograph (B) shows a two dimensional
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Figure 4.3 Histogram showing 3D data of nuclear mass and nuclear volume obtained
from intestinal lesions arising in Apc+/'/MshTA mice
A) Data is presented as the average nuclear mass (indicated on the Y axis) of cells within
wild type (WT) mice and in lesion types I-IV. The nuclear mass obtained from BrdU
positive nuclei is shown in blue and the nuclear mass obtained from BrdU negative nuclei
# O
is shown in red. B) Data is presented as the average nuclear volume (pm ) (indicated on Y
axis) of cells within wild type (WT) mice and in intestinal lesion type I-IV. The nuclear
volume obtained from BrdU positive nuclei is shown in blue and the nuclear volume
obtained from BrdU negative nuclei is shown in red. Error bar is represented range of the
mean.
128
Figure 4.4 Double labelling of P-catenin and BrdU in small intestine in wild type
mice and intestinal tumour lesions in ApcM,n+/~, ApcMm+/~/p53v~ mice
(A) Photograph showing double labelling of p-catenin and BrdU in normal intestine
(mag. x200), P-catenin expressed at the epithelial cell membrane is shown in red and
BrdU positive nuclei in the intestinal crypt is shown in brown colour. (B) Photograph
showing double labelling of P-catenin and BrdU in the intestinal lesion (mag. x400),
high intensity of P-catenin staining in the nuclei and cytoplasm of the intestinal lesion is
shown in red and BrdU positive nuclei in the intestinal crypt are shown in brown colour.
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B
Figure 4.5 Double labelling of [3-catenin and BrdU in pancreas in wild type mice
and pancreatic lesions in ApcMm+/", ApcM'"+/Vp53~/~ mice
(A) Photograph showing double labelling of P-catenin and BrdU in normal pancreas
(mag. x400), p-catenin localisation at the cell membrane is shown in red. (B)
Photograph showing double labelling of P-catenin and BrdU in the pancreatic lesion
(mag. x400), P-catenin localisation in the nuclei and cytoplasm of pancreatic lesion is
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Figure 4.6 Histogram showing 3D data of pancreatic nuclear mass obtained from
wild type mice
(A) Data is presented as percentage of cells having nuclear volume (pm3) indicated on
the X axis. (B) Data is presented as percentage of cells having nuclear mass indicated on
the X axis. Error bar represents standard error of mean (SEM). The data was obtained
from pancreatic acinar cells from wild type mice.
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4.2.2.Two dimensional analysis of nuclear volume
(A) Analysis of nuclear volume in spontaneous intestinal lesions in
(Ape Min+/-/p53 ''AandMsh2 "
My first aim was to compare the data obtained from three-dimensional analysis (see
previous section) of nuclear content with a two-dimensional analysis of nuclear volume
of the intestinal and pancreatic lesions arising in mice mutant in Ape, p53 and Msh2.
Immunohistochemistry was performed on three micron sections to identify the
lesions showing high intensity of (3-catenin staining. The area of the nuclei in the
intestinal lesions from Ape Min+/'t (Ape Mm+/~/p53 ~A) and Msh2 were measured with the
HOME microscope together with normal crypt nuclei from each genotype and in the
wild type animals. The Kolmogorov-Smirnov statistical test was used to assess the
significance of differences in the nuclear volume between the different types of lesions
in each genotype of mice. Control data was obtained from normal intestine in wild type
mice and from morphologically normal intestinal crypts in each genotype. The nuclear
volume obtained from intestinal lesions in all lesion types in each genotype of mice were
greater than control data obtained from morphologically normal tissue in mutant mice
(p<0.05) as shown in Figure 4.7 and tables of statistic (see appendix D). The distribution
of nuclear volume (Figure 4.8) and the cumulative percentage of cells having a given
nuclear volume showed that the nuclear volume obtained from tumour lesions was larger
than the nuclear volume in wild type mice and morphologically normal intestinal crypt
cells (p< 0.05) as shown in Figure 4.9, 4.10, 4.11 and 4.12.
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Figure 4.8 Histogram showing distribution of nuclear volume in intestinal lesions
arising in Apc+/'/MshTAmice
Data is presented as the average percentage of cells having nuclear volume equal or
greater than the size categories (nuclear volume ranged from 1 to 600+ pm3) indicated
on the X axis. Data is presented for each lesion category (type I, II, III and IV as
described in the text). Error bars indicate standard error of the mean (SEM) obtained
from at least 3 mice. Control data is indicated for wild type intestine obtained from wild
type mice (top left) and for morphologically normal intestinal crypts from Apc+/VMsh2~/'
mice (top right).
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Apc+/-/Msh2-/- type I —■— Apc+/-/Msh2-/- type II —▲—Apc+/-/Msh2-/- type in
Apc+/-/Msh2-/- type IV ——Apc+/-/Msh2-/- norm —•—WTWT
Figure 4.9 Graph showing the distribution of nuclear volume in intestinal lesions
arising in mice which were Apc+/~/Msh2r/~
Data is presented as a cumulative percentage of cells having nuclear volumes equal or
greater than the size categories indicated on the X axis (nuclear volume ranged from 1 to
600+ pm3). Data is presented for each lesion category (type I, II, III and IV as described
in the text). Control data is given, for normal obtained from morphologically normal
intestinal crypts in Apc+'VMsh2~ ~ mice and wild type mice.
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—♦— Apc+/- type I —■—Apc+/- type II —A— Apc+/- type ID —X— Apc+/- type IV
—Apc+/- norm —WTWT
Figure 4.10 Graph showing the distribution of nuclear volume in intestinal lesions
arising in mice which were Apc+/~
Data is presented as a cumulative percentage of cells having nuclear volumes equal or
greater than the size categories (nuclear volume ranged from 1 to 600+ pm ) indicated
on the X axis. Data is presented for each lesion category (type I, II, III and IV). Control
data is given obtained from morphologically normal intestinal crypts from Apc+/~ mice
and wild type mice.
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—♦—Msh2-/- type in —■—Msh2-/- type IV —▲—Msh2-/- norm —X—WTWT
Figure 4.11 Graph showing the distribution of nuclear volume in intestinal lesions
arising in mice which were Msh2~ ~
Data is presented as a cumulative percentage of cells having nuclear volumes equal or
greater than the size categories (nuclear volume ranged from 1 to 600+ pm3) indicated
on the X axis. Data is presented for lesion category (type III and IV). Control data was
obtained from morphologically normal intestinal crypts in mice and wild type
mice.
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—♦—Apc+/-/p53-/- type I —■—Apc+/-/p53-/- type II
—▲—Apc+/-/p53-/- type EI —X—Apc+/-/p53-/- type IV
——Apc+/-/p53-/- norm —#—WTWT
Figure 4.12 Graph showing the distribution of nuclear volume in intestinal lesions
arising in mice which were Apc+/Vp53'A
Data is presented as a cumulative percentage of cells having nuclear volumes equal or
greater than the size categories (nuclear volume ranged from 1 to 600+ pm3) indicated
on the X axis. Data is presented for each lesion category (type I, II, III and IV). Control
data was obtained from morphologically normal intestinal crypts in Apc+/7p53~ ~ mice
and wild type mice.
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(B) Analysis of nuclear volume in spontaneous pancreatic lesions in
(Ape Min+/7p53 and Msh2 A
As nuclear pleomorphism was observed in small pancreatic lesions, I wished to
characterise this increase in the nuclear volume of cells within these lesions. Lesions in
the pancreas were identified by high intensity staining of (3-catenin. The nuclear area of
cells within the pancreatic lesions, of normal pancreatic acinar cells in mutant mice and
of pancreatic acinar cells in wild type animals were measured by using the HOME
microscope. The Kolmogorov-Smirnov statistical test was used to compare differences
in the profiles of nuclear volume. Statistical data is summarised in appendix D. The
nuclear volume of morphologically normal cells in Ape Mln+/\ (Ape Mm+/7p53 "/") and
(Ape +/'/Msh2) showed significant increases (p<0.05) compared to control data from
wild type pancreas (Figure 4.13).
Nuclear volume was markedly increased in all lesion types arising in Ape Mm+/\
(Ape Mm+/7Msh2 y~) and (Ape Mm+/y p53 ~A) mice compared to morphologically normal
cells of the same genotype. For (Ape Mm+/7Msh2 and Ape Min+/~ genotype the most
extreme difference were observed in type I lesions with larger lesion types (IV and V)
approaching normality (Figure 4.14, and 4.15). Mice, which were (Ape Min+/7p53 v"),
showed the most extreme changes in nuclear volume (Figure 4.16). Here again, type I
lesions showed the highest degree of change. However, in contrast to the results
obtained with the other two genotypes, similar gross changes were observed in the
largest (type V) lesions (compared Figure 4.16 with 4.14 and 4.15).
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—♦—Apc+/-/Msh2-/- type I —■— Apc+/-/Msh2-/- type II —▲— Apc+/-/Msh2-/- type in
—X—Apc+/-/Msh2-/- type IV ——Apc+/-/Msh2-/- type V —•— Apc+/-/Msh2-/- normal
—1—WT Msh2 null, norm
Figure 4.14 Graph showing the distribution of nuclear volume in pancreatic lesions
arising in mice which were Apew7Msh2~/~
Data is presented as a cumulative percentage of cells having nuclear volumes equal or
greater than the size categories (nuclear volume ranged from 1 to 600+ pm3) indicated
on the X axis. Data is presented for each lesion category (type I, II, III, IV and V).
Control data was obtained from morphologically normal pancreatic acinar cells in
Apc+/7Msh2~/~ mice and wild type animals.
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—♦— Apc+/- type I —■— Apc+/- type II Apc+/- type III —X— Apc+/- type IV
—*— Apc+/- type V —•— Apc+/- normal —I—WTWT
Figure 4.15 Graph showing the distribution of nuclear volume in pancreatic lesions
arising in mice which were Apc+/~
Data is presented as a cumulative percentage of cells having nuclear volumes equal or
greater than the size categories (nuclear volume ranged from 1 to 600+ pm3) indicated
on the X axis. Data is presented for each lesion category (type I, II, III, IV and V).
Control data was obtained from morphologically normal pancreatic acinar cells in the
Apc+/~ mice and wild type mice.
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—♦—Apc+/-/p53 -/- type I —■— Apc+/-/p5 3 -/- type II Apc+/-/p53 -/- type III
—X—Apc+/-/p53-/- type IV —*— Apc+/-/p53-/- type V —I—Apc+/-/p53-/- normal
—WTWT ——p53 null, norm
Figure 4.16 Graph showing the distribution of nuclear volume in pancreatic lesions
arising in mice which were Apci/Vp53~/~
Data is presented as a cumulative percentage of cells having nuclear volumes equal or
greater than the size categories (nuclear volume ranged from 1 to 600+ pm3) indicated
on the X axis. Data is presented for each lesion category (type I, II, III, IV and V).
Control data was obtained from morphologically normal pancreatic acinar cells in
Apc+/'/p53'Amice and wild type mice.
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(C) Analysis of BrdU incorporation in spontaneous intestinal lesions arising in
(Ape mn+/'/Msh2and Msh2 "A
By using BrdU incorporation it was possible to (a) determine the number of cycling
cells in lesions compared with morphologically normal cells in wild type animals; and
(b) to address whether any observed increase in nuclear volume was occurring solely
because of an increase in the cell turnover or because of an underlying genetic
instability.
Mice singly or doubly mutant for Ape and Msh2 were injected with BrdU 2 hours
prior to killing to identify those cells in S phase in the intestinal lesions and compared
with wild type mice. BrdU index was calculated from the number of BrdU positive cells
in the total number of cells obtained from each lesion type in each genotype of animals.
Preliminary studies were performed, because there were constraints on the availability of
mice. This study therefore remains to be completed for all lesion types.
Preliminary data presented here suggest that, in morphologically normal cells, Msh2
mutant and Ape mutant mice have an elevated BrdU index (Figure 4.17) compared to
cells in a wild type background. Surprisingly, (Ape Mm+/VMsh2 ~A) cells did not differ
from those in a wild type background.
In Ape Min+/-mjce^ Br(ju index was seen to rise in lesions of through categories I
to III (Figure 4.17). In Msh2 null mice a similar increase was seen with larger category
size with a reduction in the index in category IV lesions. In (Ape Mm+/VMsh2 A) lesions
the pattern was again similar, although the increase in index was less marked through




■WT BApc+7- □ Msh2null □ Apc+/-,Msh2-/-
Figure 4.17 Histogram showing BrdU index in the intestinal lesions arising in
Apc+/~, Msh2~/~ and Apc^'/MshZ^ mice
Data is presented as percentage ofBrdU index, indicated on the Y axis, of BrdU positive
cells, observed in each lesion type (type I, II, III, and IV) indicated on the X axis.
Control data was obtained from the wild type animals and morphologically normal
intestinal crypt cells. Bar indicates range ofmean average.
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I finally analysed nuclear volume in relation to the BrdU index. Cumulative nuclear
volume from both BrdU positive and negative cells within each lesion type was
compared to comparable data from morphologically normal tissue for that genotype.
Across all genotype analysed, the BrdU positive cells showed the largest nuclear
volume, as predicted (p<0.05). Actual differences in nuclear volume irrespective of cell
cycle status may be inferred from a comparison of the distributions obtained for BrdU
positive cells between cells within lesions and cells with morphologically normal
epithelium. Such comparisons suggest that in some lesion categories there is a clear
difference in ploidy (for example in Ape Min+/~typeII and III lesions as shown in Figure
4.18). Alternatively, other lesions show almost identical distributions (the majority of
lesions arising in either Msh2 as shown in Figure 4.19 or ( Mm+/VMsh2 ~A) mice as
shown in Figure 4.20).
Such comparisons of course assume that BrdU positive cell populations are at an
equivalent stage in the cell cycle, which has not formally been proven for the cells
analysed here.
Only a few BrdU positive cells was observed in the pancreatic lesions [within type II
lesions arising in (Ape Min+/VMsh2 mice] and no BrdU positive cell was observed in
morphologically normal pancreatic acini. Therefore, a comparison in the pancreas was
not possible.
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—♦— type II, pos —■—Apc+/- normal, pos
—A—type H, neg —X—Apc+/- normal, neg
—♦—type HI,pos —■— Apc+/- normal, pos
—▲—type ID, neg —X— Apc+/- normal, neg
Figure 4.18 Graph showing the distribution of nuclear volume in intestinal
lesions arising in Apc ~ mice
Data is presented as the cumulative percentage of cells having nuclear volume equal or
greater than the size categories indicated on the X axis. Data is presented for each lesion
categories (type I, II, III and IV). Control data was obtained from wild type mice and
morphologically normal intestinal crypt cells. Graph A is represented a cumulative
percentage of nuclear volume in type II lesion; Graph B is represented a cumulative
percentage of nuclear volume in type III lesion compared with nuclear volume obtained
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Figure 4.19 Graphs showing the distribution of nuclear volume in intestinal lesions arising
in MshT'~ mice with BrdU incorporation
Data is presented as the cumulative percentage of cells having nuclear volume equal or greater
than the size indicated on the X axis. Data is presented for each lesion category (type I, II, III
and IV) which showed BrdU positive and BrdU negative cells. Control data was obtained from
wild type mice and morphologically normal intestinal crypt cells from Msh2~/~ mice. Graph A
presents the cumulative percentage in type I lesion; Graph B represents cumulative percentage in
:ype II lesion; Graph C represents cumulative percentage in type III lesion and Graph D
•epresents cumulative percentage in type IV lesion, compared with the nuclear volume obtained
from morphologically normal crypt cells.
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Figure 4.20 Graphs showing the distribution of nuclear volume in intestinal lesions arising
in Apc^ '/MshT ' mice with BrdU incorporation
Data is presented as the cumulative percentage of cells having nuclear volume equal or greater
than the size categories indicated on the X axis. Data is presented for each lesion category (type
I, II, III and IV). Control data was obtained from wild type mice and morphologically normal
intestinal ciypt cells from Apc+/7Msh2~/~ mice. Graph A presents the cumulative percentage of
the nuclear volume in type I lesion; Graph B presents cumulative percentage of the nuclear
volume in type II lesion; Graph C presents cumulative percentage of the nuclear volume in type
III lesion and Graph D presents cumulative percentage of the nuclear volume in type IV lesion
compared with the nuclear volume obtained from morphologically normal crypt cells.
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4.3. Discussion
4.3.1. Three dimensional study
The three-dimensional study of nuclear content in both intestinal and pancreatic
lesions was hindered by the density of the cells within lesions, which made it extremely
difficult to isolate individual nuclei and accurately measure DNA content. In addition,
three-dimensional analysis is an extremely time-consuming procedure. The distributions
of nuclear volume obtained from the intestinal lesions arising in (.Ape Min+/7Msh2 ~A)
mice obtained by 3D study analysis were approximately comparable to those obtained
using 2D analysis, however the quality of data obtained from 3D analysis was
surprisingly poor. This could have occurred as a consequence of the analysis of fewer
cells, a factor that clearly limits the power of the 3D study. Thus, although theoretically
the 3D analysis should be a more powerful approach, I found that in practice the 2D
approach yielded more data and was in fact used for all subsequent analysis. I would
conclude that in the tissue samples analysed here the 3D method is not a suitable
practical method to determine nuclear content.
4.3.2. Two dimensional study
Nuclear volume analysis in the intestinal tumour lesions arising in mutant mice
showed that there was an increase in nuclear size when compared to wild type mice and
normal intestinal crypts from each genotype of mice. The change in nuclear volume in
intestinal tumour lesions was only small but still significant. This difference probably
arose from either from a real change in ploidy or from an increase in cell turnover rate.
In fact the BrdU index (Figure 4.17) suggested that in the larger lesions, the difference in
the nuclear volume is due to an increase in the cell turnover. In a more detailed analysis
of volume only with BrdU positive cells, I obtained evidence that in at least some
lesions the increase in volume was occurring due to increased turnover. However,
notably this did not seem to be the case for type II and III lesions in Ape M'"+A mice. In
BrdU negative cells from all genotypes in all lesions, the nuclear volume is larger than
the nuclear volume obtained from morphologically normal crypt cells. This either
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reflects very subtle changes in DNA ploidy, or suggests there was an increase in the
number of cells in compartments of the cell cycle other than S phase that showed
relatively increased nuclear volume (i.e. such as an increase in cells at the G2
checkpoint).
Nuclear volume analysis in the pancreatic lesions showed a marked increased in
nuclear size when compared with pancreatic acinar cells from wild type mice and with
morphologically normal pancreatic nuclei in mutant mice. A greater increase in the
nuclear volume was observed in early lesions (type I, II and III) than in the late lesions
(type IV, V and VI) in every genotype of mice. In the late lesion stage it appears that the
size of the nuclei is again approaching normality. This suggests that there is an increase
in genomic instability in small lesions but that the cells which predominant in the large
lesions show less divergence from normality. Interestingly, a p53 deficient background
resulted in much more extreme changes in nuclear volume in all lesion types when
compared to lesions arising in either (Ape Mm+/VMsh2'/') or (Ape Min+/7p53+/+) mice.
These results support the notion that p53 mutations contribute to tumour progression by
promoting genetic instability (Gualberto et al 1998). Gualberto et al showed that
absence of wild type p53 in knockout mice permits the generation of polyploid cells.
Fukasawa et al (1997) also demonstrated that loss of the p53 tumour suppressor
functions results in genetic instability, associated with changes in chromosome ploidy
and gene amplification. My findings of an increase in nuclear volume in pancreatic
lesions arising in a p53 deficient background are supported by these studies. The
resulting genetic instability caused by p53 deficiency could be due to a number of
mechanisms, including p53's role in the regulation of centrosome duplication, a loss of
p53-dependent apoptosis for eliminating cells with genetic damage (Clarke et al 1993).
Or loss of the p53 controlled G2 checkpoint that prevents entry into mitosis after DNA
damage (Bunz et al 1998) and arrested cells with damaged DNA in Gi checkpoint. Lack
of Gj checkpoint control is an early event in the process of carcinogenesis where it is
associated with the malignant transformation of individual cells (Syljuasen et al 1999,
Venkatachalam et al 1998). Many groups have reported that inactivation of p53 renders
cells more susceptible to gene amplification and the development of aneuploidy (Levine
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et al 1991, Livingstone et al 1992, Hartwell and Kastan 1994, Jacks and Weinberg 1996,
Ko and Prives 1996).
Within pancreatic acinar cell lesions, nuclear volume was markedly increased in
comparison to that of normal cells and this difference was not due to cell turnover as
only a few cycling cells were observed. The extent of difference in nuclear volume was
found to be influenced by both losses of Ape and p53. These genotypes had little effect
on the nuclear volume of cells in intestinal lesions, suggesting that the genetic basis for
controlling genetic stability is markedly different between these two tissue types.
Overexpression of P-catenin in wild type mice has previously been shown to promote
the accumulation of functionally competent p53 (Damalas et al 1999). Subsequently,
activation of p53 is known to be capable of promoting apoptosis, which may represent a
mechanism of controlling genetic instability and be reflected in the small differences in
nuclear volume observed in the pancreatic lesions arising in (Ape Min+/7Msh2~/~) and
(Ape Mm+/7p53 +/+) mice. Overexpression of P-catenin has also recently been
demonstrated to correlate with decreased cell proliferation and apoptosis (Mahmoud et
al 1997) which support my observation that in the pancreas mitotic figures could only be
observed in very large lesions.
In Ape Mm+/~ mice, the changes in nuclear volume obtained within cells in pancreatic
lesions were greater than those observed (figure 4.15) in the intestinal lesions (Figure
4.10). However taken together this increase in the nuclear volume of cells in Ape M,n+/~
mice, provides in vivo evidence in support of the concept that Ape may function to
negatively regulates cell growth by inhibiting cell cycle transition from the G] phase to S
phase at the middle to late Gi phase (Baeg et al 1995, Heinen and Groden 1999).
Therefore, mutations or loss of Ape could lead to an increased number of cells moving
from Gi to S phase and result in an increased BrdU index as was observed in the
intestinal lesions in the preliminary study presented here (Figure 4.17). It has been
reported that EB1, a partner of Ape, is localised both to cytoplasmic microtubules in
interphase cells and to spindle microtubules during mitosis (Berrueta et al 1998,
Morrison et al 1998). The association between EB1 and APC suggests a possible role for
Ape in cellular division and the control of normal growth and differentiation of epithelial
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cells. EB1 has been shown to function as a cytokinesis checkpoint in yeast (see detail in
chapterl). Thus, Ape may indirectly regulate cytokinesis via EB1. Thus, the absence or
mutation of Ape could lead to genomic instability.
In vitro experiments suggested that p-catenin may function as an oncogene by
promoting the Gi to S phase transition and protecting cells from suspension-induced
apoptosis (Orford et al 1999). One mechanism by which this could occur is by activation
of the c-myc promoter, which has been suggested as one target of the Wnt pathway.
Interestingly, diploid cells have shown to be highly susceptible to the development of
tetraploid when c-myc overexpression is coupled to p53 deficiency (Yin et al 1999). In
fact, synergy between p53 and c-myc overexpression has been observed in many
systems including the promotion of genomic instability in a mouse model of mammary
neoplasia (McCormack et al 1998). It has been suggested that activation of c-myc would
result in an increase in cyclin D1 protein (Rosenwald et al 1993, He et al 1998).
Alternatively, overexpression of p-catenin has been demonstrated to directly activate the
cyclin D1 (Zhang et al 1997) and result in an increase expression of cyclin D1 (Tetsu
and McCormick 1999). Overexpression of cyclin D1 is known to shorten the Gi to S
transition and thus promote cell progression (Sherr 1994). Other genes have been
implicated as downstream targets of P-catenin, these may also influence neoplastic
development and include Cdk4 (Zhang et al 1997) and AP-1 (Mann et al 1999).
In (Ape Mm+/~/Msh2 ~A) mice, the average nuclear volume obtained from
morphologically normal pancreatic acinar cells and cells within lesions was again
greater than that obtained from normal cells in (Apc+/+/Msh2 y") mice, supporting the
concept that changes in nuclear volume was caused by loss of Ape function. In contrast,
Msh2 deficiency appeared to have no effect upon nuclear volume, as comparison of the
nuclear volume of the cells from pancreatic lesions in Ape Mm+/~ and (Ape Mm+/VMsh2 v")
mice it showed no marked difference. This is as predicted from studies of hereditary
non-polyposis colon cancer in human where tumour predominantly retains their diploid
status. Msh2 primarily functions in the initial recognition of mismatched nucleotides
generated during DNA replication (Fishel et al 1993, Leach et al 1993). Thus, the
absence of Msh2 leads to the loss of function of this repair pathway and the induction of
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microsatellite instability and replication error positivity (RER+). It has been reported that
Msh2 also functions in mediating the deletion of cells with DNA damaged (Toft et al
1999). These two roles show that Msh2 is critical in the surveillance of cells with DNA
damaged and the absence of Msh2 may lead to genetic instability at the sequence level
and predisposes to tumour development.
By analysing the level of BrdU incorporation, the data showed that the number of S
phase cells in the intestinal lesions was increased compared to the number of S phase
cells observed in wild type mice and morphologically normal tissue as shown in figure
4.17. In addition, the BrdU index increased when the lesion was larger. This suggested
that in late stage lesions there was an increase in the S phase component. There are two
possible explanations for this increase in the number of S phase cells; first, an increase
in cell turnover rate and second, an increase in S phase duration (Bleiberg et al 1985).
From my data, the BrdU index showed an increase in intestinal lesions but BrdU was
extremely low in pancreatic lesions. From this data it is not possible to determine which
of these possibilities was the most likely. It is possible that the failure to detect many
BrdU positive cell in the pancreas occurred because of a failure of BrdU to incorporate
within cells in this tissue or because this truly reflects a very slow turnover rate. To
independently determine the proliferation rate in pancreatic tissue, immunostaining with
the cell proliferation marker Ki67 was performed but unfortunately the pattern of
staining obtained was inconsistent and there was high background, which made it
difficult to interpret the results. Moreover, the specimen material was of limited supply
so I was unable to satisfactorily complete this section of the experiment. However, an
estimation of the mitotic index, which is another method to detect cellular proliferation,
was performed. A scorable mitotic index was only identified within very large lesions
(type VI lesion). Therefore, this would suggest that the cell turnover rate in the pancreas
is very low both in morphologically normal cells and during tumour development.
The nuclear volume of BrdU positive cells was larger than the nuclear volume of
BrdU negative cells. This is not surprising as it is well recognised that cells in S phase
have an increased DNA content due to synthesis. A similar pattern of cumulative
distribution in nuclear volume was observed in each type of lesion in all genotype of
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mice. In Ape Mm+/~ mice the BrdU index was observed to rise through lesion categories I
to III and a similar increase was seen in Msh2 mice but in Msh2 null mice type IV
lesions showed a reduction in the BrdU index. In (.Ape Min+/'/Msh2 ~A) mice, the BrdU
index was observed to rise through lesion categories I to III. These data suggested that
differences in nuclear volume are influenced by Ape mutations, which may be
responsible for later progression of intestinal tumorigenesis. The data obtained on the
Ape in background contrasts with that on the Ape Min+/~ and Msh2 background, where
the volume of S phase cells is, overall, similar between morphologically normal cells
and cells within lesions. These observations again suggest that Msh2 deficiency is not
driving marked ploidy change in contrast to the situation with Ape Min.
Taken together, the results showed that in a p53 deficient background there was an
extreme change in nuclear volume in the pancreatic lesions. These changes were
initiated by loss of Ape function but were not influenced by loss of Msh2. Intestinal
lesions showed much smaller differences in nuclear volume. Preliminary data analysing
BrdU incorporation suggests that an increase in the nuclear volume in intestinal lesions
could be accounted for both by an increase in cell turnover and also by changes in DNA
ploidy. The former of these was associated with loss of Msh2, the later with loss of Ape.
Where these mutations were combined it was of interest to note that the prevailing
pattern resembled that seen in Msh2 null mice rather than in the Ape Mm mice.
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Chapter 5
3D image analysis of the apoptotic response
in normal murine small intestine
Small intestinal epithelial crypts have been used as a model for studying the
cellular response to various stresses. Most studies have been undertaken in two
dimensions and are unable to demonstrate dynamic changes in response to injury in
the intestinal crypt. This study was designed to investigate early and delayed
apoptotic response induced by y-irradiation in the murine model by using three-
dimensional reconstruction. In this chapter, the p53 tumour suppressor gene protein,
Ape protein and Ki67 protein expression patterns are analysed and three dimensional
reconstruction attempted of normal small intestinal crypts in p53 wild type and in a
specific p53 genetic defect mouse with immunohistochemistry staining on serial
tissue sections.
y-Irradiation is an extrinsic source that causes DNA damage whilst intrinsic
damage is generated by the cell itself, either as a result of DNA metabolism or as a
result of spontaneous chemical reactivity of DNA such as DNA alkylation (e.g.
etoposide treatment), reactive oxygen species, or defects in mitosis. Apoptosis
possesses two major morphological features: cell shrinkage and nuclear condensation
(Kerr et al 1972). The microscopically visible part of the process depends upon:
(1) The characteristics of the tissue or cell system being studied,
(2) The degree of fragmentation that occurs during the apoptotic process,
(3) The removal mechanisms of the apoptotic fragments and
(4) Sensitivity of the detection procedures (Potten 1996).
Apoptosis characteristically affects scattered single cells not groups of cells, as is
the case with necrosis. Apoptosis is manifested histologically by the formation of
small, roughly spherical or ovoid cytoplasmic fragments, some of which contain
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pyknotic remnants of nuclei (Kerr et al 1972). Apoptotic bodies arising in tissues are
quickly ingested by nearby cells and degraded within their lysosomes. There is no
inflammatory response such as occurs in necrosis (Kerr et al 1994). During apoptosis,
ultrastructural alterations in of the cytoplasm are rather non-specific whereas the
nuclear characteristics are relatively drastic changes. These include chromatin
condensation and nuclear fragmentation. Cells undergoing apoptosis show
morphological changes, including plasma and nuclear membrane blebbing, cell
shrinkage, and chromatin condensation and fragmentation. These changes distinguish
apoptosis from necrosis (Wyllie et al 1980). Necrosis is caused by physical, chemical
or osmotic damage that results in disruption of internal and external membranes of
cells and cell organelles. The cytoplasm of the necrotic cell becomes grossly swollen,
the cell membrane and organelle membrane progressively disintegrate. Lytic necrosis
produces the release of denatured proteins and DNA fragments into the intercellular
space as well as local inflammatory responses. Therefore, cells undergoing apoptosis
exhibit intact external membranes until late phases of the metabolic suicide. The
adjacent cells engulf the dying cell and eliminate it before its contents are released
and thus avoid triggering local inflammatory reactions.
In 1980, Wyllie showed that apoptosis was associated with a unique change in the
nuclear DNA. There was double-stranded cleavage at the linker regions between
nucleosomes, leading to the formation of fragments that were multiples of 180-200
base pairs. These fragments could be detected by agarose gel electrophoresis. The
cleavage affected nuclear but not mitochondrial DNA and was indicative of apoptotic
cell death (Kroemer et al 1995).
Apoptosis is both a genetically controlled response to injury (White 1996) and
also has a major role in normal development. It is believed that cells can activate an
intrinsic death program and thus actively contributed to their own death. The duration
of the apoptotic process is largely unclear (Potten 1996). Apoptotic processes involve
the active participation of endogenous cellular enzymes well before membranes loose
their integrity. The resulting DNA damage is 'sensed' by the cell, via activation of
p53 or other molecules, and the cell either arrests in the cycle or undergoes apoptosis
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(Green and Martin 1995). Signal transduction pathways leading from receptors, such
as Fas and the TNF receptor, to the activation of effectors of cell death, such as the
Caspase protease family, have been elucidated (Nagata 1997).
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5.1. Materials and Methods
5.1.1. Mice
Out-bred wild type male mice and out-bred p53 genetic defects mice (Clarke et al
1993), aged between 8-10 weeks were used in this study. p53 mutant animals were
from an outbred colony segregating for Ola/129 and SWR genomes. All animals were
kept in an animal house in conditions that include good ventilation, food and water ad
libitum, 3-4 mice per cage. Groups of 3 mice were exposed in plastic cages to —
y-irradiation from a 137Cs source at 5 Gray (Gy) for 15 minutes (Clarke et al 1994).
Wild type p53 animals were killed by cervical dislocation at the following time
points, 2 and 4 hours after irradiation for observation of the early apoptotic response.
p53 null animals were sacrificed at 23, 24, and 25 hours after irradiation for
observation of the delayed apoptotic response (Clarke et al 1997, Merrit et al 1997).
Non-exposed mice were transported to the radiation unit together with the treated
mice and subjected to a similar routine for control of the apoptotic response induced
by stress.
5.1.2. Tissue processing
The whole ilea were selected for analysis because the apoptotic index is higher here
than for other regions of the small intestine (Toft, unpublished data). Intestines were
removed immediately from mice after cervical dislocation and were fixed in 10% formal
buffered saline. One centimetre tail tips of each mouse were taken for reconfirmation of
the mouse genotype. The specimens were processed manually to minimise damage to the
antigenicity. The swiss rolls of intestine (see appendix A) were dehydrated in a series of
ethanols at concentration of 50%, 70%, 85%, and 90% for 20 minutes twice and absolute
ethanol for 40 minutes, repeated 3 times. The specimens were cleared in xylene changed
three times, every 40 minutes, subsequently blocked in paraffin wax at 56 °C. The
specimens underwent 3 changes of paraffin wax, every 40 minutes. Finally, the
specimens were embedded in paraffin wax.
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5.1.3. Immunohistochemistry
The number of three micron serial sections was determined (to give the complete
intestinal crypt), three micron thick sections were cut longitudinally serially for 40
sections. Immunohistochemistry technique was performed as previously described (see
appendix A). High temperature antigen retrieval technique was performed (see appendix
A) as required for p53 and Ki67 antigens (see table 2.1), followed by endogenous
peroxidase blocking for 15-20 minutes. Non-specific binding blocking was blocked by
incubation in 20% normal serum corresponding to the secondary antibodies used for 20
minutes. The first section was incubated with Ki67 antibody (NCL-Ki67-MM1,
Novocastra, UK) which detected cell proliferation in every phase of cell cycle except Go,
the second section was incubated with APC antibody (Midgley et al 1997), the third
section was incubated with p53 antibody (NCL-p53-CM5p, Novocastra, UK) and the
fourth section was stained with haematoxylin and eosin. Immunohistochemistry was
performed as described in appendix A.
5.1.5. PCR analysis ofp53 locus
Genomic DNA was extracted from the tail tip of the mice by phenol method. PCR
amplification was performed as previously described (Clarke et al 1993, Purdie et al
1994) (see appendix A).
5.1.6. Methods for 3 dimensional reconstruction from 2 dimensional serial sections
The whole series of serial sections were previewed to identify intestinal crypts, which
express p53, Ki67 and Ape protein and were complete within the sectioned volume.
Slides were placed on the stage of the microscope and the appropriate magnification was
selected. The surrounding structures of the crypt were used as markers to carry out the
orientation. The Roche Manager system was used to capture the images utilising Image
Manager 2.3 software. Images were carefully focused in the live window, the light of
the microscope adjusted until there was a small level of artificial colour of the images.
Images were balanced by selecting where the artificial colour was white, white balance
parameter and black, black balance parameter box. Images were then captured.
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Sequential histological images were stored. Each image in the series was then recalled
from the hard drive and aligned together using the 3dfi program.
The 3dfi programme was the alignment program used to align the serial images
captured in the Roche manager system. The first image slice was selected and a Region
of Interest selected by dragging the mouse in the currently displayed image. The
principle underlying alignment is that a sequence of pairs of images is processed. One of
each pair (reference slice) is kept fixed while the other image (working slice) is rotated
and translated as needed to set optimum registration. The working slice was shown in
green, the reference slice was shown in red and the regions that overlap were a yellow
colour. The speed of translation and image update is directly related to the chosen image
size. The next image slice is then selected by clicking on up or down arrow markers and
the new image slice aligned. There is correlation window that shows the correlation
value between working slice and reference slice. This number can be used as an aid to
alignment though ultimately the user must decide which is the correct position to choose.
Now, the serial paraffin sections should be in the 3D-volume data set and are ready for
3D analysis with the Imaris software program.
Imaris software program can visualise and analyse three dimensional volume data.
The Imaris window contains the following menus: File, Restoration, Visualisation and
Modules. The tiff files were connected to the Imaris file format because it is more
effective for the Imaris software program to work with Imaris file. The Depthview
option displays the images automatically through the whole series. The Subregion
option from Visualisation menu saves the defined area of interested. The Sections
option from the Visualisation menu allows the images to be visualised in the X-Z and in
the Y-Z planes. All possible X-Z and Y-Z planes can be showed simply by moving the
cursor and the accuracy of the alignment can be assessed with this function. The
Perspective projection option from Visualisation menu is divided into three parts:
Transformation, Render mode and Animation. Transformation contains the tools to
change the viewing parameters: the distance of the object from the eye, the view angle,
the near and the far clipping planes and the field of view (focal length of objective).
Render modes, a particular algorithm that creates a projection of the three-dimensional
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image, which has been recorded. There are two principal render modes: projection mode
and ray tracing mode. An Animation sequence is a series of images computed from
different viewpoints that are gradually changed from one frame to the next. With
Perspective projection function the 3D images will be shown on the window and the
object can be visualised and analysed.
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5.2. Results
Expression of p53 protein in the intestinal crypt of irradiated p53 wild type mice
(Figure 5.1) at the different time points was evaluated by immunohistochemistry. Non-
irradiated p53 wild type and p53 null mice showed no p53 protein positivity. Numerous
nuclei positive for p53 protein were detected in p53 wild type mice exposed to —
y-irradiation at 4 hours after irradiation. This p53 nuclear protein was found in the
intestinal crypt cells, which appeared histologically normal, near the base of the crypt in
the region above the Paneth cells in the small intestine (Figure 5.3A). No positive
staining of p53 protein was seen in the nuclear fragments of apoptotic bodies in
irradiated p53 mice (Figure 5.3A). The numbers of p53 protein positive cells was highest
in p53 wild type mice at 4 hours after irradiation, approximately 12-15 nuclei per crypt,
compared to the number of p53 protein positive nuclei, approximately 5-6 nuclei per
crypt, observed in p53 wild type mice at 2 hours after irradiation. In y-irradiated p53
deficient mice and non-irradiated mice no positive staining for p53 protein was observed
at any time point.
Ape immunohistochemistry staining of wild type non-irradiated mice showed Ape
protein staining strongly at the apical surface of the intestinal epithelial villi and diffuse
staining of the cytoplasm whereas there was slightly expression of Ape protein at the
luminal surface of the intestinal crypt (Figure 5.2A). Similar pattern of Ape staining was
observed in y-irradiated and non-irradiated mice both p53 wild type and p53 deficient
mice. The positive staining of Ape was also noted in apoptotic bodies in irradiated p53
wild type mice, irradiated p53 deficient mice and also in spontaneous apoptotic bodies in
control animals. However, when I tried to confirm the Ape protein immunostaining on
apoptotic bodies by using rabbit polyclonal Ape, C-20 (Santa Cruz Biotechnology, UK)
which is raised against a peptide corresponding to amino acids 2824-2843 mapping at the
carboxy-terminal, no Ape positivity was observed of any apoptotic bodies.
y-Irradiated and non-irradiated ilea in both p53 wild type and p53 deficient mice
showed the positive staining of nuclear Ki67 protein in the upper 2/3 portion of the
intestinal crypt cells (Figure 5.2B). This pattern of nuclear Ki67 protein was found
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positive in the whole piece of the intestinal specimen. No positive staining of Ki67
protein was observed in the intestinal villi.
Apoptotic bodies were found scattered, approximately 18-20 apoptotic bodies per
crypt, in the intestinal crypt in wild type p53 mice at 4 hours after exposure to y-radiation
(Figure 5.3B). Whereas lower numbers of apoptotic bodies, approximately 5-8 apoptotic
bodies per crypt, was observed in p53 wild type mice 2 hours after y-irradiation and
approximately 3-5 apoptotic bodies per crypt was observed in p53 null mice at 23 and 24
hours after irradiation. There were very few apoptotic bodies found in non-irradiated p53
wild type and p53 deficient mice. Apoptotic bodies were clearly demonstrated with a
routine haematoxylin and eosin stain. In addition, the morphological appearance of many
of the apoptotic bodies observed in late response was larger than the morphological
appearance of apoptotic bodies observed in the early response. However, both sizes of
apoptotic bodies were found in late response but the large apoptotic bodies were more
frequently observed.
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Figure 5.1 PCR analysis ofp53 locus
Representative results from PCR analysis ofp53 genotyping. Samples were all derived
from the tail tips ofp53 mice and were as follows: lane 1 is negative control, lanes 2, 3,
4, 5, and lane 14 are p53 null mice. Lanes 6, 7, 9 and lane 13 are p53 heterozygous mice.
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Figure 5.2 Photographs showing the pattern of immunohistochemical staining of
Ape and Ki67 protein in the mouse intestine
(A) Photograph showing Ape protein staining in the intestinal epithelium (mag. x400).
(B) Photograph showing nuclear Ki67 protein staining in the intestinal crypt cells (mag.
x400, inset mag. xlOOO).
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Figure 5.3 Photographs showing the pattern of immunohistochemical staining of
p53 protein and haematoxylin-eosin staining of apoptotic bodies in the mouse
intestinal crypts in p53 wild type mice 4 hours post y-irradiation
(A) Photograph showing nuclear p53 staining in the intestinal crypt (arrows and arrow
head indicates apoptotic body, mag. xlOOO). (B) Photograph showing apoptotic bodies
in the intestinal crypts (arrows, mag. xlOOO).
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5.3. Discussion
My analysis of apoptosis in p53 mice largely confirms others' observations (Kerr et al
1972, Clarke et al 1994, Merrit et al 1994, Arai et al 1996). In this study, a large number
of apoptotic bodies were found in p53 wild type mice at 4 hours after exposure to —
y-radiation. Moderate numbers of apoptotic bodies was observed in the intestine of p53
deficient mice at 24 and 25 hours after exposure to y-radiation. The morphological
appearance of the apoptotic bodies observed in late response were larger than the
morphological appearance of apoptotic bodies in the early response, which is supported
an observation by evidence from others using electron microscopy in which the unusual
morphology of late, p53-independent death, apoptotic cells in comparison with classical
apoptotic bodies (Merrit et al 1997) was demonstrated. Many of the apoptotic cells they
found contained marginated and condensed chromatin in nuclei that were large and in
some cases appeared to be attempting mitosis and thus multinucleated whereas classical
apoptotic bodies showed chromatin condensation and nuclear fragmentation (Kerr et al
1972).
The pattern of Ki67 nuclear protein staining in irradiated and non-irradiated p53 wild
type and p53 deficient mice was similar. Potten demonstrated a reduction in proliferation
at the crypt base in mice within 3 hours after exposure to 8 Gray of y-radiation.
Proliferation was at a minimum by 15 hours post-irradiation and repopulation began at
about 15 hours and reached a peak at 22-32 hours post-irradiation (Potten et al 1990).
This study was not designed to analyse in detail the proliferation index, however, the
difference in Ki67 expression pattern could not be observed. This may be probably due
to the dose of y-irradiation used in the studies, 8 Gray of y-radiation was used in Potten's
work whereas 5 Gray of y-radiation was used in my study.
p53 nuclear positivity was found only in irradiated p53 wild type mice demonstrating
the induction of p53 gene in response to DNA damage from y-radiation, which confirms
the observations of others (Merrit et al 1994, Midgley et al 1995, Arai et al 1996). p53
nuclear protein was found expression in the intestinal crypt cells, which appeared
histologically normal, near the base of the crypt in the region above the Paneth cells in
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the small intestine, and peak levels of p53 positive nuclei were seen at position 4-5,
which is the stem cell position ((Merrit et al 1994, Arai et al 1996). The maximum peak
of p53 expression was 4 hours after exposure to 5 Gray of y-radiation.
The pattern of Ape protein staining observed in irradiated p53 wild type and p53
deficient mice was the same as the Ape staining pattern in the normal mouse intestinal
villi and intestinal crypt cells described in chapter 2. Ape protein staining showed no
alteration after y-irradiation exposure even at late response. This could mean that Ape
gene regulation is not responsive to DNA damage from y-radiation or there might be
alterations in the Ape after y-irradiation exposure, which is unable to be detected by
immunohistochemistry. Moreover, this study was designed to look at acute effects
caused by y-irradiation so the period analysed might not be enough to detect any
alteration that could be observed with immunohistochemical staining. However, others
have reported that the level of APC mRNA and protein were increased after exposure to
the methylating agent, N-methyl-N-nitro-N-nitrosoguanidine, and this response required
p53 (Narayan and Jaiswal 1997). Thus, an alteration in Ape can be detected in response
to injury by a different mechanism to the DNA damage caused by y-radiation leading to
DNA strand breakage of phosphodiester bonds whereas DNA damage caused by
methylating agents leads to adduct formation in DNA base. The Ape positivity of
apoptotic bodies was found in all apoptotic bodies. Cleavage of APC during the
apoptotic process has been demonstrated (Browne et al 1995, 1998, Webb et al 1999).
They detected a 90 kDa protein cleavage fragment, which is highly conserved in human,
rat and mouse, in apoptotic cells of all cell line investigated, which was not present in
attached cells. However, the Ape positivity of apoptotic bodies which I saw was not
observed with the other antibody (rabbit polyclonal APC, C-20, Santa Cruz
Biotechnology, UK) which is raised against a peptide corresponding to amino acids
2824-2843 mapping at the carboxy-terminal whereas rabbit polyclonal APC 3161 is
raised against amino acids 2817-2827 at the carboxy-terminal. This could be due to two
different APC antibodies recognise different epitopes of APC or Ape protein fragment in
apoptotic bodies.
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The images obtained from the serial sections were captured, aligned and stored in the
tiff file format. The image files were transferred to the Imaris software program to
reconstruct the three-dimensional images (3D). When the images were opened in Imaris
software, we found that the images were not aligned properly. Despite trying several
times the image files could not be aligned. After consultation with the programmer and
the company who supplied the alignment program, it was modified several times.
However, I was unable to align this series of images, therefore rendering and
reconstruction of the image series into three-dimensional crypts was impossible. The
other factor that may affect reconstruction of the intestinal crypt was the use of
immunoperoxidase staining on the serial sections. The intensity of the signal from
immunoperoxidase staining was too weak to be detected by the Imaris software.
From this study I may suggest (1) to solve the problem of the alignment, the program
requires further modification so that it is suitable for use with the paraffin serial sections
(2) to study and work with the Imaris software program should use other staining such as
fluorescence or haematoxylin and eosin that yield strong intensity of signal so that the
signal is able to be detected by the Imaris software program.
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Discussion
This thesis focused on the early events in tumorigenesis using various mouse models.
I first determined the pattern of Ape protein expression in normal epithelium in animals,
which were wild type and in animals bearing genetic defects in p53, Ape and the
mismatch repair gene, Msh2. I choose to use immunohistochemical analysis to
demonstrate the pattern of Ape protein expression in various mouse organs. This
expression pattern was compared to the pattern of (3-catenin and E-cadherin expression
within the same tissues. This is the first report comparing the pattern of Ape expression
in mouse tissues with the pattern of (3-catenin and E-cadherin protein expression in wild
type mice and in mice bearing genetic defects. When APC and P-catenin localisation
was compared, two patterns were seen; (1) co-localisation at the lateral cell membrane
and (2) no co-ordinated expression, with APC found in the cytoplasm and P-catenin
found at the basolateral cell membrane. The first pattern was seen in the intestinal
epithelium. The second pattern was seen in the other epithelial types examined such as
renal tubule or alveolar epithelium of mammary glands. P-Catenin and E-cadherin were
always found colocalised in all types of epithelium at the lateral cell membrane. This
implies that p-catenin always interacts with E-cadherin but that Ape does not always
interact with p-catenin. Hemizygosity for Ape did not affect the pattern of Ape protein
expression in normal epithelium in Ape Min+/~ mice. Nuclear localisation of Ape was
observed in the inner nuclear layer of the retina and in Sertoli cells, which are non-
migrating cells. Cytoplasmic localisation of Ape was also observed in all epithelium cell
types, which are migrating cells, such as intestinal epithelium and renal tubular
epithelium. These observations are supported by the findings of Neufeld and White
(1997). The pattern of Ape expression is similar to the previously reported pattern of
APC expression in human tissues (Midgley et al 1997) which implies that Ape Mm+/~
mice may indeed be appropriate models in which to study Ape protein function and that
the findings obtained may relate well to human colorectal cancer. Interestingly, the
results showed that in morphologically normal intestinal epithelium, Ape and (3-catenin
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expression colocalised at the lateral cell membrane a similar co-localisation of Ape and
P-catenin in the retinal pigment epithelium of the rat has been noted by others (Bubb,
VJ. personal communication), in this case at the basal cell membrane. This suggests that
in these tissues Ape and P-catenin function together. The observed co-localisation of
these proteins also suggests that both Ape and P-catenin may interact with each other in
the development of colorectal cancer and congenital hypertrophy of the retinal pigment
epithelium (CHRPE). It is interesting to note that although APC expression is ubiquitous
in all epithelium types such as the intestine, lung and kidney, the spectrum of disease
associated with inherited lose of APC (FAP) is limited to specific organs and manifest as
colorectal cancer, osteomas, CHRPE and desmoid tumours. This suggests that the
observed co-localisation may reflect novel functions for these proteins in certain tissues.
Unfortunately, when analysing the pattern of P-catenin staining of osteoblasts the
staining pattern was difficult to interpret because of distortion of the tissue, and therefore
in this tissue it was not possible to absolutely establish if these proteins co-localise.
Future studies should include a repeat analysis of this tissue, given the predisposition to
osteomas in FAP patients. In addition, it would be interesting to compare staining
patterns with those found in human specimens obtained from affected FAP patients. In
general the precise biological role of these proteins remain unclear, but several groups
have produced data suggesting a role in regulating cellular progression from G] to S
phase. In vitro studies have shown that Ape functions in regulation of cell progression
from Gi to S phase (Heinen and Groden, 1999), and that P-catenin can promote the G1
to S phase transition (Orford et al 1999).
I next addressed whether the pattern of P-catenin expression was dysregulated in the
intestinal and pancreatic lesions arising in mice bearing germ line defects in Ape, p53
and Msh2. Immunohistochemistry was used to analyse these lesions. As scored
immunohistochemically, levels of P-catenin in Ape Mm+/\ p53 and p53 +/+ mice were
very high in small lesions in both the intestine and pancreas. Nuclear localisation of
p-catenin was observed in small lesions in both the intestinal and pancreatic acinar cells.
This nuclear localisation is consistent with the findings of Sheng et al (1998) in which
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intestinal adenomas were induced by carcinogen exposure in Ape Mm+/~ mice. This
increase is assumed to arise as a consequence of increased levels of cytoplasmic (3-
catenin, which is subsequently translocated into the nucleus. It then complexes with a
transcription factor such as Tcf/Lef-1, thereby activating transcription of downstream
target genes (Korinek et al 1997, Morin et al 1997, Hsu et al 1998, He et al 1998). The
observed overexpression of P-catenin in small lesions of the intestine is consistent with
the findings of Samowitz et al (1999). These results suggest that mutation of P-catenin is
important in the early stages of adenoma formation but is less important for subsequent
neoplastic progression. This data agrees very well with my findings that P-catenin is
preferentially upregulated in small lesions and showed a heterogeneous pattern of
staining in the larger lesions. A widespread role for P-catenin in tumour progression is
suggested by other data including identification of mutations in P-catenin in mouse and
human hepatocellular carcinomas (de la Coste et al 1998). Others have shown that
mutation of P-catenin was an early event in chemically induced mouse hepatocellular
carcinogenesis (Devereux et al 1999). This evidence supports the hypothesis that —
p-catenin overexpression is an early event in tumorigenesis in cases where the Wnt
signalling pathway is disrupted, presumably shortly after Ape inactivation. Inactivation
of Ape results in accumulation of cytoplasmic P-catenin and excess P-catenin is
translocated into the nucleus, leading to upregulation of transcription. Therefore, it
would be interesting to perform p-catenin staining in the various stages of human
colorectal cancer specimens to prove this hypothesis.
The upregulation of P-catenin was not always evident in lesions arising in Msh2
mutant mice. This result suggests either that mutations may occur downstream of —
P-catenin in the Wnt pathway, or that dysregulation of Wnt pathway is not important in
all early lesions on a Msh2 null background and that an alternative pathway is involved
in tumorigenesis in Msh2 null background mice.
Msh2 is a key component of the mismatch repair machinery, defects of which are
known to be important in the development of hereditary non-polyposis colon cancer in
humans. Loss of function of the mismatch repair genes is associated with microsatellite
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instability and predisposes to the promotion of neoplasia following hits at other genes
such as APC. From my data, P-catenin was not always seen to be upregulated in
intestinal lesions arising in the (Ape Min+/7Msh2 ~/_) mice. This implies that in a mismatch
repair deficient environment, lesions are arising as a consequence of mutations in genes
either downstream of P-catenin or in an entirely different pathway. One set of candidate
targets downstream of P-catenin is the Tcf family of transcription factors, which are the
direct targets of P-catenin in the Wnt pathway. Indeed mutations in the Tcf genes have
recently been reported in HNPCC (Duval et al 1999). Therefore, an analysis of the status
of these transcription factors in those lesions not upregulating P-catenin would be one
logical next target for study.
During the above analysis of P-catenin dysregulation in the intestinal and pancreatic
lesions arising in the mutant mice, extensive changes in nuclear size/volume were
observed in pancreatic lesions but not in intestinal lesions. This clearly demonstrated a
highly tissue specific difference in the roles played by P-catenin and Ape in the early
stages of carcinogenesis. Nuclear pleomorphism was observed in pancreatic lesions
showing P-catenin dysregulation. To prove that the observed change in nuclear size
reflects changes in ploidy or aneuploidy an analysis of nuclear volume in both the
intestinal and pancreatic lesions was performed in conjunction with a determination of
the cell turnover rate. Nuclear volume analysis was performed using both two-
dimensional techniques and three-dimensional methods, the latter giving an absolute
value for volume rather than a relative value. Many problems were encountered using
the three dimensional method. I found the most important confounding factor to be the
density of tissue structure, which made determination of individual nuclear content a
difficult and time-consuming task. In contrast, large amount of data concerning relative
nuclear volume was obtained without difficulty using the two dimensional technique.
Two-dimensional analysis of relative nuclear volumes showed that there were small
but significant changes in nuclear volume in the intestinal lesions arising in each
genotype studied. In contrast, there was a large, statistically significant difference in
nuclear volume obtained from pancreatic lesions compared to control tissue, in
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particular in lesions arising in (Ape Mm+/7p53 A) mice. Two major findings are (a) that
nuclear volume was increased in the absence of Ape and (b) that this increase was
accelerated in the absence of p53.
Ape has been reported to have a role in the regulation of the Gi phase of the cell
cycle by negatively modulating the activity of cyclin-CDK complexes (Baeg et al 1995).
Additionally, APC has been found to localise to the nucleus with foci in the nucleoli
(Neufeld and White 1997) which may suggest a regulatory role for APC in mitosis and
ribosomal RNA synthesis. It has also been shown that the EB1 protein, which is a
partner of APC, is located at the centrosome during mitosis. By association this suggests
that APC may be located at the centrosome; and, although EB1 binding to microtubules
has been shown to be APC-independent (Berrueta et al 1998), APC could still function
in fine-tuning of EB1 function. Implications are that loss of function or mutations in Ape
could result in misalignment of the mitotic spindle and resulting changes in ploidy or
genomic instability ultimately leading to carcinogenesis.
Possible explanations for the accelerated changes in nuclear volume in the absence of
p53 include the loss of function of p53 as a cell cycle checkpoint allowing cells with
damaged DNA to replicate and progression to a malignant phenotype. There is evidence
supporting the involvement of p53 in control of Gi arrest (Martinez et al 1991) which
prevents the cells from replicating damaged DNA, apoptosis (Clarke et al 1993) and
regulation of the G2 phase of the cell cycle (Guillouf et al 1995) which prevents
chromosome segregation if the chromosome is not intact. p53 was also reported to be
important in spindle checkpoint function (Cross et al 1995, Lanni and Jacks 1998) which
ensures the maintenance of diploidy. Other studies performed in human colorectal cell
lines have shown that p53 can mediate an upregulation of APC in response to DNA
damage (Narayan and Jaiswal 1997) which may indicate synergy between mutations in
Ape and p53 in increasing genetic instability and tumour development.
Determination of nuclear volume in pancreatic lesions arising in Msh2 null mice did
not reveal any significant changes. The mismatch repair system recognises inappropriate
base-pairing resulting either from DNA damage or from DNA replication slippage.
Defects in the mismatch repair system lead to microsatellite instability, which is not
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predicted to result in a change in the nuclear volume in the Msh2 null animals. In man
this genetic instability can occur in colorectal lesions, which retain APC (Heinen et al
1995), which suggests that APC mutations do not promote microsatellite instability
neither is it preferred target for mutagenesis in all types of colorectal cancer.
The preliminary cell turnover data suggested that the differences observed in nuclear
volume in the intestinal lesions were probably explained by differences in cell turnover
rather than by the genotypes of the affected animals. In the majority of lesion types the
BrdU index was elevated corresponding to a small but significant increase in nuclear
volume. It is possible that the observed increases in nuclear volume and cell turnover
rate in the lesions occurred independently, and there are at least two possible
mechanisms underlying the increase in the number of S phase cells. One is an increase
in cell turnover rate and the other is an increase in S phase duration in the cancer cell
cycle (Baserga 1965).
The differences in nuclear volume in pancreatic lesions could not be explained by
alterations in the cell turnover rate as the number of S phase cells observed within
normal pancreatic acinar cells and pancreatic acinar cell lesions was only 0.05% by the
methodology employed in this study analysing BrdU incorporation. This is a very
surprising finding, as logically cells should be turning over in these lesions. However, a
survey analysis of mitotic index supports this notion, as mitotic figures were only
observed in carcinomas of the pancreas (lesions beyond the type V scored here).
In summary: (a) Ape is widely expressed in mouse tissues in all epithelial cell types,
connective tissue, bone and nerve tissues. In the epithelia, Ape and P-catenin are not
always co-localised but P-catenin and E-cadherin always co-localise; (b) increased P-
catenin staining by immunohistochemical method is a marker of early murine pancreatic
and intestinal lesions and this suggests it may be a useful marker of human
tumorigenesis; (c) lesions arising in a Msh2 deficient background do not always show
dysregulation of P-catenin, suggesting the presence of an alternative pathway to tumour
development; (d) marked changes in nuclear volume are seen within small pancreatic
lesions. These reflected aneuploidy or polyploidy in the pancreas but surprisingly no
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marked change was seen in the intestine; and (e) the observed genetic instability in the




Glass slides were cleaned, by immersion in detergent (Decon, Decon Laboratory, UK)
for 1 hour, at room temperature before placing in 74% ethanol for 5 minutes. The slides
were air dried at room temperature. Poly-L-lysine (Sigma, Germany) was used to coat
the glass slides so that the tissue section adheres to the slides throughout the whole
process of immunohistochemistry. Cleaned glass slides were immersed in poly-L-lysine
solution (see appendix B) for 5 seconds. The slides were allowed to drain, air-dried and
then oven dried at 50 °C, overnight. All antibodies used in the experiment were
optimised (as previously described in section 2.1.3 and table 2.1) to find the optimum
dilution for staining before performing the experiment.
Three micron thick sections were cut with a microtome. Each section was gently
picked up with a brush and placed in 56 °C water bath to stretch the section. A glass slide
was immersed underneath the tissue section in the water bath to collect the section and
the section was left to dry for a few minutes before placing the sections in a slide rack
and transferring to 37 °C oven. The sections were dried in a 37 °C oven, overnight. The
sections were dewaxed in xylene for 10 minutes, re-hydrated by passing through in a
standard series of graded alcohol; absolute, 74%, 64% ethanol for 2 minutes each before
rinsed in running tap water for 5 minutes. The antigen retrieval technique was performed
for P-catenin and E-cadherin staining as these antigens needed to be unmasked for
successful staining (see 2.1.3). Briefly, the sections were placed in a plastic slide rack
and immersed in 0.05 M citrate buffer, pH6.0 (see appendix B) and placed in the
microwave oven. The slides were microwaved at 700 watts, for 5 minutes, repeated 3
times. The sections were cooled down to room temperature before being rinsed in
running tap water for 5 minutes. The sections were immersed in H202 solution to block
endogenous peroxidase for 15-20 minutes (as described in table 2.1), followed by a rinse
in running tap water for 5 minutes. The slides were washed in 0.1%Tween 20/TBS (see
appendix B) and placed against cover plates (Shandon, UK) and hold in Sequenza rack
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(Shandon, UK) which is the apparatus used to hold the slides in routine
immunohistochemistry technique. Non-specific blocking was carried out by adding 100
pi of 20% normal serum in 0.1%Tween 20/TBS (see appendix B) corresponding to
secondary antibodies used on each section and left to incubate at room temperature for
20 minutes. The sections were incubated with volume primary antibody (as described in
table 2.1). Sections were then washed three times with 3 ml of 0.1%Tween 20/TBS (see
appendix B). Sections were incubated with secondary antibody: biotinylated rabbit anti-
mouse for (3-catenin and E-cadherin and biotinylated swine anti-rabbit for APC antibody,
for 30 minutes at room temperature. Both primary and secondary antibodies were diluted
in 20% normal serum in 0.1%Tween 20/TBS. Sections were washed with 0.1%Tween
20/TBS for 5 minutes, 3 times. Avidin biotin complex (ABComplex) horseradish
peroxidase is based on the non-covalent bond reaction between avidin, which is a
glycoprotein and biotin, which is a water-soluble vitamin. Four hydrophobic pockets on
the surface of the tertiary structure of avidin behave as specific binding sites for four
biotin residues. Biotin may be conjugated with a variety of molecules such as the enzyme
horseradish peroxidase, which is a chemical procedure, biotinylation. ABComplex
method is used to enhance the signal of antigen-antibody complex labelled with a
biotinylated secondary antibody, which was detected by horseradish peroxidase.
ABComplex/HRP (Dako, Denmark) was made by dropping one drop each of
Strep/avidin and biotinylated horseradish peroxidase (Dako, Denmark) into 5 ml of 0.1
M Tris buffer pH 7.6 (see appendix B). The solution was mixed well and left for 30
minutes at room temperature to complete the reaction. Sections were incubated with
ABComplex/HRP for 30 minutes at room temperature, followed by 3 washes with
0.1%Tween 20/TBS. The labelled complex was developed with diaminobenzidine
0.5mg/ml (DAB, see appendix B) for 5-8 minutes at room temperature and rinsed in
running tap water to stop the reaction. Subsequently the slides were lightly
counterstained with Harris haematoxylin (see appendix B) by dipping the section in
haematoxylin for 20-25 seconds, followed by a rinse in tap water to wash off excess stain
and dipping in Scott's tap water (see appendix B) for 25 seconds and a final rinse in tap
water. The sections were dehydrated in a series of alcohol: 64%, 74%, absolute alcohol
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for 2 minutes each and in xylene for 10-15 minutes. Finally, sections were coverslip
mounted with DPX by dropping few drops of DPX on coverslip and gently placing the
section onto coverslip avoiding trapping air bubbles.
2. Immunohistochemistry double staining of P-catenin and BrdU
Three microns of paraffin embedded sections were cut and mounted on poly-L-lysine
coated slides. Sections were de-waxed and re-hydrated in graded alcohol. High
temperature antigen retrieving was performed as previously described. The sections
were incubated in 2.0 N. HC1 at 27 °C for 25 minutes to denature the DNA, followed by
a rinse in running tap water. Sections were incubated in 0.1% Saponin in TBS to
permeate cell membrane for 30 minutes. Endogenous peroxidase blocking was
performed by quenching in 1.5% H202 in distilled water for 15 minutes on shaking
platform, followed by a rinse in running tap water. The sections were placed against
cover plates and held in the Sequenza rack (Shandon, UK). Sections were incubated with
20% normal rabbit serum in 0.1% Saponin/TBS (see appendix B) to block non-specific
binding for 30 minutes at room temperature. Sections were incubated with primary
antibodies; 1:50 mouse monoclonal anti-|3-catenin (Transduction laboratories, UK) and
1:100 rat monoclonal anti-BrdU (Harlan Sera lab, UK) in 20% normal rabbit serum
overnight at 4 °C. The sections were washed with 0.1% saponin/TBS three periods of 5
minutes. The sections were incubated with secondary antibody, rabbit anti-
rat/biotinylated (Immunopure, Pierce, USA) 1:900 for 30 minutes at room temperature
followed by three times washing with 0.1% saponin/TBS. Then, the sections were
incubated with ABComplex/HRP for 30 minutes (see 2.1.5) washed three times with
0.1% saponin/TBS. The sections were visualised with diaminobenzidine 0.5 mg/ml (see
appendix B) for 5-8 minutes, the slides were taken off the cover plates and placed in a
slide rack, then rinsed in running tap water to stop the reaction. The slides were placed
back into new cover plates and held in the Sequenza rack. The sections were incubated
with secondary antibody rabbit anti-mouse/biotinylated 1:400 (Dako, Denmark) for 30
minutes at room temperature. The sections were washed three times with 0.1%
saponin/TBS. This time ABComplex/AP was used as a detection system. The sections
were incubated with ABComplex/AP for 30 minutes at room temperature.
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ABComplex/AP must be made up 30 minutes before use by adding one drop of each
avidin and biotin-phosphatase conjugate into 0.1 M Tris/HCl buffer pH 7.6 (see
appendix B). Vector Red (Vector Laboratory, USA) was used as the visualised system.
Immediately before used, 2 drops of reagentl were added to 5 ml of 0.1 M Tris/HCl
buffer pH 8.2 and mixed well. Two drops of reagent 2 were added, mixed well and
finally addition of 2 drops of reagent 3 and it was mixed well. The sections were
incubated in the dark for 20-30 minutes, followed by rinsing of the sections in running
tap water. The tissue was counter stained with haematoxylin, dehydrated and coverslip
mounted in DPX.
3. Haematoxylin and Eosin staining
Three micron thick sections were cut longitudinally serially with a microtome for 40
sections. Each section was gently picked up with a brush and floated on 56 °C water bath
to stretch the piece of tissue. Clean glass slides were prepared. Then labelled with the
number corresponding to the number of the serial section and immersed underneath the
tissue section in water bath to collect the section. The sections were dried for a few
minutes before being placed in a slide rack and transferred to a 37 °C oven. The sections
were dried in a 37 °C oven, overnight. Next day, the sections were soaked in water and
immersed in Harris's Haematoxylin (Shandon, UK)(see appendix B) for 5 minutes, then
washed in water to get rid off excess stain. Subsequently, the sections were place in 1%
acid alcohol (see appendix B) for 5-10 seconds, followed by immersion in Scott's Tap
water (see appendix B) for 1-2 minutes and washed in water. The sections were stained
in 0.5% aqueous Eosin (Shandon, UK)(see appendix B) for 1 minute, washed in water.
The sections were dehydrated, mounted and cover slipped.
4. Histological microdissection of P-catenin overexpressed lesions
Histological microdissection was performed as described by Going and Lamb (1996).
Paraffin-embedded tissues were cut at 7 micron thickness with a microtome. Each tissue
section was floated on water at 56 °C to stretch the tissue section. A clean plain glass
slide was inserted underneath the section in warm water to collect the tissue section and
dried at 37 °C overnight. The tissue section was subsequently de-waxed in xylene for 10
minutes and re-hydrated in graded alcohol (see 2.1.2) and distilled water. The sections
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were then stained in 0.05% aqueous toluidine blue (see appendix B) for 20 seconds,
washed in distilled water for 5 minutes and stored in distilled water until dissection.
Excess water was blotted from the slide and placed on the stage of a stereo microscope.
Proteinase K buffer solution (pH 8.3: Tris HC1 18 mM, Tris Base 36 mM, EDTA ImM)
was dropped onto the section to cover the section. Dissection was performed with an
electrolytically sharpened 25 mm length tungsten wire needle (diameter 0.5 mm, tip
radius 2.5 microns) in a needle holder mounted in the tool holder of a Leica mechanical
micromanipulator. The section stained with toluidine blue showed pale blue stained in
the areas of tumour lesions compared to dark blue stained in the area of normal tissue in
the same section. The serial 3 micron section stained with (3-catenin was used to compare
with the 7 micron section stained with toluidine blue. Under the microscope, dissection
began by moving the needle until the tip attached to the edge of the lesion. The tip of the
needle was slowly traced around the lesion until the lesion peeled off from the glass slide
and the whole area of lesion was removed in buffer with a micropipette that was set up at
65 pi and transferred to an eppendorf tube and kept at 4 °C until further analysis.
5. PCR analysis ofApe locus
Samples from the microdissection were digested overnight in proteinase K 1 mg/ml
buffer and 1% Tween 20 (see appendix B) in a final volume of 130 pi buffer and left
overnight at 4 °C. The proteinase K was subsequently heat-inactivated at 95 °C, for 10
minutes in a PCR thermal cycler. PCR amplification of Ape was then performed as
previously described (Luongo et al 1994) using the primers
5'TCTCGTTCTGAGAAAGACAGAAGCT 3' and
5' TGATACTTCTTCCAAAGCTTTGGCTAT 3'.
Each 50 pi reaction contained; 0.05 pM of Ape PCR primers (Oswel, UK), 0.2 mM of
each dNTP, 5% DMSO, 10 mM Tris/HCl, 25 mM KC1, 50 mM MgCl2, 2.5 units Taq
DNA Polymerase (PCR reagents were supplied by GIBCO/BRL), and 2 pi of DNA
template sample, overlaid with one drop of paraffin oil. Samples were amplified under
the following conditions: 1 cycle at 94 °C for 2 minutes followed by 30 cycles at 94 °C
for 1 minute, 60 °C for 1 minute, and 72 °C for 1 minute followed by 1 cycle at 72 °C for
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10 minutes. One microliter of each PCR reaction was then subjected to a second round of
amplification for single cell PCR using the nested primers
5' AGTAAGCAGAGACACAAGCA 3' and 5' CGGTGGTAGAAGCAGAACTT 3'
(Audrey Peter, personal communication). Nested PCR was used in order to improve the
sensitivity and specificity of the reaction, the second round of amplification contained
two nested primers that are internal to the first primer pair. Each 50 pi reaction contained
0.05 pM of nested primers, 500 pM MgC^ and the same concentration of other PCR
reagents and subjected to the same parameters as in Min PCR. Sixteen microlitres of the
final PCR product was cleaved with the Hindlll restriction enzyme (GIBCO/BRL) by
incubation at 37 °C, 4 hours or overnight in a 20 pi reaction containing: 2 units of
Hindlll restriction enzyme and 2 pi of reaction buffer (see appendix B), pucl9 was
included as a cleavage control. The PCR product was digested by Hindlll to a 123 base
pair fragment, which is Mm allele. Fifteen microlitres of each Hindlll digested product
and digested pucl9 were loaded into 4% agarose gel by mixed with 20 pi of loading
buffer containing ethidium bromide (see appendix B). Four microlitres of molecular
weight marker V (Boehringer Mannheim, Germany) was loaded so that the molecular
weight of PCR product could be calculated. Electrophoresis conditions were 5 volt/cm
for an hour in TBE buffer. Samples were examined under UV light and photographed.
6. PCR analysis ofp53 locus
PCR amplification was performed as previously described (Clarke et al 1993, Purdie
et al 1994). Three primers were added to the reaction mixture, a pair specific to wild type
allele and a third specific to targeted allele. The first upstream primer is in exon 6,
5' GTGGTGGTACCTTATGAGCC 3' and the second, which is specific for targeted
DNA is 5' CATCGCCTTCTATCGCCTTC 3'. The downstream primer is in intron 7,
5' CAAAGAGCGTTGGGCATGTG 3'. Each 50pl reaction contained: 0.5 pM each
primer, dNTPs 200pM, DMSO 5%, MgCl2 1.0 pM, KC1 200 mM, Tris/HCl 200 mM,
detergent (W-l) 5%, Taq DNA polymerase 2 units and 2 pi of DNA sample (PCR
reagents were supplied from GIBCO/BRL). One drop of paraffin oil was overlaid onto
the surface of the mixture. Sample were amplified under the following conditions: lcycle
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at 94 °C for 2 minutes followed by 30 cycles at 94 °C for 1 minute, 62 °C for 1 minute
and 72 °C for 1 minute and followed by 1 cycle at 72 °C for 10 minutes. Four microlitres
of molecular weight marker VI (Boehringer Mannheim, Germany) and 15 pi of each
PCR product were loaded into 2%gel after mixing with 20 pi loading buffer containing
ethidium bromide (see appendix B). Electrophoresis was run in TBE buffered under
conditions of 5 volts/cm, for an hour. Samples were analysed on 2% agarose gel under
UV light and photographed.
7. DNA extraction by phenol method
Genomic DNA was extracted from the tail tip of the wild type p53 and p53 deficient
mice by a phenol method. TE9: SDS (see appendix B) 0.5 ml was added to the tail
sample in an eppendorf tube, followed by 25 pi proteinase K (20 mg/ml) and incubated
overnight at 37 °C in the orbital shaker. Next day, TE saturated phenol (see appendix B)
0.5 ml was added to the sample, mixed thoroughly and microfuged for 2 minutes. The
top layer of aqueous supernatant was carefully removed to a clean tube and an equal
volume of PC-9 added (see appendix B), mixed and microfuged for 2 minutes. The
aqueous supernatant was removed to a clean tube and an equal volume of chloroform:
iso-amyl alcohol added (see appendix B), mixed thoroughly and microfuged for 2
minutes. The aqueous supernatant was removed to a clean tube and 0.25 ml of 7.5 M
ammonium acetate (see appendix B) and 3.75 ml of cold absolute ethanol added to
precipitate the DNA, mixed well and centrifuges at 10000 rpm for 5 minutes. The
supernatant was discarded and the tube was inverted over a clean paper towel for 20
minutes to allow the DNA pellet to dry. DNA was resuspended in 250 pi of TE and
stored at 4 °C. The optical density was measured at 260 nm and 280 nm; the ratio of
which should be 1.8 for DNA. The concentration of the DNA was calculated by using
the following equation: DNA concentration (pg/ml) = OD 260 nm x 50 x 1000/10.
Where 10 pi is the quantity of DNA measured and 1000 pi is the volume into which it
was diluted. An OD of 1 = 50 pg/ml for double stranded DNA.
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8. Method for nuclear volume analysis with HOME
For nuclear volume analysis the Applications program is used. If this is the first time
the system has been used, it has to calibrate the stage and the objectives have to be
calibrated. To ensure correct measurements with the microscope, the relative height and
width of the screen has to be checked. In addition, the stage has to be checked for
rotation. If this is problem the stage will have to be re-balanced. To calibrate the stage a
grid will appear on the screen, this grid is superimposed onto the grid located on the
calibration slide (lOx). The two grids should overlap almost perfectly. Normally when
entering the application the next screen you are presented with is the zero calibration
screen. Place the calibration slide on the microscope. Match the centre of the screen
cross (green overlay) with the centre of the calibration slide; the centre of the slide
calibration cross occurs within the lOOx ellipse, the correct Y axis on the calibration
slide is the black line showing the objective sizes, the X and Y lines on the calibration
slide should be straight. Now, in the AxioHOME measurement environment. The
application menu, General Morphometry is used. A typical General Morphometry
sessions consists of the following stages; Entry of Slide Reference Number, Selection of
toolbox type i.e. object or structure, Creation or Selection of a protocol, Measurement,
Display of results and Saving the file. Briefly one selects the appropriate protocol, then
draws around the nucleus according to the marker selected, either the positive or
negative nucleus of interest. This step must be done under oil immersion objective lens.
The nuclei were only considered for sampling if the nuclear membrane was sharp and
intact over 75% of its circumference. At least five hundred nuclei were measured from
each type of lesions for each genotype. For assessment of nuclear volume, the individual
radius was calculated from nuclear intercept length and multiplied by 4/3 7tr .
Furthermore, the running means of nuclear volume of each lesion types in different
genotypes were assessed and graphically compared. The advantage of using AxioHOME
is that all the cell positions are recorded on the hard drive if there is any uncertainty a
nucleus is able to be re-scored by the original observer or by an independent observer.
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9. Method for three dimensional analysis of the nuclear volume
Triple labelled sections were examined using the confocal laser scanning microscope
(CLSM). The section was placed in a petri dish and immersed in phosphate buffered
saline. The lesions were identified by the presence of excessive rhodamine staining at
the wavelength 514 nm, indicating areas of (3-catenin overexpression. Immersion
objective lens (magnification of x630) was used during laser scanning. The lesion was
scanned through with each wavelength of laser (488 nm, 514 nm and 647 nm
respectively) to avoid cross-talk between channels. The section was scanned through at
lmicron steps. The scanned images from the three channels were overlaid afterward to
build up the whole volume of sections and saved in the tiff file format. Images of 1.0
micron thick were transferred from CLSM and stored in CDROM and analysed with
Imaris software and VoxelShop Pro program.
The images were opened in the Imaris program and the Subregion of interest was
selected. This subregion was screened through the whole series and opened with shadow
projection. With perspective projection images were seen in three dimensions so that it
was possible to ascertain if images were of complete whole nuclei or not. The images
were analysed in VoxelShop Pro, threshold segmentation option was used to select the
BrdU positive cells (642 nm) and BrdU negative cells (488 nm) from the tumour lesions
in intestine and pancreas. The threshold was set at 40% of the maximum threshold. This
threshold was obtained from calibration with Fluorescent latex microspheres
(Polyscience Inc., excitation 488 nm) that were 10.16 pm diameter. The images of the
microspheres were used to calibrate threshold segmentation. The threshold was set to the
maximum and decreased increments by 5% until the images of the microspheres were
cleared from the background. That threshold was 40% from the maximum. After
threshold segmentation, the objects were extracted by setting the minimum volume at 50
pm. to screen out the debris, and the object statistic option used to yield values for the




40% formalin 25 ml




Acetic acid 10 ml
0.05M Citrate buffer
Citric acid 1.05 g
Distilled water 500 ml, adjust pH 6.0
0.1M EDTA buffer
EDTA 1.86 g
Distilled water 500 ml, adjust pH 8.0
Tris/HCl pH 7.6
0.2 M. Tris 24 ml
0.1 N. HC1 38 ml
Make up to 100 ml with distilled water,
adjust pH 7.6.
xlO Tris bufferred saline (TBS)
Tris 30.25 g
Distilled water 500 ml
Adjust pH 7.6
Make up to 2000 ml with distilled water and
recheck pH
Hydrogen peroxide solution
1.5% H202: 15 ml of 30% H202 in 285 ml
of distilled water
3.0% H202: 30 ml of 30% H202 in 270 ml
of distilled water
0.5% H202 in methanol: 5 ml of 30% H202
in 295 ml of methanol
0.1 % Trypsin solution
Trypsin 10 mg
CaCl2 10 mg
Distilled water 100 ml, adjust pH 7.8
Tris/HCl buffer for DAB solution
0.2 M. Tris 24 ml
0.1 M HC1 38 ml
Imidazole 0.0681 g




Distilled water 500 ml
0.1M Sodium phosphate buffer pH 7.0
Sodium phosphate 14.2 g
Distilled water 1000 ml, pH7.0
20mM sodium phosphate buffer pH 7.0
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0.1M Sodium phosphate pH 7.0 20 ml
Distilled water 80 ml, adjust pH 7.0
Magnesium sulphate 20.0 g
Distilled water 1000 ml
0.1M Glycine buffer pH 3.0
Glycine 7.507 g





Distilled water 5 ml
Working DAB solution (0.5 mg/ml);
X50 DAB solution 100 pi
Tris/HCl buffer pH 7.6 4.8 ml Immediately
before use, add 0.1 ml of 1% H202 in
distilled water
Poly-L-Lysine
Poly-L-lysine 0.1% (w/v) 1ml
Distilled water 40 ml
0.1% Tween 20/TBS
TBS 1000 ml
Tween 20 1000 pi
Acid alcohol
70% alcohol 99 ml
Concentrated HC1 1 ml
Scott's Tap water
Potassium bicarbonate 2.0 g
0.5% Eosin (Shandon, UK)
Eosin 0.5 g in 100 ml distilled water
Harris'haematoxylin (Shandon Harris's
haematoxylin Acidified, UK)
0.05% aqueous toluidine blue
1% toluidine blue 1ml
Distilled water 19 ml
0.5 M. Tris/HCl pH 9.0
Tris 60.55 g
Distilled water 1000 ml adjust pH 9.0 with
HC1
0.25% Coomassie brilliant blue (Sigma,
Germany)
Coomassie brilliant blue 250 mg
Dissolve in 100 ml 50% methanol, 10%
acetic acid
50% methanol: methanol 50 ml and distilled
water 50 ml
10% acetic acid: acetic acid 10 ml and
distilled water 90 ml
Destaining solution
10% ethanol: ethanol 10 ml and distilled
water 90 ml
7% acetic acid: acetic acid 7 ml and




distilled water 80 ml
0.02% Sodium azide
Sodium azide 0.02 mg
Distilled water 100 ml
Taq DNA Polymerase (GIBCO/BRL)
Catalog Number 18038-026, Lot No.
JPE421 UK
Hindlll Restriction Enzyme
(GIBCO/BRL) Catalogue Number 15207-
020, Lot No. JNS402
xl Agarose gel buffer (TBE)
Tris 10.8 g
Boric acid 5.5 g
EDTA 3.72 g
Add distilled water to 800 ml and adjust pH
8.0, make up to a final volume 1000 ml with
distilled water
TE saturated phenol
Mix equal parts of phenol and TE
Allow to separate and discard top aqueous
layer. Store at 4 °C.
TE
10 mM Tris pH 8.0
1 mM EDTA
Store at 4 °C
3% Agarose gel
Agarose gel 3.0 g
TBE 100 ml
Blue gel loading buffer (TBE)
30% Glycerol
0.25% Bromphenol blue
in lx TBE buffer
Digestion buffer for microdissected tissue
Tris/HCl pH 8.3
0.25 M EDTA, pH8.0
Proteinase K 1 mg/ml
Tween 20 1%
Ethidium bromide
Ethidium bromide 100 mg
Distilled water 10 ml
Final working concentration is 5 pi of
ethidium bromide (10 mg/ml) volume in
agarose buffer
Phenol
Phenol crystals 1 kg was melted at 65 °C
TE 1000 ml
Mix, allow to separate and discard TE
Add a further 1000 ml of 0.1%
8-Hydroxyquiniline in TE Store at 4 °C
7.5 M. Ammonium acetate
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Ammonium acetate 607.89 g
Dissolve in distilled water 1000 ml. Store at
4 °C
TE-9









Mix and leave to settle at 4 °C for 2 hours.
Repeat twice and discard top layer.
lOx PCR Buffer
200 mM Tris/HCl pH 8.4
500 mM KC1
lxHindlll reaction Buffer




Appendix C Antibodies and visualisation system kits
Ki67 (NCL-KI67-MM1, Novocastra, UK); mouse monoclonal antibody. Product number: NCL-
Ki67-MM1
p53 (NCL-p53-CM5p, Novocastra, UK); rabbit polyclonal antibody Product number:
NCL-p53 CM5
APC; rabbit polyclonal antibody 3161, Midgley et al 1997
(3-catenin (Mouse IgGi, Clone 14,Transduction Laboratories, UK); mouse monoclonal
antibody. Product number: C 19220
3-catenin, mouse monoclonal antibody, clone number 5H10. Catalog number MAB2081. Lot
number 18040942. Chemicon International Inc, USA
E-cadherin (Anti-mouse E-Cadherin, Clone ECCD-2, R&D System, UK); rat monoclonal
antibody. Product number: BTA 2
E-Cadherin, mouse IgG2a clone 36. Catalog number C20820. Transduction Laboratories, UK
Monoclonal Rat anti-Bromodeoxyuridine (BrdU), clone BUI/75 (ICR1). Product code MAS
250p. Harlan Sera-Lab Limited, UK
Donkey Anti-Rabbit IgG (ImmunoPure, Pierce, USA) peroxidase conjugated. Product number:
31458
Swine Anti-Rabbit- Biotinylated HRP-conjugated, Fab fragment. Dako, Denmark product
number: E043
Rabbit Anti-Mouse-Biotinylated HRP-conjugated, Fab fragment. Dako, Denmark Product
number: E0413
Rabbit anti-Rat IgG, (H+L) Biotin conjugated. Lot number 881209023. Product number
31836. Pierce, USA.
Goat anti-Rat Cy5 conjugated secondary antibody. Chemicon International Inc, USA
Goat anti-Mouse Rhodamine conjugated secondary antibody. Catalog number AP181R.
Chemicon International Inc, USA
YOYOl Iodide (491/509). Catalog number Y-3601. Molecular Probes, Inc. The
Netherlands.
StrepABComplex/HRP. Product number: K0377, Dako, Denmark
ABComplex/AP Product number: K0376, Dako, Denmark
Vector Red, Alkaline phosphatase substrate Kit I. Catalog number SK-5100. Vector
Laboratories, Inc, USA.
Protein A Sepharose 4 Fast Flow Code number 17-0974-01 Lot number 254140 Pharmacia
Biotech AB Uppasala Sweden
Cell proliferation labelling reagent bromodeoxyuridine (BrdU) Catalog number RPN 201
Amersham Life Science
Nitrocellulose membrane Amersham Life Science
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N:WT N:I N:II N:III N:IV WT:I WT:II WT:III WT:IV 1:11 I:III I:IV II:III II:IV III:IV
1-49.99 1.052 0.556 1.052 1.052 0.989 -0.5 0 0 -0.06 -0.5 -0.5 0.433 0 -0.06 -0.06
50-99.99 18.32 14.77 20.82 20.65 20.76 -3.56 2.501 2.327 2.441 -6.06 -5.88 5.996 0.174 -0.06 0.114
100-149.99 23.43 31.48 37.25 31.68 39.63 8.054 13.82 8.254 16.21 -5.77 -0.2 8.152 5.566 2.385 7.952
150-199.99 20.07 29.54 32.33 24.18 35.79 9.477 12.26 4.114 15.73 -2.78 5.363 6.249 8.147 3.466 11.61
200-249.99 12.81 20.39 16.38 14.45 23.02 7.577 3.572 1.639 10.21 4.006 5.938 2.633 1.933 6.638 8.571
250-299.99 5.182 12.92 8.406 5.697 13.23 7.734 3.224 0.515 8.048 4.51 7.218 0.314 2.709 4.824 7.533
300-349.99 2.438 7.437 4.563 3.08 7.542 4.999 2.125 0.642 5.104 2.874 4.356 0.105 1.483 2.979 4.462
350-399.99 1.266 3.951 2.698 1.812 4.363 2.685 1.432 0.546 3.097 1.253 2.139 0.413 0.886 1.665 2.551
400-449.99 0.389 2.568 1.078 1.158 2.503 2.178 0.688 0.768 2.114 1.49 1.41 -0.06 -0.08 1.426 1.346
450-499.99 0.292 1.212 0.52 0.654 1.403 0.92 0.228 0.362 1.111 0.692 0.558 0.191 -0.13 0.883 0.749
500-549.99 0.195 0.874 0.266 0.302 1.101 0.679 0.071 0.107 0.906 0.608 0.572 0.227 -0.04 0.835 0.799
550-599.99 1E-06 0.448 0.072 0.151 1.041 0.448 0.072 0.151 1.041 0.376 0.297 0.592 -0.08 0.969 0.89





C 0.053 0.047 0.047 0.045 0.047 0.05 0.05 0.047 0.05 0.043 0.04 0.042 0.04 0.043 0.04
Table 4.1 Table showing the difference in spontaneous intestinal lesions arising in
ApcMl"+,-/p53~'~ mice
The data presented shows the difference in nuclear volume between each lesion type
(type I, II, III and IV as described in the text), wild type mice (WT) and normal (N)
intestinal crypt cells. The nuclear volume size categories are shown in the first column
and the critical value (C) was calculated at p=0.05, with Kolmogorov Smirnov test, are
shown in the bottom row. Values of p in excess of the critical value indicate a significant




N:WT N:I N:II N:III N:IV WT:I WT:II WT:III WT:IV 1:11 I:III I:IV 11:111 II:IV III:IV
1-49.99 0 -0.23 -0.34 0 0 0.234 0.345 0 0 -0.11 0.234 0.234 0.345 0.345 0
50-99.99 4.273 -4.78 -3.89 6.196 4.813 9.051 8.167 1.924 0.54 0.884 10.97 9.591 10.09 8.707 1.383
100-149.99 27.88 14.5 25.11 42.22 29.97 13.38 2.769 14.34 2.087 10.61 27.72 15.47 17.11 4.856 12.25
150-199.99 22.77 13.59 18.43 29.7 19.65 9.184 4.341 6.929 -3.12 4.843 16.11 6.065 11.27 1.222 10.05
200-249.99 13.35 5.886 9.212 14.33 8.025 7.46 4.134 0.982 -5.32 3.326 8.443 2.139 5.116 -1.19 6.303
250-299.99 5.722 2.789 3.319 6.203 2.446 2.933 2.403 0.481 -3.28 0.53 3.414 -0.34 2.885 -0.87 3.758
300-349.99 2.629 1.405 1.653 3.376 1.295 1.224 0.976 0.747 -1.33 0.248 1.971 -0.11 1.723 -0.36 2.081
350-399.99 1.266 0.703 0.413 1.062 0.648 0.563 0.853 -0.2 -0.62 -0.29 0.359 -0.06 0.649 0.234 0.414
400-449.99 0.389 0.117 0.207 0.357 0.185 0.272 0.183 -0.03 -0.2 0.089 0.239 0.068 0.15 -0.02 0.172
450-499.99 0.292 0.117 0.207 0.182 0.185 0.175 0.086 -0.11 -0.11 0.089 0.065 0.068 -0.02 -0.02 -0
500-549.99 0.195 0.117 -0 -0 0.093 0.077 0.195 -0.19 -0.1 -0.12 -0.12 -0.02 -0 0.093 -0.09
550-599.99 1E-06 0.117 0 0 -0 -0.12 1E-06 -0 -0 -0.12 -0.12 -0.12 0 -0 7E-06
600+ 1E-06 2E-
04





C 0.06 0.06 0.068 0.067 0.058 0.056 0.064 0.063 0.053 0.064 0.063 0.053 0.071 0.062 0.061
Table 4.2 Table showing the difference of nuclear volume in spontaneous intestinal
lesions arising in ApcMm+/' mice
The data presented shows the difference in the nuclear volume between each lesion type
(type I, II, III and IV as described in the text), wild type (WT) mice and normal (N)
intestinal crypt cells. The nuclear volume size categories are shown in the first column
and the critical value (C) was calculated at p=0.05, with Kolmogorov Smirnov test, are
shown in the bottom row. Values of p in excess of the critical value indicate a significant




N:WT N:I N:II N:III N:IV WT:I WT:
II
WT:III WT:IV I-.II I:III I:IV II:III II:IV III:IV
1-49.99 0.24 0.15 0.24 0.022 0.149 -0.09 0 -0.22 -0.09 -0.09 0.128 0.001 0.219 0.092 -0.13
50-99.99 3.936 4.288 1.096 -1.05 0.971 0.351 -2.84 -4.98 -2.97 3.192 5.336 3.317 2.144 0.125 -2.02
100-
149.99
6.607 14.69 15.05 6.66 6.804 8.078 8.439 0.053 0.197 -0.36 8.026 7.881 8.386 8.242 -0.14
150-
199.99
7.795 16.65 20.93 8.294 7.508 8.856 13.14 0.499 -0.29 -4.28 8.356 9.142 12.64 13.42 0.786
200-
249.99
6.41 14.51 16.17 6.514 4.098 8.1 9.764 0.104 -2.31 -1.66 7.996 10.41 9.66 12.08 2.417
250-
299.99
2.728 10.27 10.04 4.455 2.626 7.545 7.312 1.727 -0.1 0.233 5.817 7.647 5.585 7.414 1.829
300-
349.99
1.429 6.277 5.774 4.15 2.096 4.848 4.345 2.722 0.668 0.503 2.127 4.181 1.624 3.678 2.054
350-
399.99
0.786 3.934 2.802 2.084 1.077 3.149 2.016 1.298 0.291 1.132 1.85 2.858 0.718 1.725 1.007
400-
449.99
0.389 2.523 1.846 1.86 0.641 2.133 1.457 1.47 0.252 0.676 0.663 1.881 -0.01 1.205 1.219
450-
499.99
0.292 1.261 0.923 1.156 0.367 0.969 0.631 0.863 0.075 0.338 0.106 0.894 -0.23 0.556 0.789
500-
549.99
0.195 0.721 0.308 0.571 0.184 0.526 0.113 0.376 -0.01 0.413 0.15 0.537 -0.26 0.124 0.387
550-
599.99
1E-06 0.45 0.103 -0 5E-04 0.45 0.103 -0 5E-04 0.348 0.45 0.45 0.103 0.102 -0
600+ 1E-06 -0 -0 0 5E-04 -0 -0 -0 5E-04 1E-
05
-0 -0 -0 -0 -0
C 0.057 0.053 0.055 0.057 0.054 0.053 0.054 0.056 0.053 0.051 0.053 0.05 0.055 0.051 0.053
Table 4.3 Table showing the difference of nuclear volume in spontaneous intestinal
lesions arising in ApcM,n+/7Msh2'/' mice
The data presented shows the difference in the nuclear volume between each lesion type
(type I, II, III and IV as described in the text), wild type (WT) mice and normal (N)
intestinal crypt cells. The nuclear volume size categories are shown in the first column
and the critical value was calculated at p=0.05, with Kolmogorov Smimov test, are
shown in the bottom row. Values of p in excess of the critical value indicate a significant
difference at the p< 0.05 level.
196
Nuclear volume N:WT N:III N:IV WT:III WT:IV 111:1V
1-49.99 0.256 0.163 0.132 -0.09 -0.12 0.031
50-99.99 13.86 16.65 16.15 2.783 2.282 0.501
100-149.99 9.507 28.07 23.87 18.56 14.36 4.204
150-199.99 16.26 33.62 31.41 17.36 15.15 2.212
200-249.99 12.45 21.26 22.06 8.813 9.615 -0.8
250-299.99 5.562 12.34 13.17 6.776 7.604 -0.83
300-349.99 2.373 7.52 7.698 5.147 5.325 -0.18
350-399.99 1.266 4.124 4.228 2.859 2.962 -0.1
400-449.99 0.389 1.789 1.369 1.4 0.98 0.42
450-499.99 0.292 1.071 0.621 0.779 0.329 0.45
500-549.99 0.195 0.714 0.123 0.52 -0.07 0.591
550-599.99 5E-06 0.446 -0 0.446 -0 0.446
600+ 5E-06 1E-05 -0 1E-05 -0 2E-05
C 0.057 0.057 0.059 0.056 0.057 0.057
Table 4.4 Table showing the difference of nuclear volume in spontaneous intestinal
lesions arising in Msh2w' mice
The data presented shows the difference in nuclear volume between each lesion type
(type I, II, III and IV as described in the text), wild type (WT) mice and normal (N)
intestinal crypt cells. The nuclear volume size categories are shown in the first column.
The critical value (C) was calculated at p=0.05, with Kolmogorov Smirnov test, are
shown in the bottom row. Values of p in excess of the critical value indicate a significant




I II III IV normal I II III IV normal III IV normal
1-49.99 0.262 -0.34 0 0.063 1.052 0.406 0 -0.22 -0.03 0.812 -0.09 -0.06 0.796
50-99.99 -5.5 -10.7 -0.4 -1.9 14.05 3.907 -5.34 -7.31 -5.41 14.39 0.456 -0.16 4.458
100-149.99 -21.4 -16.6 6.085 -14.1 -4.45 0.024 -5.38 -8.2 -16 16.82 10.31 -1.85 13.92
150-199.99 -18.7 -16.6 2.815 -18.8 -2.7 -0.62 0.878 -3.61 -16 12.27 13.25 -0.57 3.807
200-249.99 -15 -7.71 -0.66 -15.5 -0.54 0.522 6.193 -1.53 -12.5 6.4 7.174 -0.6 0.361
250-299.99 -10.7 -5.63 -0.03 -11.3 -0.54 -0.19 4.088 1.212 -8.15 2.454 6.26 -0.44 -0.38
300-349.99 -6.22 -3.1 0.105 -6.44 -0.19 -0.15 2.22 2.079 -4.44 1.009 4.505 0.221 0.065
350-399.99 -3.25 -2.28 -0.75 -3.72 -0 0.464 0.584 0.752 -2.81 0.48 2.313 -0.14 -0
400-449.99 -2.45 -0.87 -0.8 -2.32 0 -0.05 0.769 0.702 -1.86 -0 0.632 -1.13 -0
450-499.99 -1.09 -0.31 -0.47 -1.22 0 0.049 0.403 0.501 -1.04 0 0.417 -0.78 -0
500-549.99 -0.76 -0.27 -0.3 -1.01 0 -0.15 0.042 0.269 -0.92 0 0.412 -0.98 -0
















C 0.05 0.059 0.056 0.046 0.058 0.046 0.048 0.048 0.046 0.054 0.047 0.051 0.054
Table 4.4.1 Table showing the difference of nuclear volume in spontaneous
intestinal lesions arising in ApcMin+/~, ApcMm+/'/p53'/', ApcMm+/'/Msh2~'' and Msh2~ ~
mice
The data presented shows the difference in nuclear volume in each lesion type (type I, II,
III and IV as described in the text) between each genotype mice and also in normal crypt
cells. The nuclear volume size categories are shown in the first column. The 2nd - 6th
column are ApcMmJr/7p53''' compared with ApcMin+/' mice, the 7th - 11th column are
ApcMm+/7p53~A compared with ApcMin+/7Msh2'A mice and the 12th -14th column are
ApcMin+/7p53'/' compared with Msh2'/' mice. The critical value (C) was calculated at
p=0.05, with Kolmogorov Smirnov test, are shown in the bottom row. Values of p in
excess of the critical value indicate a significant difference of the p< 0.05 level.
198
Nuclear volume I II III IV normal III IV normal III IV normal
1-49.99 0.144 0.345 -0.22 -0.09 -0.24 -0.09 -0.12 -0.26 0.126 -0.03 -0.02
50-99.99 9.402 5.326 -6.91 -3.51 0.336 0.86 1.742 -9.59 7.768 5.247 -9.93
100-149.99 21.46 11.21 -14.3 -1.89 21.27 4.223 12.27 18.37 18.51 14.16 -2.9
150-199.99 18.04 17.48 -6.43 2.833 14.98 10.44 18.27 6.512 16.87 15.44 -8.46
200-249.99 15.56 13.9 -0.88 3.008 6.936 7.831 14.94 0.897 8.709 11.93 -6.04
250-299.99 10.48 9.715 1.246 3.174 2.994 6.294 10.88 0.16 5.048 7.706 -2.83
300-349.99 6.072 5.321 1.974 2.002 1.2 4.4 6.659 0.256 2.425 4.657 -0.94
350-399.99 3.712 2.869 1.502 0.909 0.48 3.063 3.58 -0 1.56 2.671 -0.48
400-449.99 2.405 1.64 1.503 0.456 -0 1.432 1.184 -0 -0.07 0.728 -0
450-499.99 1.144 0.716 0.973 0.182 0 0.889 0.436 -0 -0.08 0.254 -0
500-549.99 0.603 0.308 0.571 0.091 0 0.714 0.031 -0 0.144 -0.06 -0
550-599.99 0.333 0.103 -0 5E-04 0 0.446 0 -0 0.446 -0 -0
600+ -0 -0 0 5E-04 0 1E-
05
0 -0 1E-05 -0 -0
C 0.053 0.063 0.063 0.05 0.061 0.063 0.054 0.062 0.056 0.054 0.058
Table 4.4.2 Table showing the difference of nuclear volume in spontaneous
intestinal lesions arising in ApcMin+l~, ApcMin+/7Msh2'/' and Msh2~'~ mice
The data presented shows the difference in nuclear volume in each lesion type (type I, II,
III and IV as described in the text) between each genotype mice and also in normal crypt
cells. The nuclear volume size categories are shown in the first column. The 2nd-6th
column are ApcMin+/~ compared with ApcM,n+/7Msh2~/~ mice, the 7th-9th column are
ApcM,n+/~ compared with Msh2v' mice and the 10th-12th column are Msh2'A compared
with ApcMm+/7Msh2~/~ mice. The critical value (C) was calculated at p=0.05, with
Kolmogorov Smirnov test, are shown in the bottom row. Values of p in excess of the
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Dysregulated expression of /?-catenin marks early neoplastic change in Ape
mutant mice, but not all lesions arising in Msh2 deficient mice
Rungtiva Kongkanuntn', Vivien J Bubb1, Owen J Sansom1, Andrew H Wyllie1, David J Harrison1
and Alan R Clarke*-1
!CRC Laboratories, Department of Pathology, University Medical School, Teviot Place, Edinburgh, EH8 9AG, Scotland
We have analysed the pattern of /Lcatenin expression by
immunohistochemistry in mice singly or multiply mutant
for Ape, p53 and Msh2. We observed increased
expression of /Lcatenin in all intestinal lesions arising
on an ApcMin + / — background. In all categories of lesion
studied mosaic patterns of /Lcatenin expression were
observed, with the proportion of cells showing enhanced
expression decreasing with increasing lesion size. p53
status did not alter these patterns. We also show that /?-
catenin dysregulation marks pancreatic abnormalities
occurring in ApcMin + /— and (ApcMin + l—, p53—/—)
mice. In these mice both adenomas and adenocarcinomas
of the pancreas arose and were characterized by
increased expression of /Lcatenin. We have extended
these analyses to intestinal lesions arising in mice mutant
for the mismatch repair gene Msh2. In these mice,
increased expression of /Lcatenin was again observed.
However, in contrast with ApcMin + / — mice, a subset of
lesions retained normal expression. Taken together, these
findings show that increased expression of /Lcatenin is an
efficient marker of early neoplastic change in both
murine intestine and pancreas in Ape mutant mice.
However, we also show that dysregulation of /Lcatenin is
not an obligate step in the development of intestinal
lesions, and therefore that genetic events other than the
loss of Ape function may initiate the transition from
normal to neoplastic epithelium.
Keywords: /Lcatenin; Ape; p53; Msh2; intestine;
pancreas
Introduction
Germline mutations in the adenomatous polyposis coli
gene (APC) gene at 5q21 characterize an inherited
disorder known as familial adenomatous polyposis coli
(FAP) (Kinzler et al., 1991). FAP patients develop
numerous adenomas throughout both the small and
large intestine, some of which ultimately progress to
carcinoma. However, a more general role for APC
mutations in neoplasia is suggested by the fact that
FAP patients have an increased predisposition to
tumours of the brain, thyroid and bone and also to
focal proliferative lesions ('desmoid tumours') of the
connective tissue. Mutated APC has also been reported
in a range of sporadic tumours, including pancreatic
*Correspondence: AR Clarke
Received 16 March 1999; revised 20 August 1999; accepted
23 August 1999
and gastric tumours and the majority of adenomas and
carcinomas of the colorectum (Miyoshi et al., 1992;
Horii et al., 1992; Nakatsuru et al., 1992). Further¬
more, loss of heterozygosity at 5q21 has been observed
in sporadic tumours of the breast and oesophagus
(Boynton et al., 1992; Thompson et al., 1993;
Kashiwaba et al., 1994).
Several different murine models of FAP have been
generated by random chemical carcinogenesis (Moser
et al., 1992), conventional gene targeting (Fodde et al.,
1994; Oshima et al., 1995) and by the use of Cre-Lox
technology (Shibata et al., 1997). All of these models
are characterized by high levels of spontaneous
intestinal neoplasia, confirming a role for Ape in the
development of these lesions. Several observations
using these models support the notion that Ape has
more widespread tumour suppressor activity. First,
desmoid tumours have been reported to occur
spontaneously in Ape mutant mice (Shoemaker et al.,
1997; Smits et al., 1998). Second, ApeMin heterozygotes
show an increased susceptibility to mammary carcino¬
ma both spontaneously and following genotoxic stress
such as carcinogen treatment or X irradiation (Moser
et al., 1993, 1995; van der Houven et al., 1997). Finally,
Ape heterozygosity on a p53 null background has been
shown to strongly predispose to pancreatic neoplasia
(Clarke et al, 1995).
How loss of function of Ape predisposes to
malignancy remains unclear, however disruption of
the normal function of /l-catenin has been implicated in
this process (Rubinfeld, 1993; Su et al., 1993). Levels of
/Lcatenin are modulated by Ape through the mamma¬
lian Wnt signalling pathway, where Ape interacts with
both glycogen synthase kinase 3(3 (GSK3/?) and f-
catenin. The central portion of Ape contains sites at
which it can be phosphorylated by GSK3/? and also
through which it complexes with /J-catenin. Phosphor¬
ylation by GSK3/? increases the stability of the Apc//?-
catenin complex and is thereby thought to increase the
rate of /J-catenin degradation (Rubinfeld et al., 1996).
From the above it is clear that disruption of Ape
function can lead to an increase in the cellular levels of
/Lcatenin. However, this is not the only potential
mechanism for such an increase. Wnt-1 has been
shown to regulate free pools of catenin (Papkoff et al.,
1996) and both axin and the axin homologue conductin
have been reported to alter jS-catenin activity through
interaction with Ape, jS-catenin and GSK3/? (Behrens
et al., 1998; Ikeda et al., 1998; Kishida et al., 1998).
The potential relevance of increased levels of /Lcatenin
becomes clear in the light of findings which show that
jS-catenin functionally interacts with and activates
members of the Tcf family of DNA binding
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transcription factors, including both Lef-1 and Tcf 4
(Behrens et al1998; Korinek ^ al., 1997). Activation
of transcriptional signalling by /Ecatenin-Tcf complexes
has been shown to occur as a consequence of
mutations in both Ape and /Ecatenin (Morin et al.,
1997; Rubinfeld al., 1997) and mutations of /E
catenin have been reported in human colorectal cancers
(Sparks e/ al., 1998). Dysregulated transcription has
therefore been proposed as the basis for early
neoplastic change, although the target genes through
which this may be mediated remain as yet undeter¬
mined (Nusse, 1997).
/Ecatenin also regulates E-cadherin in conjunction
with a-catenin, and loss of function of any of these
proteins abrogates E-cadherin activities, including
maintenance of the adherens junction complex.
Amongst other activities this complex mediates cell-
to-cell adhesion and thereby the control of cell motility
(Chen et al., 1997). Modulation of cell adhesion
appears to be a common mechanism in neoplastic
change, and altered E-cadherin activity has been found
in a number of cancers of epithelial origin including
lobular breast carcinoma, colorectal carcinoma and
gastric adenocarcinoma (Birchmeier and Behrens,
1994). In a transgenic murine model of pancreatic /E
cell carcinogenesis, loss of function of E-cadherin has
been shown to be a critical step in the transition from
adenoma to carcinoma (Perl et al., 1998).
Immunohistochemical analysis of both human and
murine intestinal tumours has shown that both
adenomas and well differentiated carcinomas are
characterized by high levels of /Ecatenin (Inomata et
al., 1996; Takayama et al., 1996). However, both /E
catenin and E-cadherin are reported to be expressed at
significantly lower levels in more aggressive malignan¬
cies, strongly suggesting that over-expression of /E
catenin is only crucial in early tumour development
(Takayama et al., 1996).
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Figure 1 The pattern of /Tcatenin staining in the intestine of ApcMin + /— and (ApcMm + /—, p53—/—) animals. Mice mutant for
Msh2 (De Wind et al., 1995), p53 (Clarke et al., 1993) and ApcMin (Moser et al., 1992) were maintained as outbred colonies
segregating for Ola/129, Balb C, SWR and C57B1/6 genomes. Mice were monitored on a daily basis for signs of ill health and were
killed when they showed signs of disease. All tissues were paraffin embedded using standard methods after overnight fixation in
either buffered formalin or methacarn (four parts methanol, two parts chloroform, one part acetic acid v/v). High temperature
antigen retrieval was performed (Alman et al., 1997), sections were cooled to room temperature and immersed in 1.5%H202
solution to block endogenous peroxidase for 15 min. Sections were then incubated with 1: 50 mouse monoclonal /Tcatenin antibody
(IgGl5 clone 14, Transduction Laboratories, USA) for 60 min, and subsequently with 1:400 Rabbit Anti-Mouse Biotinylated
secondary antibody (DAKO) for 30 min. The sections were incubated in StrepABComplex/HRP (DAKO) for 30 min. The labelled
complex was developed with diaminobenzidine (DAB, 0.5 mg/ml) for 5-8 min. at room temperature, (a-g) Photographs
demonstrating the various features observed in animals with these genotypes. All the features illustrated here were observed
irrespective of p53 status. All scale bars represent 10 /mi (a) /Lcatenin staining in morphologically normal crypts of the small
intestine. /3-catenin was detected throughout the cytoplasm of epithelial cells but was strongly localized to the lateral borders. Strong
nuclear localization was observed in cells at the crypt base (arrows), (b) Heterogeneous expression in a type I lesion. The majority of
cells show the normal pattern of staining, with localization to the lateral borders. A subset of cells show increased cytoplasmic and
nuclear staining, (c) Uniformly increased /?-catenin staining within a type 1 lesion, (d) Increased /f-catenin staining in a type II
lesion, (e) Heterogeneous expression in a type II lesion. Cells showing increased /Tcatenin showed localized to the cytoplasm and in
some instances localization to the nucleus, (f) Heterogeneous expression of /Lcatenin within a type III lesion, (g) Reduced expression
within a type IV lesion. Where expression of /?-catenin was retained this was often localized to the nucleus
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In order to further characterize the association
between tumourigenesis and dysregulation of /Lcatenin
we have analysed the pattern of /Lcatenin expression
in normal and neoplastic tissue derived from mice
mutant for the tumour suppressor genes p53 and Ape.
This analysis is performed on mice which carry a
mutant Ape allele. Loss of the remaining wild type
Ape allele results in dysregulated expression of /?-
catenin. Because we also wished to address the
possibility that dysregulation of /Lcatenin is not an
obligate step in intestinal neoplasia, we also analysed
mice deficient for the DNA mismatch repair gene
Msh2 (De Wind et al., 1998), a murine model of
hereditary non-polyposis colorectal cancer (HNPCC).
Msh2— /— mice develop lymphomas with a peak
incidence at 2-3 months of age (De Wind et al., 1995;
Reitmair et al., 1996). Of the 50% of Msh2~l— mice
which survive beyond 6 months of age, 70% develop
intestinal neoplasms (Reitmair et al., 1996). We report
here the pattern of /Lcatenin expression in lesions
arising in mice mutant for Msh2— /— and (Msh2— /
-, ApcMin + /—).
We first investigated the pattern of expression of /?-
catenin in intestinal lesions arising in ApcMin and p53/
ApcMin mutants. In morphologically normal epithelium,
/Lcatenin was localized at the cell membrane. Nuclear
localization was observed in some cells: these were
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Figure 2 /Tcatenin expression patterns within each class of
intestinal lesion, (a) Percentage of each lesion type showing either
upregulation of /Tcatenin in all cells (black bars); a mosaic or
heterogeneous pattern of upregulation as defined in the text (grey
bars); or no upregulation (open bars). The number of lesions
scored is shown over each column. Insufficient numbers of
category V lesions were identified to permit scoring, (b)
Histogram showing the percentage of cells expressing high levels
of /?-catenin within lesions characterized by mosaic expression of
/TCatenin. Black bars, ApcMin + l— \ Grey bars (ApcMin + /—,
p53— /—);. Hatched bars (.ApcMin +1—, Msh2— /— ). Mean values
are given for each lesion category, as defined in the text. Error
bars represent SEM. Insufficient numbers of mosaic lesions were
identified in Msh2— /— mice to permit analysis
always located at the crypt base (Figure la). This
observation suggests a role for /Lcatenin in the base of
the crypt as /Lcatenin is thought to mediate transcrip¬
tional regulation within the nucleus, and indeed
interaction with the transcription factor Lef-1 is
known to promote nuclear localization of /Lcatenin
(Huber et al., 1996).
In both ApcMin + /— and (ApcMin + /—, p53—/—)
mice, expression of /?-catenin is more intense in
dysplastic crypts and small adenomas. To control for
staining variability between sections, changes in the
intensity of expression were always scored relative to
normal epithelium within the same section. The lesions
were subclassified as in Clarke et al. (1995): (i) single
dysplastic crypts, showing nuclear pleomorphism and
stratification; (ii) complex lesions, comprising several
architecturally distorted crypts in the lamina propria
with virtually normal overlying surface epithelium; (iii)
small adenomas, identified by the overall disturbance
of architecture including the surface and distinguished
from the previous category on the basis of increased
size and surface involvement; (iv) large adenomas, and
(v) adenocarcinoma. The pattern of /Lcatenin staining,
summarised in Figure 2, was essentially identical in
ApcMin+ ]— and (ApcMin + /—, p53—/—) mice, with all
features described below noted in both groups. A
substantial proportion of all lesion types showed
heterogeneous expression of /Lcatenin expression, even
where only single crypts were involved (type I lesions,
Figure lb,e and 2). The term 'heterogeneous' is used
here to describe lesions in which only a proportion of
cells were characterized by increased expression.
Although heterogeneous /Lcatenin was observed in all
lesions types, the proportion of cells overexpressing /?-
catenin were at their highest in type I-III lesions
(Figure lc-d and 2). Mosaic type IV lesions showed
the lowest proportion of cells staining positive for /?-
catenin (Figure If). Large areas of reduced staining
were observed in some late stage lesions, including
those categorized both as type IV and V (Figure lg). In
all categories of lesion the predominant pattern was of
increased /Lcatenin staining within the nucleus, within
the cytoplasm and also at the cell membrane. However
a pattern of strong nuclear localization without
concomitant cytoplasmic staining was also observed
within some lesions as has been previously reported
(Sheng et al., 1998).
These results show that high levels of /Lcatenin are
present in the majority of intestinal lesions, presumably
as a direct consequence of perturbation of the Wnt
pathway. Furthermore, areas showing high levels of /?-
catenin included those composed of heterogeneous or
single dysplastic crypts in the intestine, supporting the
notion that dysregulated /Lcatenin expression is an
extremely efficient marker of early neoplastic change in
the murine intestine. Lower levels of expression were
seen in focal areas within some larger adenomas and
adenocarcinomas, suggesting that genotypic changes
which lead to elevated /Lcatenin are only relevant to
the early stages of neoplasia. This concept is supported
by observations of localized areas of reduced or absent
/Lcatenin expression within some adenomas; and also
by studies of human tumorigenesis, where down-
regulation of both /?-catenin and E-cadherin has been




We next investigated the pattern of expression of /?-
catenin in intestinal lesions arising in Msh2 mutant
animals and Msh2/ApcMin mutants (summarized in
Figure 2). Previous studies have shown that the Msh2
mutation predisposes to intestinal tumorigenesis and
also accelerates neoplasia in ApcMin + /— mice (De Wind
et al., 1995, 1998; Reitmair et al1996). In Msh2—/—
animals we identified type I , II and III lesions which
showed normal /Fcatenin expression (Figure 3b), a
phenomenon we did not observe in ApcMin + /—mice
(Figure 3a). However, all type IV adenomas were
characterized by increased levels of /Fcatenin expres¬
sion. No type V lesions were identified. In (Msh2—/—,
ApcMin + / —) mice there was a significant increase in the
frequency of adenomas, as has been previously reported
(Reitmair et al., 1996). The majority of these lesions
stained strongly for /?-catenin (Figure 3c), however we
again identified a small number of type I,II and III
lesions (x 10%) with the pattern of /?-catenin expression
characteristic of normal cells (Figure 3d). All type IV
lesions analysed showed altered j6-catenin expression,
with an almost identical pattern to that observed in
ApcMin + /—mice. No type V lesions were identified.
We therefore successfully identified small lesions in
both Msh2 and Msh2/ApcMin mice which showed
normal levels and distribution of /?-catenin. These
findings show that dysregulated /?-catenin is not an
obligate event in early lesion formation, and
furthermore that Msh2 deficiency predisposes to
such apparent /Fcatenin-independent events. Thus,
Msh-2 deficiency may predispose to dysplasia
through mutations in other components of the Wnt
signalling pathway which do not affect /?-catenin
levels or indeed through mutations in other path-
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Figure 3 The pattern of /Pcatenin expression in the intestine of Msh2—/— mice (a,b) and (Msh2 —/—, ApcMin + / —) mice (c,d).
Immunohistochemical analysis was performed as described in the legend to Figure 1. All scale bars represent 10 jum. (a) Increased ft-
catenin staining in a type I lesion, (b) Normal pattern of /?-catenin expression in a type II lesion, with /Pcatenin strongly localized to
the lateral borders, (c) Increased /1-catenin expression in a type II lesion, (d) Normal ^-catenin expression in a type II lesion, with
retained localization to the lateral borders. A type I lesion showing /Pcatenin dysregulation is indicated for comparison (arrow)
ways. All large adenomas (type IV) were character¬
ized by increased jS-catenin, showing that this degree
of morphological change is absolutely associated with
events which dysregulate /?-catenin levels.
We have previously described the phenotype of mice
mutant for both p53 and Ape (Clarke et al., 1995). In
addition to intestinal lesions these mice develop
pancreatic neoplasia, either adenoma or acinar
adenocarcinoma, with almost 100% penetrance. The
cell type observed in these lesions was predominantly
acinar, although some foci showed ductal transdiffer-
entiation. The involvement of Ape in the development
of pancreatic lesions was confirmed by loss of the
remaining wild type allele in adenocarcinomas (Clarke
et al., 1995). We therefore next wished to assess the
extent of dysregulation of /Tcatenin in these lesions.
Within morphologically normal pancreatic cells, /?-
catenin was observed at the cell membrane, with no
obvious nuclear localization. In (ApcMin + /— p53 — / —)
mice all foci showing histological change were
characterized by high levels of /Tcatenin. Increased
(3-catenin expression in Msh2 and Ape mutant mice
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staining was also seen in foci which were virtually
histologically normal. Such increased staining was
never observed in pancreas samples derived from wild
type mice. Foci varied in size, with some containing
only single or a few cells in the plane of section (Figure
4a,b). The observation of few or single cell lesions
strongly suggests that dysregulated expression occurs
very early in neoplasia.
In lesions identified in formalin fixed tissues,
increased /?-catenin expression was seen within both
the nucleus and cytoplasm (Figure 4c). However,
cytoplasmic staining was rarely observed in Methacarn
fixed sections, suggesting that the observed cytoplasmic
localisation was an artefact of tissue fixation. Using
either fixation protocol we observed rare (<1%)
lesions which did not show increased nuclear staining
(Figure 4d). Nuclear atypia was seen in the majority of
lesions, although the extent of nuclear pleomorphism
varied considerably from mild to severe within each
lesion (Figure 4b,e). Acinar cell lesions classified as
adenoma were also characterized by increased /?-
Figure 4 The pattern of /Lcatenin staining in the pancreas of ApcMin + /— and (ApcMin + /—, p53—/—) mice.
Immunohistochemical analysis was performed as described in the legend to Figure 1. (a-e) are representative of the patterns of
/Tcatenin staining and histological atypia observed in the pancreas of both Ape in + /—mice and (ApcMin + /—, p53 — /— ) mice, (f
h) are representative of these patterns in pancreatic adenomas and adenocarcinomas arising in (ApcMin + /—, p53—/—) mice. All
scale bars represent 10 pm. (a) Methacarn fixed. A single pancreatic acinar cell characterised by increased nuclear and cytoplasmic
expression. The surrounding acinar cells are representative of the normal pattern of /i-catenin staining, with localization to the cell
borders, (b) Methacarn fixed. Small focus of acinar cells with increased expression. These foci were often composed of cells with
increased nuclear size, prominent examples of which are indicated by arrows. This focus also contains a cell (short arrow) with no
increase in nuclear levels of /Lcatenin. (c) This picture demonstrates the pattern of staining observed in formalin fixed tissues. Cells
(arrowed or restricted to the upper right hand portion of this photograph) showing increased nuclear and cytoplasmic levels of /?-
catenin staining, (d) Methacarn fixed. A dysplastic adenoma showing increased /i-catenin expression, but with no apparent nuclear
localization, (e) Methacarn fixed. Increased /Tcatenin staining in a pancreatic focus, showing strong nuclear localization. Again,
these foci were often composed of cells with increased nuclear size, (f) Methacarn fixed. Heterogeneous /i-catenin expression in an
adenoma containing areas of acinar-ductal transdifferentiation (arrowhead). No increase in /Tcatenin staining was detectable in
normal ducts (arrow), (g) Low levels of /Tcatenin within an acinar adenocarcinoma, (h) Methacarn fixed. Areas of ductal
differentiation within an acinar adenocarcinoma which have retained high levels of /i-catenin expression
p-catenin expression in Msh2 and Ape mutant mice
R Kongkanuntn et al
7224




Figure 5 PCR amplification of Ape alleles from microdissected lesions. PCR analysis. Histological microdissection was performed
as previously described (Going and Lamb, 1996). Samples were digested in proteinase K (1 mg/ml) and 1% Tween 20. The
proteinase K was subsequently heat-inactivated at 95°C, for 10 min. PCR amplification was then performed essentially as previously
described (Luongo et al 1994) using the primers (5'TCTCTT CTGAGAG CAGAAGTT) and (5'ATAGCCAA AGTTATGGAA
GAAGTATCA). Representative results from PCR analysis of microdissected lesions. Determination of Min status was by PCR and
Hindlll digest of PCR product as previously described (Luongo et al., 1994). WT, the amplification product from the wild type Ape
allele. Ape , the amplification product from the mutant allele. Samples were all derived form lesions arising within ApcMin mutant
mice and were as follows: lanes 1 and 2, pancreatic foci showing /Lcatenin dysregulation; lane 3 normal pancreas; lanes 4 and 5,
small intestinal lesions; lanes 6 and 7 normal intestinal epithelium. All results were obtained using microdissected areas containing a*
minimum of 50 cells
catenin staining. Some of these lesions contained areas
of acinar-ductal transdifferentiation which were also
strongly stained (Figure 4f). Adenocarcinomas con¬
tained areas in which /Lcatenin intensity was reduced
(Figure 4g), however areas of ductal differentiation
within these tumours retained high levels of /Lcatenin
(Figure 4h).
These results prompted us to analyse ApcMin mice.
When these animals are maintained on a wild type
background they do not develop pancreatic adenomas
(Clarke et al., 1995). Surprisingly, although we
confirmed absolute absence of neoplasms of the
pancreas, we did find multiple foci of /Lcatenin
dysregulation identical to those observed in (ApcMin
+ /—p53—/—) mice. Our previous analysis (Clarke et
al., 1995) had identified focal mild dysplasia in one out
of seven ApcMin heterozygotes. Subsequent re-exam¬
ination of these sections showed multiple ill-defined
areas containing cells characterized by nuclear size
variation. These areas overexpressed /Lcatenin. Thus,
/Lcatenin immunohistochemistry efficiently highlighted
focal areas of early histological change in the pancreas
of both (ApcMi" + / — p53—/—) and ApcMin + / —mice.
We also analysed pancreatic tissue derived from
Msh2— /—mice and (Msh2— /—, ApcMin + / — ) mice,
neither of which develop spontaneous pancreatic
neoplasms. No abnormal expression of /Lcatenin or
histological atypia was observed in Msh2— /—mice.
However, in (Msh2 — /—, ApcMin + /—) mice we again
identified foci of /Lcatenin overexpression, and these
did not differ in morphological appearance from those
seen in ApcMin + / — animals.
In the pancreas, dysregulated /Lcatenin expression
was seen in 100% of lesions which appeared
morphologically abnormal. Previously, we had noted
the presence of these lesions at high frequency only in
(p53 — /— , ApcMin + /—) mice and rarely in wild type
mice. The occurrence of high /Lcatenin expression in
areas of minimal histological abnormality in ApcMin
heterozygotes allows an order of genetic events to be
proposed for this model of pancreatic neoplasia. In the
presence of wild type p53 such dysregulated expression
does not lead to neoplasia, but it is associated with
nuclear size variation, raising the possibility that loss of
Ape function may promote chromosomal instability.
We are currently characterizing this phenomenon in
greater detail. By contrast, a p53 null environment
allows progression to adenoma and then adenocarci¬
noma. Loss of p53 is therefore essential for adenoma
formation in the time frame analysed here. Notably,
the requirement for genetic change differs between
pancreas and intestine, as within the murine intestine
p53 loss does not increase either adenoma burden or
neoplastic progression (Clarke et al., 1995).
To characterize the status of the remaining Ape
allele in both the intestinal and pancreatic lesions
arising in ApcMin + /— mice we performed PCR analysis
on microdissected foci. Serial sections were generated
and areas of increased /Lcatenin staining identified.
These areas were microdissected and DNA isolated.
Loss of the remaining Apcwt allele was assessed
following PCR amplification. This approach allowed
us to analyse intestinal and pancreatic lesions of, at the
lowest limit, approximately 50 cells per cross section.
Using this method we demonstrate loss of the
remaining wild type Ape allele in both the intestinal
and pancreatic lesions analysed from ApcM/" + /— and
ApcMin + / — , p53 — /— mice (Figure 5). This finding is
consistent with the concept that /Lcatenin dysregula¬
tion occurs as a consequence of loss of Ape function.
Taken together, these results show that /Lcatenin
dysregulation occurs in both the intestine and
pancreas, and that where present it is associated with
the very first steps in the development of neoplasia.
These findings demonstrate that altered expression of
/Lcatenin is a key marker of Ape dysregulation in both
these tissues, and suggest that altered /Lcatenin
expression may be a useful diagnostic marker of early
neoplastic change in human disease. However, we also
show that /J-catenin dysregulation is not an obligate
step in the generation of intestinal lesions in an Msh2
deficient background, and therefore that other
mechanisms may underlie such early neoplastic change.
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